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Background: Despite widespread use of therapies such as inhaled corticosteroids (ICSs), people with
chronic obstructive pulmonary disease (COPD) continue to suffer, have reduced life expectancy and utilise
considerable NHS resources. Laboratory investigations have demonstrated that at low plasma concentrations
(1–5 mg/l) theophylline markedly enhances the anti-inflammatory effects of corticosteroids in COPD.
Objective: To determine the clinical effectiveness and cost-effectiveness of adding low-dose theophylline
to a drug regimen containing ICSs in people with COPD at high risk of exacerbation.
Design: A multicentre, pragmatic, double-blind, randomised, placebo-controlled clinical trial.
Setting: The trial was conducted in 121 UK primary and secondary care sites.
Participants: People with COPD [i.e. who have a forced expiratory volume in 1 second (FEV1)/forced vital
capacity (FVC) of < 0.7] currently on a drug regimen including ICSs with a history of two or more
exacerbations treated with antibiotics and/or oral corticosteroids (OCSs) in the previous year.
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Interventions: Participants were randomised (1 : 1) to receive either low-dose theophylline or placebo for
1 year. The dose of theophylline (200 mg once or twice a day) was determined by ideal body weight and
smoking status.
Primary outcome: The number of participant-reported exacerbations in the 1-year treatment period that
were treated with antibiotics and/or OCSs.
Results: A total of 1578 people were randomised (60% from primary care): 791 to theophylline and
787 to placebo. There were 11 post-randomisation exclusions. Trial medication was prescribed to 1567
participants: 788 in the theophylline arm and 779 in the placebo arm. Participants in the trial arms were
well balanced in terms of characteristics. The mean age was 68.4 [standard deviation (SD) 8.4] years, 54%
were male, 32% smoked and mean FEV1 was 51.7% (SD 20.0%) predicted. Primary outcome data were
available for 98% of participants: 772 in the theophylline arm and 764 in the placebo arm. There were
1489 person-years of follow-up data. The mean number of exacerbations was 2.24 (SD 1.99) for participants
allocated to theophylline and 2.23 (SD 1.97) for participants allocated to placebo [adjusted incidence rate
ratio (IRR) 0.99, 95% confidence interval (CI) 0.91 to 1.08]. Low-dose theophylline had no significant
effects on lung function (i.e. FEV1), incidence of pneumonia, mortality, breathlessness or measures of quality
of life or disease impact. Hospital admissions due to COPD exacerbation were less frequent with low-dose
theophylline (adjusted IRR 0.72, 95% CI 0.55 to 0.94). However, 39 of the 51 excess hospital admissions
in the placebo group were accounted for by 10 participants having three or more exacerbations. There were
no differences in the reporting of theophylline side effects between the theophylline and placebo arms.
Limitations: A higher than expected percentage of participants (26%) ceased trial medication; this was
balanced between the theophylline and placebo arms and mitigated by over-recruitment (n = 154 additional
participants were recruited) and the high rate of follow-up. The limitation of not using documented
exacerbations is addressed by evidence that patient recall is highly reliable and the results of a small
within-trial validation study.
Conclusion: For people with COPD at high risk of exacerbation, the addition of low-dose oral theophylline
to a drug regimen that includes ICSs confers no overall clinical or health economic benefit. This result was
evident from the intention-to-treat and per-protocol analyses.
Future work: To promote consideration of the findings of this trial in national and international COPD
guidelines.
Trial registration: Current Controlled Trials ISRCTN27066620.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 23, No. 37.
See the NIHR Journals Library website for further project information.
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Plain English summary
Chronic obstructive pulmonary disease (COPD) is a long-term lung disease that cannot be cured. Themain symptom is shortness of breath on exertion. In the UK, about 1.2 million people have COPD.
It is a major cause of death and costs the NHS > £1B a year. Sudden ‘flare-ups’ of symptoms often need
emergency treatment, shorten life expectancy and reduce people’s ability to get on with their lives.
Theophylline is a drug that has been around for decades. In the past, it was used in high doses to treat
COPD by opening up airways. However, its benefits were limited and it often caused unpleasant side
effects. High-dose theophylline has been replaced by drugs administered by inhalers, such as inhaled
corticosteroids (ICSs). Recent work in the laboratory and in animal models suggests that, at low dose,
theophylline could make ICSs work better in COPD with none of the side effects of high-dose theophylline.
The Theophylline With Inhaled CorticoSteroid (TWICS) trial tested whether or not adding low-dose
theophylline reduces flare-ups in people with COPD taking ICSs. A total of 1578 people with COPD from
121 centres all over the UK took part. Participants were randomly divided into two groups: one group took
low-dose theophylline and the other took dummy placebo pills. Participants were asked to attend visits at
6 and 12 months.
A total of 791 participants were prescribed low-dose theophylline and 787 were prescribed dummy placebo
pills. Although not everyone took the tablets for a whole year, it was possible to count the number of
flare-ups in 98% of those taking part. In total, there were 3430 flare-ups. On average, the people taking
low-dose theophylline had 2.24 flare-ups and the people taking placebo had 2.23 flare-ups.
Overall, the trial showed that, for people with COPD, taking low-dose theophylline on top of steroid
inhalers makes no real difference.
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Scientific summary
Background
Chronic obstructive pulmonary disease (COPD) is an incurable lung disease characterised by airway
inflammation and progressive airflow limitation; typical symptoms include slowly worsening shortness of
breath on exertion, productive cough and wheeze. The progressive airflow limitation of COPD is associated
with symptoms becoming increasingly worse, ill health, work absence, disability and premature mortality.
In the UK, there are 1.2 million people with diagnosed COPD. It is the fifth leading cause of death, is also
a leading cause of emergency hospital admission and costs the NHS in excess of £1B per year.
Acute deteriorations in symptoms, known as exacerbations, are an important clinical feature of COPD; many
patients require treatment with antibiotics and/or corticosteroids and the severest exacerbations necessitate
hospital admission. Exacerbations are associated with increased ill health and a poorer prognosis and are
the most costly aspect of COPD for the NHS. Recent studies have identified a frequent COPD exacerbator
(defined as two or more exacerbations in a year) phenotype. Such patients can be reliably identified by
patient recall and are highly likely to exacerbate in subsequent years. Despite advances in management,
there is still an unmet need for improved pharmacological treatment of COPD, particularly the prevention
of exacerbations.
Oral theophylline has been used in the treatment of COPD for > 70 years. Conventionally, theophylline has
been used as a bronchodilator; however, in order to achieve modest clinical effects, relatively high blood
concentrations (of 10–20 mg/l) are required, which are also associated with a wide range of well-recognised
side effects. The availability of more effective inhaled therapies as well as theophylline’s narrow therapeutic
index, its modest clinical effect and its side effect profile have resulted in current COPD guidelines relegating
high-dose theophylline to third-line therapy, although in low- to middle-income countries it is often used
earlier in clinical practice.
In recent years, molecular mechanisms contributing to the reduced corticosteroid sensitivity of the airway
inflammation of COPD have been elucidated. In vitro and animal models have demonstrated that, at low
plasma concentrations (of 1–5 mg/l), there is a marked synergistic effect between theophylline and
corticosteroids, with theophylline inducing a 100- to 10,000-fold increase in the suppressive effect of
corticosteroids on the release of pro-inflammatory mediators. A number of small exploratory studies of
short duration have confirmed that, at low dose, theophylline increases the anti-inflammatory properties
of inhaled corticosteroids (ICSs), as evidenced by molecular signatures. Two small, year-long, hospital-based
placebo-controlled trials of low-dose theophylline in COPD have reported conflicting results. The Global
Initiative for Chronic Obstructive Lung Disease (GOLD) management strategy guideline [GOLD. Global
Strategy for the Diagnosis, Management and Prevention of COPD. 2017. URL: https://goldcopd.org/
gold-2017-global-strategy-diagnosis-management-prevention-copd (accessed March 2018)] highlights that
the clinical relevance of low-dose theophylline has not been fully established and that clinical evidence on
low-dose theophylline, particularly on exacerbations, is limited and contradictory.
The Theophylline With Inhaled CorticoSteroid (TWICS) trial was a pragmatic, double-blind, randomised,
placebo-controlled clinical trial built on emerging evidence that low-dose (plasma concentration of 1–5 mg/l)
theophylline may produce a beneficial synergistic effect in COPD by increasing the corticosteroid sensitivity
of the airway inflammation underlying COPD and, as a consequence, reduce the rate of COPD exacerbation
when used in conjunction with ICSs.
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Objectives
The primary objective was to determine the clinical effectiveness and cost-effectiveness of adding low-dose
theophylline to ICS therapy in patients with COPD and a history of two or more exacerbations treated with
antibiotic and/or oral corticosteroids (OCSs) in the previous year. The primary clinical outcome was the
number of exacerbations in the 1-year treatment period that required treatment with antibiotics and/or
OCSs. The primary economic outcome was cost per QALY gained during the 1-year treatment period.
The secondary objectives were to compare the following outcomes between participants treated with
low-dose theophylline and those treated with placebo:
l hospital admissions with a primary diagnosis of exacerbation of COPD
l total number of episodes of pneumonia
l total number of emergency hospital admissions
l lung function
l all-cause and respiratory mortality
l drug reactions and serious adverse events (SAEs)
l health-related quality of life
l disease-specific health status
l total inhaled corticosteroid dose/usage
l health-care utilisation
l modelled lifetime incremental cost per quality-adjusted life-year (QALY)
l time to first exacerbation (an additional secondary objective).
Methods
The TWICS trial was a pragmatic, double-blind randomised, placebo-controlled, UK multicentre clinical trial
that compared the addition of low-dose theophylline to current COPD therapy that included ICS with the
addition of placebo to current COPD therapy that included ICS for 52 weeks, in patients with COPD who
had experienced two or more exacerbations in the previous year treated with OCSs and/or antibiotics.
The aim was to recruit 1424 participants, with ≥ 50% being recruited from primary care.
Inclusion criteria
Participants were people with COPD likely to experience an exacerbation during the 52-week treatment
period. The key inclusion criteria were:
l aged ≥ 40 years
l smoking history of > 10 pack-years
l predominant respiratory diagnosis of COPD [forced expiratory volume in 1 second (FEV1)/forced vial
capacity (FVC) of < 0.7]
l current use of ICS therapy
l patient report of two or more exacerbations treated with antibiotics and/or OCSs in the previous year.
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Exclusion criteria
The key exclusion criteria are listed below. They include concomitant treatment with drugs with the potential
to increase plasma theophylline concentration above the low-dose range of 1–5 mg/l:
l severe or unstable ischaemic heart disease
l a predominant respiratory disease other than COPD, including alpha-1-antitrypsin deficiency
l current use of drugs with the potential to increase plasma theophylline.
Participant identification and recruitment
Participants were identified and recruited from both primary and secondary care sites across the UK.
Recruitment strategies differed between centres depending on local geographic and NHS organisational
factors.
Randomisation/treatment allocation
Participants were randomised using an internet-based computerised randomisation system created and
administered by the Centre for Healthcare Randomised Trials (CHaRT) in the University of Aberdeen.
Participants were stratified by trial centre/area and recruitment setting (primary and secondary) and then
randomised with equal probability to the intervention (low-dose theophylline) or control (placebo) arm.
Intervention
The treatment period was 52 weeks with either 200-mg tablets of Uniphyllin modified release (MR) (Napp
Pharmaceuticals Ltd, Cambridge, UK) or a visually identical placebo. Dosing was based on pharmacokinetic
modelling incorporating the major determinants of theophylline steady-state concentration, designed to
achieve a steady-state plasma theophylline of 1–5 mg/l. The dosing of both the active and placebo drugs
was determined by a participant’s ideal body weight (IBW) and smoking status:
l 200 mg of Uniphyllin MR once daily (or one placebo once daily) for non-smoking participants, or
participants who smoked but had an IBW of ≤ 60 kg
l 200 mg of Uniphyllin MR twice daily (or one placebo twice daily) for participants who smoked and had
an IBW of > 60 kg.
All supplies of trial tablets were delivered to participants’ homes, except for participants recruited in
secondary care sites who received their initial 4-week supply from their local clinical trials pharmacy.
Data collection
Outcome data were collected by face-to-face assessments conducted at recruitment/baseline (week 0),
6 months (week 26) and 12 months (week 52). Participants unable to attend the 6- and 12-month
assessments were followed up by telephone or home visit, or were sent the questionnaires to complete at
home. The key data collected were:
l number of COPD exacerbations requiring antibiotics/OCSs (i.e. moderate/severe exacerbations)
l number of unscheduled hospital admissions
l health-related quality of life [measured using the EuroQol-5 Dimensions, three-level version (EQ-5D-3L)]
l disease-related health status [measured using the COPD Assessment Test (CAT)]
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l modified Medical Research Council (mMRC) dyspnoea score
l post-bronchodilator spirometry (FEV1, FVC)
l health-care utilisation
l adverse reactions and SAEs
l adherence, persistence with trial medication.
Sample size
The sample size was based on the ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate
Endpoints) study, which indicated that, in our trial population, the expected mean number of COPD
exacerbations within 1 year would be 2.22 [standard deviation (SD) 1.86]. An estimated 669 participants
were needed in each trial arm to detect a 15% reduction in COPD exacerbations (i.e. from a mean of 2.22 to
1.89) with 90% power at the 5% significance level. Allowing for 6% loss to follow-up, this was inflated to
712 participants in each trial arm, giving 1424 in total.
Statistical analysis
All analyses were prespecified in the statistical and health economic analysis plan approved in advance of
analysis. All analyses were in accordance with the intention-to-treat (ITT) principle, with a per-protocol
analysis performed as a sensitivity analysis. The per-protocol analysis excluded participants who were not
compliant, with compliance being defined as taking ≥ 70% of their expected doses of trial medication.
Results
Recruitment to the trial took place between 6 February 2014 and 31 August 2016. A total of 1578 people
were randomised: 791 to theophylline and 787 to placebo. Participants were recruited in 121 trial sites
(88 primary care and 33 secondary care); 941 (60%) participants were identified in primary care. There
were 11 post-randomisation exclusions (theophylline, n = 3; placebo, n = 8). A total of 1567 participants
were prescribed trial medication: 788 in the theophylline arm and 779 in the placebo arm. A higher
proportion (26%) of participants than the expected 6% ceased their trial medication. To counteract this,
recruitment continued beyond 1424 participants in the time available; therefore, the total number
recruited was 1578.
The baseline characteristics of the participants allocated to theophylline and placebo were balanced: the
mean age was 68.4 (SD 8.4) years, 54% were male, the mean body mass index (BMI) was 27.2 kg/m2
(SD 6.1 kg/m2), 31.7% smoked, 80% were using inhaled corticosteroids (ICSs)/long-acting β2-agonists
(LABAs)/long-acting muscarinic antagonists (LAMAs), the mean FEV1 was 51.7% (SD 20.0%) predicted,
13.6% had very severe airflow obstruction (i.e. FEV1 of < 30% predicted), 37.7% had severe airflow
obstruction (i.e. FEV1 of 30–50% predicted), 39.6% had moderate airflow obstruction (i.e. FEV1 of
50–80% predicted) and 9.2% had mild airflow obstruction (FEV1 of > 80% predicted). The mean number
of participants reporting exacerbations in the previous year was 3.6 (SD 2.2). CAT scores indicated that
COPD had a high impact on participants’ lives: the mean CAT score was 22.6 (SD 7.7)] and the mean
EQ-5D-3L utility score was 0.63 (SD 0.28).
Intention-to-treat analysis
Primary outcomes
For the ITT analysis, primary outcome data were available for 98% of participants: 772 in the theophylline
arm and 764 in the placebo arm. There were 1489 person-years of follow-up data. In total, there were
3430 exacerbations (theophylline; n = 1727; placebo, n = 1703), the mean number of exacerbations in
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participants allocated to theophylline was 2.24 (SD 1.99) and for participants allocated to placebo it was
2.23 (SD 1.97) [unadjusted incidence rate ratio (IRR) 1.00, 95% confidence interval (CI) 0.92 to 1.09;
adjusted IRR 0.99, 95% CI 0.91 to 1.08].
As there was no statistically significant difference in the exacerbation rate between treatment arms, the
economic analysis was limited to a within-trial analysis. There was a significant difference in unadjusted mean
total costs (£452, 95% CI £133 to £771), which were higher in the placebo arm than in the theophylline
arm. This was driven by a significant difference in exacerbation costs between arms of £447 (95% CI £186 to
£709). This difference was a result of higher costs in the placebo arm for hospitalisations. After adjusting mean
costs for baseline characteristics, there was no significant difference between arms in either exacerbation or
total costs, although total costs were £222 (95% CI –£27 to £472) higher in the placebo arm.
Adjusted mean QALYs were 0.621 [standard error (SE) 0.006] in the theophylline arm and 0.616 (SE 0.007)
in the placebo arm; there was no significant difference between arms. Overall, theophylline dominates
placebo, with lower costs and higher QALYs. However, this result is not significant and care should be taken
when interpreting it.
Secondary outcomes
There were 319 severe COPD exacerbations treated in hospital: 134 in the theophylline arm and 185 in the
placebo arm. The mean number of severe COPD exacerbations treated in hospital was 0.17 (SD 0.49) in
the theophylline arm and 0.24 (SD 0.66) in the placebo arm (unadjusted IRR 0.72, 95% CI 0.55 to 0.95;
adjusted IRR 0.72, 95% CI 0.55 to 0.94). However, 39 of the 51 excess hospital admissions in the placebo
group were accounted for by 10 participants having three or more exacerbations. Low-dose theophylline
had no significant effect on non-COPD-related hospital admissions (adjusted IRR 0.99, 95% CI 0.71
to 1.38), episodes of pneumonia (incidence 1.5%, unadjusted IRR 1.55, 95% CI 0.67 to 3.62), FEV1%
predicted (adjusted mean difference –0.56, 95% CI –2.42 to 1.30), CAT score (adjusted marginal mean
difference 0.01, 95% CI –0.65 to 0.68), mMRC dyspnoea score [adjusted odds ratio (OR) 1.20, 95% CI
0.88 to 1.63], total mortality (which was 2.5% in the theophylline arm and 1.8% in the placebo arm;
p = 0.400) or COPD-/respiratory-related mortality (which was 0.9% in the theophylline arm and 1.1% in
the placebo arm; p = 0.762).
Low-dose theophylline was not associated with a significant increase in adverse reactions (ARs) or SAEs: the
percentage of participants reporting ARs was 48.1% in the theophylline arm and 43.9% in the placebo arm
(p = 0.116), the total number of ARs was 883 in the theophylline arm and 818 in the placebo arm and the
percentage of participants reporting SAEs was 13.2% in the theophylline arm and 14.0% in the placebo
arm (p = 0.616). There were no differences in the profiles of ARs or SAEs between the theophylline and
placebo arms.
Per-protocol analysis
Primary outcome
Of the 1578 participants randomised, 1567 were prescribed trial medication, of whom 31 were missing
some primary outcome data: 16 in the theophylline arm and 15 in the placebo arm. Adherence/compliance
was < 70% for 356 participants: 181 (23.4%) in the theophylline arm and 175 (22.9%) in the placebo arm
(p = 0.802). The reasons given by participants for ceasing trial medication and the numbers reporting each
reason were the same in the theophylline and placebo arms.
For the per-protocol analysis, primary outcome data were available for 1180 (75%) participants, 591 in
the theophylline arm and 589 in the placebo arm; there were 1146 person-years of follow-up data. There
were 2556 exacerbations: 1298 in the theophylline arm and 1258 in the placebo arm. The mean number
of exacerbations in participants allocated to theophylline was 2.20 (SD 1.96), and in participants allocated
to placebo it was 2.14 (SD 1.92) (unadjusted IRR 1.02, 95% CI 0.92 to 1.13; adjusted IRR 1.00, 95% CI
0.91 to 1.10).
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Secondary outcomes
There were 218 severe COPD exacerbations treated in hospital: 92 in the theophylline arm and 126 in the
placebo arm. The mean number of severe COPD exacerbations treated in hospital was 0.16 (SD 0.45) in
the theophylline arm and 0.21 (SD 0.61) in the placebo arm (adjusted IRR 0.70, 95% CI 0.50 to 0.97).
For the other secondary outcomes, the per-protocol analysis did not differ significantly from the results of
the ITT analysis.
Conclusions
This is the first pragmatic, double-blind, randomised, placebo-controlled trial to assess the effectiveness of
adding low-dose theophylline to a drug regimen containing ICSs in people with COPD at high risk of
exacerbation. The analyses demonstrated that, overall, low-dose theophylline has no clinical or health
economic benefit.
Implications for health care
This is the largest trial of low-dose theophylline in COPD to date. National and international COPD guidelines
will need to consider the findings of this trial when making recommendations on the treatment of COPD
and the prevention of COPD exacerbations.
Recommendations for research
A further study investigating the clinical effectiveness and cost-effectiveness of low-dose theophylline in
reducing severe COPD exacerbations requiring admission to hospital needs careful consideration. Such a
study would necessarily be very large.
Trial registration
This trial is registered as ISRCTN27066620.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Chronic obstructive pulmonary disease (COPD) is defined by the Global Initiative for Chronic ObstructiveLung Disease (GOLD) as:
a common preventable and treatable disease characterised by persistent airflow limitation that is
usually progressive and associated with an enhanced chronic inflammatory response in the airways
and the lungs to noxious particles or gases. Exacerbations and comorbidities contribute to the overall
severity in individual patients.
Global Strategy for the Diagnosis, Management and Prevention of COPD.1 Reproduced with
permission from GOLD. © GOLD 2017
People with COPD typically present with breathlessness on exertion, a productive cough and wheeze. COPD
is usually diagnosed from the age of 40 years onwards and prevalence increases with age.2 In Westernised
countries, COPD is predominantly (80–90%) caused by cigarette smoking,3 but outdoor air pollution and
occupational exposure to dusts, vapours and fumes can be significant contributory factors.4,5 COPD is closely
associated with social deprivation, and makes a major contribution to health inequalities in the UK.6 The
progressive airflow limitation of COPD is associated with increasing disability, work absence, long-term
morbidity, common physical and psychological comorbidities and premature mortality. People with COPD
are more likely to have associated comorbidities,7 including ischaemic heart disease,8 hypertension,9 heart
failure,10,11 diabetes mellitus,12 osteoporosis,13 depression14 and lung cancer,15 which increase morbidity and
complicate the management of COPD.7
Acute deteriorations in symptoms, known as exacerbations, are an important clinical feature of COPD. These
are usually precipitated by viral/bacterial infection and/or air pollution and are characterised by increasing
breathlessness and/or cough, sputum expectoration and malaise. Many exacerbations are severe enough
for patients to seek medical help, which usually takes the form of antibiotics and/or corticosteroids from
their general practitioner (GP); more severe exacerbations frequently necessitate admission to hospital for
more intensive treatment. Exacerbations are associated with accelerated rate of lung function decline,16
reduced physical activity,17 reduced quality of life (QoL),18 increased mortality19 and increased risk of
comorbidities such as acute myocardial infarction and stroke.20
The observational Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE)
study of 2138 COPD patients shed light on factors that influence COPD exacerbations.21 This study identified
a frequent exacerbator (defined as two or more exacerbations in a year) phenotype that affects ≈25% of
COPD patients. Patients with this phenotype have an 84% chance of at least one exacerbation in the
subsequent year; moreover, this frequent exacerbator phenotype is stable for at least 3 years and can be
reliably identified by patient recall. This has been supported by further work demonstrating that the strongest
predictor for exacerbations is the number of exacerbations in the preceding year.22 Frequent exacerbators
account for a disproportionate amount of the annual NHS spend on COPD.
The burden of chronic obstructive pulmonary disease on individuals
and the NHS
Chronic obstructive pulmonary disease is a major personal and public health burden.23,24 Data from 591
UK general practices comprising The Health Improvement Network (THIN) indicate that the prevalence of
diagnosed COPD in the UK increased from ≈991,000 in 2004 to 1.2 million in 2012.2 COPD is the fifth
leading cause of death in the UK, accounting for ≈5% of all deaths (≈30,000 deaths in 2014). More than
80% of COPD patients, irrespective of disease severity, report a reduced QoL.24–26 Comorbidities are an
important feature of COPD, contributing to ill health and treatment burden. It has been estimated that,
in the UK, 33% of people with COPD have hypertension, 19% have ischaemic heart disease, 18% have
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depression, 11% have diabetes mellitus and 6% have heart failure.23 Over 50% of people currently
diagnosed with COPD in the UK are < 65 years of age, and 24 million working days are lost each year
as a result of COPD, with £3.8B per year being lost through reduced productivity.23
Chronic obstructive pulmonary disease costs the NHS > £1B per year. In 2001, average annual NHS direct costs
were £819 (> £1300 in severe COPD) for each COPD patient; 60% of this was accounted for by exacerbations
and 19% was due to drug costs.27 The Hospital Episode Statistics database shows that emergency hospital
admissions for exacerbations of COPD in the UK have steadily increased as a percentage of all admissions, from
0.5% in 1991 to 1% in 2000 and to 1.5% in 2008/9.28 In 2008/9, COPD exacerbations resulted in 164,000
hospital admissions in the UK, with an average length of stay of 7.8 days, accounting for 1.3 million bed-days.28
COPD is the second leading cause of emergency admission to hospital in the UK and is one of the most
costly inpatient conditions treated by the NHS.23,24 At least 10% of emergency admissions to hospital are as a
consequence of COPD, and this proportion is even greater during winter. Approximately 25% of patients who
have been diagnosed as having COPD are admitted to hospital at some point, and ≈15% of COPD patients are
admitted each year.23,24 Over 30% of patients admitted to hospital with an exacerbation of COPD are re-admitted
within 30 days, and an average of 12% of COPD patients die in the year following admission to hospital.19
Despite advances in management that have led to the current National Institute for Health and Care
Excellence (NICE) COPD guidelines,24 there is still an unmet need for improved pharmacological treatment
of COPD, particularly the prevention of exacerbations.
Standard chronic obstructive pulmonary disease therapy
Standard COPD therapy remains suboptimal. At the time when the Theophylline With Inhaled CorticoSteroid
(TWICS) trial was conceived, most international COPD management guidelines recommended the use of
inhaled corticosteroids (ICSs) – usually in combination with inhaled long-acting β2-agonists (LABAs), known
as ICS/LABA – to reduce COPD exacerbation rates and to improve lung function and QoL.1,24 Although
more recent guidelines advocate the use of LABAs in combination with long-acting muscarinic antagonists
(LAMAs), ICS/LABA and ICS/LABA/LAMA combinations remain major therapeutic options and continue to
be used very widely in the treatment of COPD.29,30 However, when compared with the marked responses
observed in asthma, ICSs in COPD fail to fully suppress airway inflammation and patients continue to
have exacerbations despite high ICS doses. Furthermore, little or no positive impact of ICS on mortality or
disease progression is evident31,32 and concerns have been raised about long-term sequelae of high-dose
ICS use in COPD.33,34 A relative insensitivity of COPD airway inflammation to the anti-inflammatory effects
of high-dose ICS has been demonstrated in induced sputum and airway biopsies of people with COPD.35–37
In recent years, molecular mechanisms contributing to the reduced corticosteroid sensitivity of COPD have been
elucidated. The chronic airway inflammation of COPD is driven by expression of multiple inflammatory genes
regulated by acetylation of core histones, which open up the chromatin structure, allowing transcription factors
and ribonucleic acid (RNA) polymerase II to bind to deoxyribonucleic acid (DNA), enabling gene transcription
and increased synthesis of inflammatory proteins.38 In COPD, there is increased acetylation of core histones
associated with the promoter regions of inflammatory genes, with the degree of acetylation being positively
associated with disease severity.39 Histone acetylation is reversed by histone deacetylase (HDAC) enzymes.
Corticosteroids appear to work by reversing histone acetylation through the recruitment of a specific HDAC
called HDAC2,38,40,41 thereby switching off activated inflammatory genes. In people with COPD, increased
histone acetylation appears to be a consequence of markedly reduced HDAC2 activity/expression in airways,
lung tissue and alveolar macrophages.39 It has been shown that the oxidative stress of COPD activates the
enzyme phosphoinositide 3-kinase (PI3K)-δ, which then phosphorylates downstream kinases, resulting
in the phosphorylation and inactivation of HDAC2.41,42 The critical role played by reduced HDAC2 in the
corticosteroid resistance of COPD is demonstrated by the finding that the corticosteroid resistance of COPD
bronchoalveolar macrophages is completely reversed by overexpressing HDAC2 (using a plasmid vector) to
levels seen in control patients without COPD.40
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Low-dose theophylline may have synergistic anti-inflammatory effects
with corticosteroids
Oral theophylline has been used in the treatment of COPD for > 70 years, but usually at doses required to
achieve relatively high blood concentrations (10–20mg/l). It has been observed that the reduced HDAC2
activity of COPD can be reversed in a dose-dependent manner by low doses of theophylline; moreover,
low-dose theophylline reduces corticosteroid insensitivity in COPD such that there is a marked synergistic
interaction between theophylline and corticosteroids in suppressing the release of inflammatory mediators
from alveolar macrophages from COPD patients. This in vitro work has shown that at (low) concentrations
of 1–5mg/l theophylline increases HDAC2 activity (sixfold) but at (high) concentrations of over ≈10mg/l
theophylline inhibits rather than stimulates HDAC2 activity.43,44 These studies show that at concentrations of
1–5mg/l, there is a marked synergistic effect between theophylline and corticosteroids, with theophylline
inducing a 100- to 10,000-fold increase in the suppressive effect of corticosteroids on the release of
pro-inflammatory mediators. Such an increase in corticosteroid potency is worthy of clinical interest, particularly
if associated with reduced exacerbation rate. An explanation for the ability of low-dose (i.e. 1–5 mg/l)
theophylline to increase HDAC activity has been described: it specifically inhibits the enzyme PI3K-δ with
consequent restoration of HDAC2 activity to normal in COPD macrophages, rendering them steroid responsive.
In mice exposed to cigarette smoke,42 steroid-resistant lung inflammation has also been found to be reduced
by low-dose theophylline when given together with steroids. Similarly, rats exposed to cigarette smoke were
found to have markedly decreased lung HDAC2 expression, and that reduced HDAC2 expression was
correlated with increased lung destruction index.45 The increased lung destruction index was restored to
normal with ICS treatment in combination with low- (but not high-) dose theophylline. It was concluded
that low-dose theophylline might provide protection from cigarette smoke damage and improve the
anti-inflammatory effects of steroids by increasing HDAC2 activity.
In human peripheral blood mononuclear cells, corticosteroid insensitivity and reduced HDAC2 activity
after oxidative stress have been shown to be reversed with low concentrations of theophylline.46 In a
study of human alveolar macrophages extracted from resected lung samples, the addition of hydrogen
peroxide reduced HDAC expression and was associated with an increase in interleukin 8 (IL-8) and matrix
metalloproteinase-9 (MMP-9) release.47 The addition of low-dose theophylline restored HDAC expression to
levels above that observed with LABA, ICS and ICS/LABA.
These basic research studies suggest that low-dose (i.e. 1–5mg/l) theophylline could increase HDAC activity and
hence reduce corticosteroid resistance in COPD patients, thereby enabling ICS to switch off inflammation and
potentially reduce exacerbation rates more effectively. This is supported by findings from two small randomised
controlled trials (RCTs) and a population-based health administration database study. The first RCT in 35
patients with acute COPD exacerbations found that low-dose theophylline increased responsiveness to
corticosteroids as measured by increased HDAC activity and further reduced concentrations of pro-inflammatory
mediators in induced sputum compared with ICSs alone.48 In the second small (n = 30) pilot RCT of COPD
patients, the combination of low-dose theophylline with high-dose ICSs was associated with increased HDAC
activity, improved lung function and reduced sputum inflammatory cells and mediators, whereas either drug
alone was ineffective.49 A Canadian health administration database study of 36,492 COPD patients reported
that treatment with theophylline alone or in combination with ICS was more protective against exacerbations
than treatment with LABA or ICS/LABA [relative risk (RR) 0.89, 95% confidence interval (CI) 0.87 to 0.92].50
More recent studies, however, have not replicated the results of earlier studies. Fexer et al.51 used data
from a German ambulatory COPD management programme and closely matched 1496 COPD patients
commenced on theophylline with 1496 COPD patients not commenced on theophylline. The use of
theophylline was associated with an increased likelihood of exacerbation [hazard ratio (HR) 1.41, 95% CI
1.24 to 1.60] and hospital admission (HR 1.61, 95% CI 1.29 to 2.01). Although it was concluded that
theophylline is associated with an increased incidence of exacerbations and hospitalisations, it should be
noted that this study did not identify those patients on low-dose theophylline.51 The Spanish Low-dose
Theophylline as Anti-inflammatory Enhancer in Severe Chronic Obstructive Pulmonary Disease (ASSET) trial
DOI: 10.3310/hta23370 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 37
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Devereux et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
3
recruited patients with COPD while hospitalised for a COPD exacerbation and randomised to low-dose
theophylline (100 mg twice a day) or matched placebo in addition to usual ICS/LABA treatment.52 In total,
70 patients were randomised (theophylline, n = 36; placebo, n = 34) and 46 completed the year of treatment
(theophylline, n = 23; placebo, n = 23). The addition of theophylline had no effect on the COPD exacerbation
rate or plasma/sputum concentrations of HDAC and inflammatory mediators. It should be noted that the
study was small and designed to detect a 50% reduction in exacerbations.
Conventionally, oral theophylline has been used as a bronchodilator in COPD; however, to achieve modest
clinical effects, relatively high blood concentrations (of 10–20mg/l) are required. The bronchodilator effect
of high-dose theophylline is the consequence of inhibition of phosphodiesterase (PDE) and the consequent
relaxation of airway smooth muscle. However, non-specific inhibition of PDE by theophylline is also associated
with a wide range of well-recognised side effects that may occur within the conventional therapeutic range of
plasma theophylline, namely nausea, gastrointestinal upset, headaches, insomnia, seizures, cardiac arrhythmias
and malaise. Theophylline toxicity is dose related, and this is an issue with conventional theophylline use
because the therapeutic ratio of theophylline is small and most of the beneficial bronchodilator effect occurs
when near-toxic doses are given.53 Theophylline is metabolised by cytochrome P450 mixed function oxidase;
as a consequence, theophylline use is further complicated by significant drug interactions with drugs commonly
prescribed to people with COPD, for example clarithromycin or ciprofloxacin.54 The narrow therapeutic index,
modest clinical effect and side effect profile of theophylline, together with drug interactions, the need for blood
concentration monitoring and the availability of more effective inhaled therapies, have resulted in current COPD
guidelines relegating high-dose theophylline to third-line therapy.1
The TWICS trial was a pragmatic, double-blind, randomised, placebo-controlled clinical trial that was built
on emerging evidence that low-dose (i.e. 1–5 mg/l) theophylline may produce a beneficial synergistic effect
in COPD by increasing the corticosteroid sensitivity of the airway inflammation underlying COPD and,
as a consequence, reduce the rate of COPD exacerbation when used in conjunction with ICSs.
Hypothesis
The hypothesis being tested was that the addition of low-dose theophylline to ICS therapy in COPD reduces
the risk of COPD exacerbation requiring treatment with antibiotics and/or oral corticosteroids (OCSs) during the
year of treatment, delivers QoL improvements and is cost-effective.
Objectives
The primary objective of the trial was to determine the clinical effectiveness and cost-effectiveness of adding
low-dose theophylline to ICS therapy in patients with COPD and a history of two or more exacerbations
treated with antibiotics and/or OCSs in the previous year in relation to the number of exacerbations in the
1-year treatment period requiring therapy with antibiotics and/or OCSs.
The secondary objectives were to compare the following outcomes between participants treated with
low-dose theophylline and those treated with placebo:
l hospital admissions with a primary diagnosis of exacerbation of COPD
l total number of episodes of pneumonia
l total number of emergency hospital admissions
l lung function
l all-cause and respiratory mortality
l drug reactions and serious adverse events (SAEs)
l health-related QoL
l disease-specific health status
INTRODUCTION
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l total ICS dose/usage
l health-care utilisation
l incremental cost per exacerbation avoided
l lifetime cost-effectiveness based on extrapolation modelling
l modelled lifetime incremental cost per quality-adjusted life-year (QALY).
An additional secondary objective was the time to the first exacerbation of COPD.
Outcomes
Primary outcomes
The primary outcome was the total number of exacerbations of COPD necessitating changes in
management (minimum management change: use of OCSs and/or antibiotics) during the 1-year treatment
period, as reported by the participant.
The primary economic outcome was cost per QALY gained during the 1-year treatment period.
Secondary outcomes
l Total number of COPD exacerbations requiring hospital admission.
l Total number of episodes of pneumonia.
l Total number of emergency hospital admissions (all causes).
l Lung function [forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC)] post
bronchodilator, measured using spirometry performed to American Thoracic Society (ATS)/European
Respiratory Society (ERS) standards.
l All-cause and respiratory mortality.
l Serious adverse events and adverse reactions (ARs).
l Total dose of ICS.
l Utilisation of primary or secondary health care for respiratory events.
l Disease-specific health status measured using the COPD Assessment Test (CAT) and modified Medical
Research Council (mMRC) dyspnoea scale.
l Generic health-related QoL measured using the EuroQoL-5 Dimensions, three-level version (EQ-5D-3L)
index.
l Modelled lifetime incremental cost per QALY.
An additional secondary outcome was the time to the first exacerbation of COPD.
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Chapter 2 Methods/design
Trial design
The trial protocol has been published in an open-access journal.55
The TWICS trial was a pragmatic, double-blind, randomised, placebo-controlled, parallel-arm, UK multicentre
clinical trial that compared the addition of low-dose theophylline or placebo for 52 weeks with current
COPD therapy that included ICSs in patients with COPD who had experienced two or more exacerbations of
COPD in the previous year treated with OCSs and/or antibiotics. The aim was to recruit 1424 participants,
with at least 50% recruited in primary care. The trial was approved by Scotland A Research Ethics Committee
(REC) (reference number 13/SS/0081) and the Medicines and Healthcare products Regulatory Agency (MHRA)
(EudraCT 2013-001490-25, Clinical Trial Authorisation 21583/0218/001). All participants provided written
informed consent, which included consent to inform a participant’s GP of involvement in the trial and
consent to pass on a participant’s name and address to a third-party distributer that delivered the trial
drug to participants’ homes. Figure 1 provides a schematic representation of the trial design and schedule.
Face-to-face trial assessments were carried out at recruitment/baseline and at 6 and 12 months, as shown
in Figure 2.
The trial was registered on 19 September 2013 as ISRCTN27066620.
Participants
Inclusion criteria
The participants in the TWICS trial were people with COPD who were likely to experience an exacerbation
during the 52-week treatment period as evidenced by two or more exacerbations of COPD in the previous
6 months 12 months
Recruitment/baseline
visit
Placebo tablet (once daily/twice daily)
Patients identified based on
inclusion/exclusion criteria
Oral theophylline (200 mg once daily/twice daily)
Randomisation
FIGURE 1 Trial design.
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year treated with OCSs or antibiotics. Participants had to meet all of the following inclusion criteria,
which are typical of studies of people with COPD with exacerbations as the primary end point:
l aged ≥ 40 years
l a smoking history of ≥ 10 pack-years
l an established predominant respiratory diagnosis of COPD (GOLD/NICE guideline definition:
post bronchodilator FEV1/FVC of < 0.7)1,2
l current use of ICS therapy at the baseline/recruitment visit
l a history of at least two exacerbations requiring treatment with antibiotics and/or OCS use in the
previous year, based on patient report
l clinically stable with no COPD exacerbation for at least the previous 4 weeks
l able to swallow trial medication
l able and willing to give informed consent to participate
l able and willing to participate in the trial procedures, undergo spirometric assessment and complete the
trial questionnaire.
Recruitment/baseline visit
• Assessed for eligibility based on inclusion and exclusion criteria
• Informed consent taken
• Assessment: drug history, smoking history, spirometry, CAT, mMRC dyspnoea score, EQ-5D-3L,
   health-care utilisation
Centre for Healthcare Randomised Trials, University of Aberdeen, web/telephone randomisation service
2-week follow-up telephone call
6-month follow-up
12-month follow-up
12-month review of primary and secondary care records for a sample of participants
Intervention arm
(n = 712)
Oral theophylline 200 mg once or twice
daily depending on ideal body weight and
smoking status
Control arm
(n = 712)
Placebo once or twice daily depending on
ideal body weight and smoking status
Centralised randomisation 
(n = 1424)
• Tolerating trial medication, ARs, SAEs
• Exacerbations, hospital admissions, health-care utilisation, drug history, spirometry, disease-specific
   health status (CAT, mMRC dyspnoea score), generic health-related quality of life (EQ-5D-3L), ARs,
   SAEs, weight, smoking status
• Exacerbations, hospital admissions, health-care utilisation, drug history, spirometry, disease-specific
   health status (CAT, mMRC dyspnoea score), generic health-related quality of life (EQ-5D-3L), ARs, SAEs
• Exacerbations, hospital admissions, health-care utilisation
FIGURE 2 Flow diagram of trial schedule.
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Potential participants with COPD who did not fulfil the lung function criterion of FEV1/FVC of < 0.7 at the
recruitment/baseline visit were asked to complete a slow vital capacity (SVC) manoeuvre, and FEV1/SVC of
< 0.7 was accepted as evidence of airflow obstruction. Historical evidence of FEV1/FVC of < 0.7 was deemed
acceptable for those participants who did not achieve FEV1/FVC of < 0.7 or FEV1/SVC of < 0.7 or who were
unable to complete spirometry at the recruitment/baseline assessment. Eligibility for inclusion was confirmed
by a medically qualified person.
Exclusion criteria
The exclusion criteria for the TWICS trial were typical of studies of people with COPD but also included
criteria specific for theophylline, notably concomitant treatment with drugs that were likely to increase
plasma theophylline concentration above the low-dose range of 1–5 mg/l. Potential participants were
excluded if they fulfilled any of the following criteria:
l severe or unstable ischaemic heart disease
l a predominant respiratory disease other than COPD
l any other significant disease/disorder that, in the investigator’s opinion, put the patient at risk because
of trial participation, or might influence the results of the trial or the patient’s ability to participate in
the trial
l previous allocation of a randomisation code in the trial or current participation in another interventional
study [Clinical Trial of an Investigational Medicinal Product (CTIMP) or non-CTIMP]
l women who were pregnant or breastfeeding, or were planning a pregnancy during the trial period
l current medication includes theophylline
l known or suspected intolerance to theophylline
l current use of drugs known to interact with theophylline and/or increase plasma theophylline54 –
¢ antimicrobials: aciclovir, clarithromycin, ciprofloxacin, erythromycin, fluconazole, ketoconazole,
levofloxacin and norfloxacin
¢ cardiovascular drugs: diltiazem, mexiletine, pentoxifylline and verapamil
¢ neurological drugs: bupropion, disulfiram, fluvoxamine and lithium
¢ hormonal drugs: medroxyprogesterone and oestrogens
¢ immunological drugs: methotrexate, peginterferon alpha and tacrolimus
¢ miscellaneous: cimetidine, deferasirox, febuxostat, roflumilast and thiabendazole.
Patients with COPD as a consequence of alpha-1-antitrypsin deficiency were excluded; however, short- or
long-term use of azithromycin56 or use of topical oestrogens or aciclovir were not exclusion criteria.
Identification
Potential participants were recruited from both primary and secondary care sites across the UK. To ensure
generalisability, the intention was that the majority of participants (> 50%) would be recruited from
primary care. Recruitment strategies differed between centres depending on local geographic and NHS
organisational factors.
Primary care and other community-based services
In England, recruitment from general practices was conducted in conjunction with the National Institute for
Health Research (NIHR) Clinical Research Network (CRN) at the national and local levels. Practices could
participate as independent research sites or as participant identification centres (PICs) for secondary care or
other primary care research sites.
In general practices, the local CRN/collaborating recruitment site/trial office liaised directly with practice
staff who performed database searches (based on search criteria including the use of inhaled preparations
containing corticosteroids, a record of one exacerbation treated with OCSs in the previous year and the
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use of interacting medications) to identify potential participants. Potentially suitable patients were sent an
invitation letter and a participant information leaflet (PIL). For general practices acting as independent
research sites, interested potential participants were invited to contact the practice-based trial team for
more information and to arrange a recruitment visit. For general practices acting as PICs, interested
potential participants were invited to contact the local trial team at the associated secondary or primary
care research site for more information and to arrange a recruitment visit. All invitation material, consent
forms, trial case report forms and participant-completed questionnaires can be found on the project web
page at www.journalslibrary.nihr.ac.uk/programmes/hta/115815/#/ (accessed 23 April 2019).
In Scotland, the Scottish Primary Care Research Network mirrored the role undertaken by the English CRN
by identifying potential participants in primary care, with interested patients being invited to make contact
with a local trial team based in secondary care.
Potential participants were also identified from other community COPD services, such as pulmonary
rehabilitation, COPD community matrons, smoking cessation services and integrated/intermediate care
services for patients with COPD. Potentially suitable participants identified by these services were sent an
invitation letter and a PIL, and if interested, participants were asked to contact the local trial team (usually
in secondary care) for more information and to arrange a recruitment visit.
Secondary care
Potential participants were also identified from patients attending (or who had previously attended)
respiratory outpatient appointments or who had been inpatients at the hospitals of the individual
recruiting centres. Potentially suitable patients were sent an invitation letter and a PIL from a member of
their hospital care team (usually their consultant). Interested patients were invited to contact the local
hospital-based trial team for more information and to arrange a recruitment visit.
Recruitment/baseline visit
At the recruitment visit, a participant’s eligibility was confirmed by a medically qualified doctor and fully
informed consent was recorded in writing. Baseline data (see Data collection) were also collected.
Randomisation/treatment allocation
Participants were randomised, usually by a research nurse, using a computerised randomisation system
available as both an interactive voice response telephone system and an internet-based application; the
internet application was used for all randomisations within the trial. The randomisation service was created
and administered by the Centre for Healthcare Randomised Trials (CHaRT) in the University of Aberdeen.
Consenting participants were stratified by trial centre (for participants recruited in secondary care) or area
(for participants recruited in primary care) and by where the participant had been identified (primary or
secondary care) and then randomised with equal probability to the intervention (low-dose theophylline)
and control (placebo) arms.
The random allocation sequence for the TWICS trial was generated using permuted blocks. This provided
randomly generated blocks of entries of varying sizes permuted for each combination of trial centre/area
and where the participant had been identified (primary or secondary care). Each entry was assigned a
treatment according to a randomly generated sequence utilising block sizes of two or four. Each treatment
option was assigned an equal number of times within each block, ensuring that the total number of entries
assigned to each treatment remained balanced. The sequence of blocks was also random, so it was not
possible for anyone to determine the next treatment to be allocated based on previous allocations made
during the randomisation process.
METHODS/DESIGN
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It was possible to randomise a participant only if the relevant eligibility criteria had been met. In addition
to trial centre/area and where the participant had been identified (primary or secondary care), sex, height,
weight, smoking status (and, for smokers, number of cigarettes per day) and date of birth were captured
during the randomisation process to calculate the correct dosage of trial medication for that participant
and assign an appropriate drug pack.
With this information captured, the randomisation process assigned a trial number (i.e. a participant
identification), allocated a treatment and assigned a drug pack. The user/caller was notified of the trial
number and drug pack either on screen or during the randomisation telephone call. The allocated
treatment remained blinded throughout, with neither the user/caller nor the participant (or anyone
involved in the participant’s care or the assessment of outcomes) made aware of the allocation. All of the
data captured or assigned were saved to a secure database.
The random permuted blocks that defined how treatments were allocated to participants were created
by the CHaRT programming team during the system development process. The system built to utilise
these permuted blocks was tested by a run of simulated randomisations that allowed the outcomes to be
cross-checked and validated. Before the randomisation system went ‘live’, enough blocks were created
to ensure that entries existed for the maximum expected number of participants across the maximum
expected number of trial centres/areas. However, the randomisation system was flexible enough to allow
the option to add further permuted blocks to the list if more were required during the lifetime of the trial.
In such circumstances, randomly generated sequences in blocks of two and four continued to be utilised.
Intervention
The active intervention was 200-mg tablets of Uniphyllin modified release (MR) taken once or twice a day for
52 weeks. The placebo was manufactured to be visually identical, and was also taken once or twice a day for
52 weeks. The packaging and labelling of active and placebo interventions were identical. The intervention
was for 52 weeks of therapy. The 200-mg tablets of Uniphyllin MR and placebo were supplied by Napp
Pharmaceuticals Ltd (Cambridge, UK). Napp Pharmaceuticals Ltd is the holder of the marketing authorisation
for 200-mg tablets of Uniphyllin MR (marketing authorisation number: PL 16950/0066–0068). Uniphyllin
Continus 200 mg, 300 mg and 400 mg is licensed for the treatment and prophylaxis of bronchospasm
associated with COPD, asthma and chronic bronchitis; consequently, theophylline was administered within
licensed indication.54 Placebo tablets were manufactured by Mundipharma Research Ltd (Cambridge, UK).
Dosage
The pre-clinical studies outlined in Chapter 1 demonstrate the critical importance of plasma theophylline
concentration, with plasma concentrations of 1–5mg/l having the maximal effect in reducing corticosteroid
insensitivity, whereas at concentrations of > 10mg/l theophylline is inhibitory, augmenting corticosteroid
insensitivity. Theophylline dosing in the TWICS trial was based on pharmacokinetic modelling57–66 of theophylline,
incorporating the major determinants of theophylline steady-state concentration (Css) [i.e. weight, smoking status
and clearance of theophylline (i.e. low, normal, high)], and was designed to achieve a Css plasma theophylline of
1–5mg/l, and to certainly be < 10mg/l (> 10mg is the concentration associated with high-dose theophylline,
possible side effects and augmentation of corticosteroid insensitivity). For full details, see Appendix 1.
The dosing of both the interventional arm (200-mg tablets of Uniphyllin MR) and the control arm (placebo
tablets) was determined by a participant’s ideal body weight (IBW) and self-reported smoking status:
l A dose of 200 mg of theophylline MR (one tablet) once daily (or one placebo once daily) was taken by
participants who did not smoke, or participants who smoked but had an IBW of ≤ 60 kg.
l A dose of 200 mg of theophylline MR (one tablet) twice daily (or one placebo twice daily) was taken by
participants who smoked and had an IBW of > 60 kg.
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Ideal body weight was used unless a participant’s actual weight was lower than the ideal body weight; in
such cases, actual body weight was used to determine dose.
Ideal body weight was calculated using the following standard equations:67
IBW female = 45 + ½0.9 (height in cm – 152) kg, (1)
IBW male = 50 + ½0.9 (height in cm – 152) kg: (2)
For the calculation of dose, to be classed as a ‘non-smoker’ at recruitment, a participant must have
abstained from smoking for ≥ 12 weeks. Participants who had given up smoking recently (< 12 weeks ago)
were classed as smokers.
Protocol-defined changes in dose during the treatment period
Table 1 summarises changes in dose during the treatment period based on changes in smoking status or
weight.
Changes in smoking status
Changes in smoking status are known to influence the pharmacokinetics of theophylline (smokers clear
the drug more rapidly). Self-reported smoking status was checked at every contact and participants were
advised, in writing and verbally, to contact their trial team if their smoking status changed during the
treatment period. Participants who stopped smoking during the treatment period were reclassified as
‘non-smokers’ if they abstained from smoking for ≥ 12 weeks. Smoking participants whose IBW (and
actual body weight) was > 60 kg and who stopped smoking had their dose reduced to 200 mg once daily
(od) (one tablet once a day); those with an IBW of ≤ 60 kg maintained their 200 mg od dose. Participants
who started smoking during the treatment period were reclassified as ‘smokers’ when they had smoked
for ≥ 12 weeks. Non-smoking participants whose IBW (and actual body weight) was > 60 kg and who
started smoking had their dose increased to 200 mg twice a day (bd) (one tablet twice a day).
TABLE 1 Protocol-defined changes in dose during the trial
Characteristics at baseline
Initial
dose
Changes to smoking during
follow-up Changes to weight during follow-up
IBW (kg) ABW (kg)
Smoking
status
Change to
smoking status Dose change Change to weight Dose change
> 60 > 60 Smoker bd Stop smoking Reduce to od Lose; ABW now ≤ 60 kg Reduce to od
> 60 ≤ 60 Smoker od Stop smoking No change Gain; ABW now > 60 kg Increase to bd
≤ 60 > 60 Smoker od Stop smoking No change Lose; ABW now ≤ 60 kg No change
Gain No change
≤ 60 ≤ 60 Smoker od Stop smoking No change Gain No change
> 60 > 60 Non-smoker od Start smoking Increase to bd Lose; ABW now ≤ 60 kg No change
Gain No change
> 60 ≤ 60 Non-smoker od Start smoking No change Gain No change
≤ 60 > 60 Non-smoker od Start smoking No change Lose; ABW now ≤ 60 kg No change
Gain No change
< 60 ≤ 60 Non-smoker od Start smoking No change Gain No change
ABW, actual body weight; bd twice a day; od, once daily.
METHODS/DESIGN
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Changes in weight
Changes in weight are known to influence the pharmacokinetics of theophylline. Participants who smoked
and had an IBW of > 60 kg but an actual body weight of ≤ 60 kg had their dose reduced to 200 mg od.
Participants who smoked and had an IBW of > 60 kg but whose actual body weight increased to > 60 kg
had their dose increased to 200 mg bd.
Changes in concomitant medication
When informed of their patient’s participation in the trial, GPs were advised to manage their patient for
exacerbations as per normal clinical practice but to assume that the participant was taking low-dose
theophylline. GPs were advised to avoid, whenever possible, prescribing drugs that were likely to increase
plasma theophylline concentrations; they were provided with a list of such drugs. In the event that drugs
known to increase theophylline concentration had to be prescribed for ≤ 3 weeks, GPs/participants were
asked to suspend the trial medication and recommence it after the course of the interacting drug had
been completed, for example prescription of clarithromycin for an exacerbation of COPD. If the interacting
drug was to be prescribed for > 3 weeks, GPs/participants were asked to discontinue the trial medication
but remain in the trial, and were followed up in accordance with the trial protocol.
Participants were asked to carry a trial card and to show this to anyone prescribing medication for them.
This advised the prescriber to assume that the participant was taking low-dose theophylline and included
a link to the list of drugs that may increase plasma theophylline concentrations.
Theophylline in the form of intravenous aminophylline is sometimes used in the treatment of severe acute
exacerbations of COPD in the hospital setting. It was anticipated that, during the trial, some participants would
be hospitalised with life-threatening exacerbations of COPD and that the treating physician may wish to use
intravenous aminophylline. The commonly used clinical protocol for intravenous aminophylline was established
during the era of high-dose oral theophylline, when patients would be prescribed oral theophylline aiming for
a plasma concentration of 10–20 mg/l and a loading dose of aminophylline would raise plasma theophylline
concentrations to toxic concentrations (i.e. > 20mg/l). For a patient not established on oral theophylline, the
intravenous protocol comprises a bolus of intravenous aminophylline (usually 250mg, or 5 mg/kg) followed by
a maintenance dose (0.5 mg/kg/hour). For a patient established on oral theophylline, the bolus dose is omitted
(because of concerns regarding toxicity) and a maintenance infusion (0.5 mg/kg/hour) is commenced. In the
era of high-dose theophylline, it was critical to establish if a patient was taking oral theophylline before a
physician started a patient on intravenous aminophylline.
Pharmacokinetic modelling of the low-dose theophylline dosing regimen demonstrated that a 250-mg
(or 5 mg/kg if a participant’s weight was < 50 kg) loading dose of aminophylline could be administered to trial
participants and their plasma theophylline would remain within the therapeutic high-dose bronchodilating
concentration of 10–20mg/l (see Appendix 1). As per guideline recommendations for plasma theophylline
monitoring,24 we advised that plasma theophylline be measured 24 hours after commencing intravenous
aminophylline (allocation status would not be discernible from such a concentration). The trial drug was
discontinued during intravenous aminophylline therapy, but restarted after discontinuation of intravenous
aminophylline therapy.
The advice regarding use of intravenous aminophylline was summarised on a participant’s trial card.
In reality, no treating physician contacted the trial team with concerns about intravenous aminophylline.
Supply of trial medication
Each participant received their first bottle of 4 weeks of trial medication (or placebo) from a participating
clinical trials pharmacy. For secondary care sites, this was usually the clinical trials pharmacy based at that
secondary care site. For participants recruited in primary care study sites, the first bottle of medication was
dispensed from the clinical trials pharmacy in NHS Grampian and couriered to a participant’s address.
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Each participant also received two further supplies of six bottles (each bottle being a 4-week supply).
These supplies were dispatched to participants by a third party (AndersonBrecon, Hereford, UK) and
delivered to participants’ addresses via a courier. These shipments were made around weeks 3 and 27 to
enable continuity of supply. Receipt of trial medication to a participant’s home address was confirmed by
signature on receipt.
Data collection
Baseline, outcome and safety data were collected by face-to-face assessments conducted at recruitment/
baseline (week 0), 6 months (week 26) and 12 months (week 52). Participants were telephoned 2 weeks
after starting the trial medication to ensure that they were tolerating the medication. The schedule for data
collection in the trial is outlined in Table 2. If a participant was unable to attend a scheduled follow-up
assessment visit because of an acute illness, for example exacerbation of COPD, or other reasons, the visit was
postponed and the participant was assessed within 4 weeks of the scheduled assessment visit. Participants
unable to attend a face-to-face assessment at 6 and 12 months were followed up by telephone or home visit,
or were sent the questionnaires to complete at home.
The following data were collected.
Demographic and clinical data
Demographic, contact, clinical history and, if necessary, clinical examination data were captured at the
recruitment visit.
TABLE 2 Schedule of trial assessments
Assessment
Time point
Post-study
GP recordsRecruitment
2 weeks
(telephone)
Month 6
(face to face)
Month 12
(face to face)
Assessment of eligibility criteria ✓
Written informed consent ✓
Demographic data; contact details ✓
Clinical history ✓
Drug history ✓ ✓ ✓
Smoking status ✓ ✓ ✓ ✓
Height ✓
Weight ✓ ✓ ✓
Total number of COPD exacerbations
requiring OCSs/antibiotics
✓ ✓ ✓
Hospital admissions ✓ ✓ ✓
Health-related quality of life ✓ ✓ ✓
Disease-related health status
(CAT, mMRC dyspnoea, HARQ)
✓ ✓ ✓
Post-bronchodilator lung function ✓ ✓ ✓
AEs/drug reactions ✓ ✓ ✓
Health-care utilisation ✓ ✓ ✓
Patient compliance ✓ ✓
AE, adverse event; HARQ, Hull Airway Reflux Questionnaire.
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Drug history
Regular use of prescription drugs was recorded at recruitment and at the 6- and 12-month assessments.
ICS use was checked at recruitment and at 6 and 12 months. Many participants brought their repeat
prescription list with them to the assessments. Participants were asked how many times a day they used
their ICS preparation and the dose.
Smoking history
Smoking history (i.e. age commenced, age ceased and average number of cigarettes smoked per day)
and current smoking status were recorded at recruitment, and pack-year consumption was computed.
At the 6- and 12-month assessments, current smoking status was recorded.
Height and weight
Height was measured using clinic stadiometers at baseline. Weight was assessed using clinic scales at
recruitment and at the 6- and 12-month assessments.
Number of chronic obstructive pulmonary disease exacerbations
The primary outcome measure of the total number of COPD exacerbations requiring antibiotics/OCSs while
on trial medication was ascertained at the 6- and 12-month assessments. Participants were encouraged
to record any exacerbations in a space provided on the outer packaging (carton) used to ship medication
or on the participant follow-up card, and to bring this to their follow-up assessments. If follow-up at
12 months could not be completed, GPs were contacted and asked to provide information on the number
of exacerbations experienced by the participant in the treatment period, and whether or not these resulted
in hospital admission.
The ATS/ERS guideline definition of COPD exacerbation was used: a worsening of a patient’s dyspnoea,
cough or sputum beyond day-to-day variability sufficient to warrant a change in management.55,68 The
minimum management change was treatment with antibiotics or OCSs. A minimum of 2 weeks between
consecutive hospitalisations or the start of a new therapy was necessary to consider events as separate.
A modified ATS/ERS operational classification of exacerbation severity was used for each exacerbation:68
l level I – increased use of a short-acting β2 agonist (SABA) (mild)
l level II – use of OCSs or antibiotics (moderate)
l level III – care by services to prevent hospitalisation (moderate)
l level IV – admitted to hospital (severe).
An exercise to validate patient-reported exacerbations was carried out (see Appendix 2).
Hospital admissions
The number of unscheduled hospital admissions while on trial medication was ascertained at the 6- and
12-month assessments. Emergency admissions consequent on COPD were also identified. Participants were
encouraged to record any hospital admissions in the space provided on the outer packaging (carton) used
to ship medication or on the participant follow-up card, and to bring this to their follow-up assessments.
If follow-up at 12 months could not be completed, participants’ GP or hospital records were checked to
ascertain the number of hospital admissions during the treatment period.
Health-related quality of life
Health-related quality-of-life data were captured at recruitment and at the 6- and 12-month assessments
by questionnaire using the EQ-5D-3L index,69,70 which has been used widely in studies of COPD. The
completed instrument can be translated into quality-of-life utilities suitable for calculation of QALYs
through the published UK tariffs.71
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Disease-related health status
Disease-related health status was ascertained at recruitment and at the 6- and 12-month assessments by
participant completion of the CAT.71–74 CAT is an eight-item unidimensional measure of the impact of
COPD on a patient’s health. CAT has a scoring interval of 0–40, with 0–5 being the norm for healthy
non-smokers and > 30 being indicative of a very high impact of COPD on quality of life.72 CAT is reliable
and responsive, correlates very closely with the St George’s Respiratory Questionnaire and is preferred
because it provides a more comprehensive assessment of the symptomatic impact of COPD and is shorter
and, thus, easier to complete.72–74
Participants were also asked to grade their breathlessness using the mMRC dyspnoea scale at recruitment
and at the 6- and 12-month assessments.75 The mMRC dyspnoea scale has been in use for many years to
grade the effect of breathlessness on daily activities. The mMRC dyspnoea scale is a single question that
assesses breathlessness related to activities; the scoring interval is 0–4, with 0 being ‘not troubled by
breathlessness except on strenuous exercise’ and 4 being ‘too breathless to leave the house, or breathless
when dressing or undressing’. The mMRC score has been validated against walking test performance and
other metrics of COPD health status, for example the St George’s Respiratory Questionnaire.76
In self-selected recruitment centres, the Hull Airway Reflux Questionnaire (HARQ) was completed by
participants at recruitment and at 6 and 12 months. HARQ was used to assess symptoms not elucidated by
CAT or the mMRC dyspnoea scale. HARQ is a validated, self-administered questionnaire that is responsive
to treatment effects.77
Post-bronchodilator lung function
Lung function was measured at recruitment and at 6 and 12 months using spirometry performed to ATS/ERS
standards.78 Spirometry is a routine part of the clinical assessment of people with COPD. Post-bronchodilator
(LABA within 8 hours, SABA within 2 hours) FEV1 and FVC were measured. If necessary, lung function
was measured 15 minutes after administration of a participant’s own SABA. The European Coal and Steel
Community predictive equations were used to compute predicted values for FEV1 and FVC.79 When spirometry
was contraindicated, or participants were not able to complete spirometry, it was omitted.
Health-care utilisation
Health-care utilisation during the previous 6 months was ascertained at recruitment and at the 6- and
12-month assessments using a modified version of the Client Service Receipt Inventory (CSRI).80 CSRI is a
research questionnaire for retrospectively collecting cost-related information about a participant’s use of
health and social care services.
Adverse reactions and serious adverse events
This trial complied with the UK NHS Health Research Authority guidelines for reporting adverse events
(AEs).81 ARs and SAEs occurring during the 12-month follow-up period were ascertained at the 2-week
telephone call and at the 6- and 12-month assessments. Participants were notified of recognised ARs and
encouraged to contact their local trial centre if they experienced these.
Hospitalisations for treatment planned prior to randomisation and hospitalisations for elective treatment of
pre-existing conditions were not considered, recorded or reported as SAEs. Complications occurring during
such hospitalisation were also not considered, recorded or reported as SAEs, unless there was a possibility
that the complication arose because of the trial medication (i.e. a possible AR). Exacerbations of COPD,
pneumonia or hospital admissions as a consequence of exacerbations of COPD or pneumonia were not
considered, recorded or reported as AEs or SAEs because they were primary and secondary outcomes for
the trial.
METHODS/DESIGN
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Serious adverse events were assessed as to whether or not the SAE was likely to be related to the
treatment using the following definitions:
l unrelated – when an event is not considered to be related to the trial drug
l possibly – although a relationship to the trial drug cannot be completely ruled out, the nature of the
event, the underlying disease, concomitant medication or temporal relationship make other
explanations possible
l probably – the temporal relationship and absence of a more likely explanation suggest that the event
could be related to the trial drug
l definitely – the known effects of the trial drug or its therapeutic class, or based on challenge testing,
suggest that the trial drug is the most likely cause.
The reference safety information used to assess whether or not the event was expected was section 4.8 of
the Summary of Product Characteristics for theophylline.54
Compliance
Compliance/adherence and persistence with trial medication were assessed at the 6- and 12-month
assessments. Participants were asked to return empty drug bottles and unused medication; compliance
was calculated by pill counting.82 Participants were deemed to be compliant if they had taken ≥ 70% of
the expected doses.
Participant withdrawal
Participants who withdrew from treatment (e.g. because of unacceptable side effects, or because they
were prescribed a contraindicated medicine for > 3 weeks) but who agreed to remain in the trial for
follow-up were followed up at 6 and 12 months. Those who did not want to attend for clinical follow-up
at 6 and 12 months could be followed up by telephone or home visit, or could opt to receive questionnaires
at home. Participants who wanted to withdraw from trial follow-up could continue to contribute follow-up
data by agreeing to have data extracted from their primary and secondary care medical records.
Sample size
The sample size of 1424 was estimated on the basis of the ECLIPSE study reporting the frequency of COPD
exacerbations in 2138 patients.21 For patients identical to the target population (who in a 1-year period have
had at least two self-reported COPD exacerbations requiring antibiotics or OCSs), the mean number of
COPD exacerbations within 1 year was 2.22 (SD 1.86).21 Given a similar rate in the placebo arm, 669 participants
were needed in each arm of the trial to detect a clinically important reduction in COPD exacerbations of
15% (i.e. from a mean of 2.22 to 1.89) with 90% power at the two-sided 5% significance level. Allowing
for 6% loss to follow-up,83 this was inflated to 712 participants in each trial arm, giving 1424 in total.
The sample size of 1424 included a 6% loss to follow-up based on a Cochrane Review of oral theophylline
in COPD.83 During the present trial, a higher proportion of participants than expected ceased their trial
medication (although most were not lost to follow-up). With the appropriate REC and regulatory
approvals, recruitment continued beyond 1424 in the time available, with the total number recruited being
1578 to counteract this loss of person-years on medication. Recruitment ended in August 2016.
Statistical analysis
All analyses were prespecified in the statistical analysis plan, which was approved by both the Trial Steering
Committee (TSC) and the Data Monitoring Committee (DMC) in advance of analysis. The statistical analysis
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plan can be found on the project web page at www.journalslibrary.nihr.ac.uk/programmes/hta/115815/#/
(accessed 23 April 2019). Unless prespecified, a 5% two-sided significance level was used to denote
statistical significance throughout and estimates are presented alongside their 95% CIs. No adjustments
were made for multiple testing. All analyses were conducted in accordance with the intention-to-treat (ITT)
principle, with a per-protocol analysis performed as a sensitivity analysis. The per-protocol analysis excluded
participants who were not compliant, with compliance being defined as taking ≥ 70% of their expected
doses of trial medication. All analyses were undertaken in Stata® version 14 (StataCorp LP, College Station,
TX, USA).
Categorical variables are described with number and percentage in each category. Continuous variables
are described with mean and SD if normally distributed and median and interquartile range (IQR) if
skewed. The number of missing data is reported for each variable.
Primary outcome
The primary outcome (i.e. the number of COPD exacerbations requiring antibiotics and/or OCSs in the
12-month treatment period following randomisation) was compared between randomised groups using a
generalised linear model (GLM) with log-link function, overdispersion parameter and length of time in trial
as an offset. The estimated treatment effect is presented as unadjusted rate ratio followed by adjusted rate
ratio for a set of prespecified baseline variables. The adjustment variables were centre (as a random effect),
where the participant was identified (primary or secondary care), age (in years) centred on the mean, sex
(male/female), smoking in pack-years, FEV1% predicted, number of COPD exacerbations in the previous
year, treatment with LAMA/LABA or a combination, and treatment with long-term antibiotics. Participants
who did not provide a full 12 months of follow-up information were included to the point at which they
were lost to follow-up, with their time in the trial utilised in the offset variable.
Secondary outcomes
The total number of COPD exacerbations requiring hospital admission and the total number of emergency
admissions (all causes) were analysed in the same way as the primary outcome. Occurrence of pneumonia
during follow-up was analysed with a mixed-effects logit model. QoL measures (i.e. CAT, EQ-5D-3L, HARQ)
and lung function (i.e. FEV1 and FVC) measured at baseline and at the 6- and 12-month follow-ups were
compared between groups using a mixed-effects model unadjusted and adjusted for the same prespecified
covariate set as described for the primary outcome. Fixed effects included visit number and treatment,
with participant and participant–visit interaction fitted as random effects. A treatment–visit interaction
was included to assess the differential treatment effect on rate of change in outcome. An autoregressive
[AR(1)] correlation structure was used throughout. All participants in the ITT population were included
in the analysis and missing outcome data were assumed to be missing at random. Breathlessness as
measured by the mMRC dyspnoea scale was analysed using a mixed-effects GLM using a logit link function.
All-cause mortality rate and COPD-related mortality and time to first exacerbation were compared between
randomised groups using Kaplan–Meier survival curves and Cox regression for adjustment. Total dose
of ICS at the end of follow-up and change in total daily dose from baseline were calculated and compared
between randomised groups using an independent-samples t-test and linear regression for adjustment.
The proportion of participants changing medication during the follow-up period was compared using a
chi-squared test.
Sensitivity analyses
To assess the impact of death on the treatment effect for the primary outcome, the total number of
exacerbations and the number of exacerbations requiring hospital admission, we undertook a sensitivity
analysis excluding those participants who died during the trial period. A sensitivity analysis for QoL and
lung function was also undertaken by repeating the mixed-effects models on only those participants who
survived until the 12-month follow-up.
METHODS/DESIGN
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Prespecified subgroup analysis
The analysis for the primary outcome was repeated for a number of subgroups. The subgroups were age
(< 60, 60–69, ≥ 70 years), sex, body mass index (BMI) (< 18.5, ≥ 18.5–< 25, ≥ 25 kg/m2), smoking status
at recruitment (ex-/current smoker), baseline treatment for COPD [triple therapy (ICS/LAMA/LABA),
double therapy (ICS/LAMA or ICS/LABA) or single therapy (ICS only)], GOLD stage (I or II, III, IV), number
of exacerbations in the 12 months prior to recruitment (2, 3 or 4, ≥ 5), taking OCSs at recruitment (yes/no)
and dose of inhaled ICS at recruitment (1600 or ≥ 1600 µg per day of beclomethasone equivalents).
A subgroup analysis was undertaken by the addition of a treatment–covariate interaction term and
using the ‘lincom’ command in Stata to obtain group-specific estimates. We report observed mean (SD)
exacerbations in each subgroup by treatment group, the treatment effect [incidence rate ratio (IRR) and
99% CIs] along with the p-value for the interaction term. We used 99% CIs because of the exploratory
nature of the subgroup analysis.
Health economics
Resource use
Health-care resource utilisation during the previous 6 months was collected at the 6- and 12-month
assessments using a modified version of the CSRI.84 The CSRI is a research questionnaire for retrospectively
collecting cost-related information about a participant’s use of health and social care services. The main
resources whose use was collected during the follow-up period were as follows:
l theophylline intervention
l costs of exacerbation treatment; this was broken down into two groups of costs – (1) the location
of the treatment, ‘home’, ‘care by services to prevent hospitalisation’ and ‘admitted to hospital’ and
(2) the treatment cost of the exacerbations, including medication
l cost of COPD maintenance medications
l other health service use (including inpatient, outpatient and primary care use); none of these included
exacerbation costs
l non-COPD emergency hospital admissions
l regular medication.
Baseline resource use was collected for current use of COPD maintenance treatment and regular medication.
For calculating baseline resource use and costs, we have assumed use to be for the 6 months prior to
baseline. The number of exacerbations needing treatment in the previous 12 months and the number of
exacerbations resulting in hospitalisation in the previous 12 months were also collected.
Unit costs
All resource use was valued in Great British pounds (GBP) and indexed to 2016, using the Health Service
Cost Index85 to adjust if necessary.
l Medication costs were obtained from the British National Formulary (BNF).86
l For exacerbations, non-COPD emergency admissions, inpatient stays, outpatient attendances and
primary care, costs were obtained from NHS Reference Costs 2015 to 2016,87 Information Services
Division (ISD),88 Personal Social Services Research Unit (PSSRU),85 the BNF86 and papers by Oostenbrink
et al.89 and Scott et al.90
The total cost per participant was calculated by assigning unit costs to resource use for each participant.
Total mean costs were calculated using a GLM with a gamma family and clustering for centre number.
After multiple imputation, total costs were adjusted for baseline characteristics using standard regression
methods, to account for any differences in cost-related variables at baseline.91
Unit costs and their sources are presented in Table 3.
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TABLE 3 Unit costs and sources
Resource Unit Unit cost (£) Source
Intervention
Theophylline 200 mg od 0.05 BNF86
200 mg bd 0.11 BNF86
Exacerbation treatment
Oxygen Per day 19 Oostenbrink et al.89
Medication Daily dose Various BNF86
Inpatient costs
Ward stay (elective) Bed-day 362 NHS Reference Costs 2015 to 2016 (elective excess bed-day
unit cost)87
Ward stay (non-elective) Bed-day 298 NHS Reference Costs 2015 to 2016 (non-elective excess
bed-day unit cost)87
COPD-related ward
stay
Bed-day 262 NHS Reference Costs 2015 to 2016 (weighted average of COPD
hospital stays DZ65)87
Long stay on ward Day 133 PSSRU (not-for-profit care home fee: mean £931 per week)85
Outpatient costs
Day case Day 521 ISD costs book (day cases, all specialties)88
Outpatient
appointment
Appointment 177 NHS Reference Costs 2015 to 2016 (total outpatient
attendances unit cost)87
Primary care costs
Emergency GP visit Per contact 86 Based on Scott et al.90 for out-of-hours home visit
Routine GP visit Per contact 31 PSSRU (including direct care staff costs, without qualifications,
9.22 minutes)85
Community/district
nurse
Per contact 38 NHS Reference Costs 2015 to 2016 (Community Health
Services – N02AF – district nurse)87
Hospital at home team Per contact 84 NHS Reference Costs 2015 to 2016 (Community Health
Services – N08AF – specialist nursing asthma and respiratory
nursing liaison)87
GP telephone Per contact 23.43 PSSRU (including direct care staff costs, without qualification
costs, 7.1 minutes)85
GP home visit Per contact 77.22 PSSRU (including direct care staff costs, without qualification
costs, 11.4 minutes visit plus 12 minutes of travelling time)85
Blood test Per contact 14.42 ISD costs book88 (laboratory services, haematology plus
practice nurse appointment, PSSRU 201685)
Dental service Per contact 77 NHS Reference Costs 2015 to 2016 (general dental service
attendance)87
Hearing aid clinic Per contact 53 NHS Reference Costs 2015 to 2016 (audiology)87
Occupational therapist Per contact 79 NHS Reference Costs 2015 to 2016 (occupational therapist)87
Diabetic nurse Per contact 71 NHS Reference Costs 2015 to 2016 (specialist nursing, diabetic)87
Cardiac nurse Per contact 81 NHS Reference Costs 2015 to 2016 (specialist nursing, cardiac)87
Long-term condition
nurse/community
matron
Per contact 89 NHS Reference Costs 2015 to 2016 (active case management)87
Paramedic Per contact 181 NHS Reference Costs 2015 to 2016 (ambulance, see, treat, refer)87
Chiropodist/community
clinic/endoscopy
Per contact 60 NHS Reference Costs 2015 to 2016 (mean of community health
services, no separate chiropodist or community clinic cost)87
Physiotherapist Per contact 49 NHS Reference Costs 2015 to 2016 (physiotherapist)87
METHODS/DESIGN
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Health outcomes
The economic outcome used was the QALY, a combination of quality and quantity of life. The QoL measure
was generated using completed EQ-5D-3L questionnaires. Participants completed the questionnaire at
baseline and at 6 months and 12 months.
Patient-reported health-related QoL obtained from EQ-5D-3L questionnaires was valued in terms of utilities
(on a scale from –0.59 to 1, where 1 is full health) using a standard UK value set,71 which were converted into
QALYs using standard area under the curve methods; patient utility measurements from each follow-up point
were weighted by the time interval between follow-up points. Discrete changes in utility values between
follow-up time points were assumed to be linear. After multiple imputation, QALYs were adjusted for baseline
characteristics using standard regression methods.
TABLE 3 Unit costs and sources (continued )
Resource Unit Unit cost (£) Source
Podiatrist Per contact 40 NHS Reference Costs 2015 to 2016 (podiatrist)87
Practice nurse Per contact 9.42 PSSRU (practice nurse, 15.5 minutes per contact)85
Speech therapist Per contact 88 NHS Reference Costs 2015 to 2016 (speech and language
therapist)87
Nurse telephone call Per contact 6.10 PSSRU (nurse-led triage)85
Treatment room nurse Per contact 27 NHS Reference Costs 2015 to 2016 (specialist nursing,
treatment room)87
Urine sample/sputum
test
Per contact 10.28 ISD costs book88 (clinical chemistry, plus practice nurse
appointment, PSSRU85)
Dietitian Per contact 81 NHS Reference Costs 2015 to 2016 (dietitian)87
Influenza vaccination Per contact 14.67 BNF86 plus practice nurse appointment, PSSRU 201685
Early support discharge Per contact 124 NHS Reference Costs 2015 to 2016 (crisis response and early
discharge services)87
Diagnostic imaging Per contact 37.3 NHS Reference Costs 2015 to 2016 (total outpatient
attendances, diagnostic imaging)87
Optometry Per contact 79.19 NHS Reference Costs 2015 to 2016 (total outpatient
attendances, optometry)87
Health-care assistant Per contact 6.20 PSSRU 2016 (band 3 nurse, 15.5 minutes)85
Talking matters Per contact 24.06 PSSRU 2009/10 (counselling services in primary care,
telephone consultation 29.7 minutes)92
Community psychiatric
nurse/stroke nurse
Per contact 77 NHS Reference Costs 2015 to 2016 (other specialist nursing)87
Counselling Per contact 78.27 PSSRU 2009/10 (counselling services in primary care,
consultation 96.6 minutes)92
Breast care nurse Per contact 59 NHS Reference Costs 2015 to 2016 (beast care nursing)87
Community mental
health team
Per contact 121 NHS Reference Costs 2015 to 2016 (other mental health
specialist team)87
Pulmonary
rehabilitation
Per contact 78 NHS Reference Costs 2015 to 2016 (other single condition
community rehabilitation teams)87
Emergency costs
Ambulance Per attendance 236 NHS Reference Costs 2015 to 2016 (see, treat convey)87
Accident and
emergency attendance
Per attendance 138 NHS Reference Costs 2015 to 2016 (emergency medicine
average unit cost)87
ISD, Information Services Division.
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Analysis
The total cost per participant in each intervention was summed and divided by the number of participants
in each arm to calculate the total mean cost per participant in each arm, along with the difference in
means and a 95% CI.
The mean number of QALYs per participant for each intervention was calculated by summing all participants’
QALYs and dividing by the number of participants in that intervention arm. The differences in the means
were also calculated, along with a 95% CI.
The incremental cost-effectiveness ratio (ICER) was calculated by dividing the difference in mean costs by
the difference in mean QALYs. The NICE threshold of £20,000 to £30,000 per QALY was used when
judging whether or not the intervention was cost-effective.93
Withdrawn participants were included in the analysis; the total time they spent in the trial was used to
adjust total costs and QALYs using regression methods.
To explore the uncertainty around the cost and QALY differences and the resulting ICER, a non-parametric
bootstrapping technique was employed with 1000 iterations. The results are presented (see Figures 7–10)
using a cost-effectiveness plane, showing all 1000 incremental cost-effectiveness pairs, and a cost-
effectiveness acceptability curve.
The analysis was carried out using Stata version 14.
Missing data
There was a small amount of multivariate missingness in collected resource data.
Resource use data were not available for some exacerbations because this was not reported by participants
or because only limited data were available from GP or hospital records. Missing resource use data on
exacerbations were dealt with as follows:
l For exacerbations with missing length of exacerbation data, the length was assumed to be the mean
length of exacerbation specific to that treatment arm.
l For exacerbations missing a marker to indicate the location of treatment, this was assumed to be at
home, as most locations of treatments were at home (> 80%).
l For exacerbations treated in hospital, missing lengths of stay were assumed to be the length
of exacerbation.
l For exacerbations missing treatment costs, a mean cost of treatment, specific to that treatment arm,
was assumed.
At a resource use level, there were small numbers of missing data, which were dealt with as follows:
l If the length of stay data were missing for emergency hospital admissions, these were imputed using
the mean length of stay specific to that treatment arm.
l If participants had no observations completed to indicate the duration of a COPD maintenance
treatment, it was assumed that the treatment duration was the 6 months prior to the date on which
the information about the COPD maintenance treatment was collected.
l If a participant indicated that they had received a COPD maintenance treatment but no medication
details were available, a mean cost, specific to that treatment arm, was imputed for that specific
maintenance medication.
l If resource use data were missing for inpatient, outpatient and primary care service use, the participant
was assumed not to have used the resource in question.
METHODS/DESIGN
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Complete cases were analysed initially and multiple imputation was used to explore the effect of missing
data on the analysis.
The multiple imputation technique used was multiple imputation by chained equations. Multiple
imputation assumes that data are missing at random; missing data may depend on observed data.
Assumptions
The following assumptions were made in the health economics analysis: a complete case is defined as a
case with data covering resource use for the 12-month follow-up period. In a small number of participants,
there was no 6-month data collection; however, the 12-month data collection covered resource use for the
whole of the 12-month follow-up period.
Patient and public involvement
A person with COPD was an independent voting member of the TSC. Initially, this was a patient from
the Aberdeen Chest Clinic who was nominated by Chest Heart & Stroke Scotland (CHSS) as part of its
Voices Scotland initiative. In 2015, this person had to resign from the TSC because of ill health and was
replaced by another patient, who is living with COPD, from the Aberdeen Chest Clinic.
Early versions of the trial protocol and PILs were reviewed by a representative from the British Lung
Foundation–North Region and by a person who lives with COPD and attends the chest clinic at the
Freeman Hospital, Newcastle. They both attended the trial initiation meeting, purposely held in Newcastle
in February 2013, and contributed suggestions and changes to the final trial design that were reflected in
the protocol and PIL.
The TWICS trial was publicised in 2014 by a press release that included supportive quotations from the
British Lung Foundation and CHSS. This publicity resulted in members of the public with COPD volunteering
to participate; with their permission, their details were passed on to their local TWICS trial site.
We anticipate that the patient and public involvement (PPI) member of the TSC will comment on the
results letter to be sent to trial participants. It is also anticipated that the publication of the trial results
will be co-ordinated with press releases from the participating academic/NHS institutions, the British Lung
Foundation and CHSS. Members of the trial team will be participating in local public engagement with
research activities.
Protocol amendments
There were seven protocol amendments, which are summarised in Table 4.
Trial oversight
A TSC, with independent members, including PPI members, oversaw the conduct and progress of the trial.
An independent DMC oversaw the safety of participants in the trial.
Breaches
Breaches of trial protocol or good clinical practice were recorded and reported to the sponsor. A summary
of breaches is included in Appendix 3. Participants who were the subject of a breach remained in the ITT
population, the safety population and the per-protocol population (if compliance criteria were met).
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TABLE 4 Summary of protocol amendments
Version number, date Summary of amendments
Version 2, 20 June 2013 Version initially approved by the REC
Version 3, 5 August 2013 To incorporate clarification of the definition of smoker and non-smoker as required by the MHRA
Version 4, 5 February 2014 l To add episodes of pneumonia as a secondary outcome and to confirm that pneumonia
will not be classified as an AE or SAE within the trial
l To clarify that, in addition to the trial intervention, participants will receive ‘usual NHS
care’ in the treatment of COPD rather than guideline-compliant care
l To clarify that patients with alpha-1-antitrypsin deficiency and COPD should be excluded
Version 5, 2 July 2014 l To clarify when spirometry may be contraindicated
l To update the version of the SmPC appended to the protocol
l To include the definition of the source data
Version 6, 4 August 2014 l To list additional potential avenues for identification of eligible patients (including smoking
cessation clinics, community spirometry clinics and other services for patients with COPD)
l To confirm that participants with limited mobility or who live some distance from the trial
site can be recruited during a home visit
Version 7, 11 August 2015 l To update the telephone number for the switchboard at Aberdeen Royal Infirmary
(for emergency unblinding)
l To describe how cases in which medications that potentially interact with theophylline are
prescribed to trial participants are documented within the trial
Version 8, 19 May 2016 To amend the protocol to allow for over-recruitment
Version 9, 14 April 2017 l To describe how requests for unblinding made by participants (or their GPs) at the end of
their 12-month follow-up should be handled
l To revise the planned validation exercise in relation to participant-reported exacerbations
MHRA, Medicines and Healthcare products Regulatory Agency; SmPC, Summary of Product Characteristics.
METHODS/DESIGN
NIHR Journals Library www.journalslibrary.nihr.ac.uk
24
Chapter 3 Baseline characteristics
Recruitment
Participants were recruited to the trial between February 2014 and August 2016. During this 31-month
period, 141 UK sites were opened to recruitment. Once opened, some sites (n = 20) failed to recruit any
participants to the trial. Reasons for this included staff changeover, lack of eligible patients, competing
priorities, practice closure and eligible patients who did not agree to take part.
In total, 1578 participants were recruited from 121 sites (Table 5). A detailed summary of recruitment, by
site, is given in Appendix 4. In summary, across 33 secondary care sites, 1101 participants were recruited,
and, across 88 primary care sites, 477 participants were recruited. Of those recruited in secondary care,
464 were identified in primary care. Overall, 59.6% of participants were identified in primary care.
The initial funding included a 24-month recruitment period. Delays in manufacturing and packaging the
trial medication led to the projected recruitment being reprofiled across 21 months. After ≈6 months
of recruitment, it became clear that we were unlikely to meet the recruitment target within 21 months.
To address this, several measures were successfully implemented: ‘second’- and ‘third’-wave sites were
opened earlier than planned; additional primary and secondary care sites were identified and a rolling
programme of opening these sites was established; a 6-month extension to recruitment was granted
by the funder; and additional recruitment time was accommodated within the existing funding. In the
31-month recruitment period we were granted approval to over-recruit beyond the original target of
1424 participants. The justification for this was the higher than anticipated numbers of participants who
ceased taking the trial medication (see Chapter 4, Treatment adherence/compliance).
Figure 3 shows the original recruitment targets, the reprofiled recruitment targets (to accommodate the
delay in manufacturing/packaging), the revised recruitment targets (after the extension to recruitment was
granted) and the actual recruitment.
Post-randomisation exclusions
Eleven participants were recruited in error and were then excluded. None of these participants took any
dose of trial medication and all are excluded from all trial analyses. Reasons for these post-randomisation
exclusions are given in Table 6.
Sixteen participants who were recruited into the TWICS trial were subsequently noted to be ineligible for
the trial at the point of recruitment. All 16 participants had taken at least one dose of trial medication
and were retained in the follow-up and included in the trial analyses. Seven of these were taking a form
of diltiazem at recruitment, and were identified during a review of all baseline medication recorded for
participants. Diltiazem can cause a slight increase in serum theophylline concentration; however, any effect
TABLE 5 Summary of recruitment
Recruitment site based in Participants identified in Number of participants
Secondary care Secondary care 637
Secondary care Primary care 464
Primary care Primary care 477
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is usually clinically insignificant.94 One of these participants took the trial medication for ≈10 days but
stopped because they experienced symptoms considered likely to be related to theophylline. A further
participant experienced some symptoms that may have been side effects related to the trial medication
and stopped after ≈4 months. One further participant experienced some symptoms that may have been
side effects related to the trial medication but did not cease taking the trial medication.
In this same review, a further five participants were noted to have been taking a contraindicated medication at
baseline. Three participants were noted to be taking a form of oestrogen. Serum theophylline concentration is
slightly increased by concomitant oestrogen but no toxicity has been reported.94 Two participants who were
co-prescribed oestrogen continued to take the trial medication through their 12-month follow-up with no ARs.
The third participant experienced symptoms (thought to be related to theophylline) and stopped taking the
trial medication after 14 days. One participant was noted to have been taking febuxostat at recruitment.
They had taken the trial medication through their 12-month follow-up and experienced symptoms that may
have been side effects related to the trial medication. High-dose febuxostat has been reported to possibly
increase serum theophylline.94 One participant was noted to have been taking roflumilast at recruitment.
Although roflumilast has no reported effect on serum theophylline concentrations, the two drugs act through
phosphodiesterase enzymes,94 albeit theophylline is a phosphodiesterase inhibitor at serum concentrations
of 10–20mg/l when used at ‘high-dose’ levels. This participant had taken trial medication throughout their
12-month follow-up without any ARs.
Three participants were taking a form of theophylline at recruitment. In two cases, this was noted only
after the participant had completed their 12-month follow-up (and the participants had taken the trial
medication throughout their 12-month follow-up). In the third case, this was noted after the participant
had taken the trial medication for 8 days; the trial medication was then stopped. In all three cases,
no ARs relating to the trial medication were noted.
One participant was recruited into the TWICS trial when they were already participating in another CTIMP
for an unrelated condition. The participant did not disclose this at the time of recruitment and it was
not clearly documented in their hospital notes. No interaction between the TWICS trial medication and
the medication used in the other trial is likely. The participant continued to take the trial medication for
≈11 months, at which point the participant ceased taking the trial medication as a result of a non-related
throat problem.
TABLE 6 Reasons for post-randomisation exclusions
Overarching reason Specific reason
Concomitant medications Already taking a form of theophylline (n = 1)
Concomitant prescription of diltiazem (n = 2)
Concomitant prescription of methotrexate (n = 1)
Not currently prescribed ICS (n = 1)
COPD diagnosis Diagnosed with right middle lobe collapse, not COPD (n = 1)
COPD diagnosis disputed by consultant (n = 1)
Fewer than two exacerbations in the previous year (n = 3)
Spirometry Did not fulfil spirometric criterion for the trial (n = 1)
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Baseline characteristics
Baseline characteristics are presented for the 1567 included participants (after exclusion of the 11 post-
randomisation exclusions). The theophylline and placebo groups were well balanced in terms of demographic
and disease characteristics at baseline.
The mean age of participants was 68.4 years (SD 8.4 years) (Table 7). Just over half of the participants (53.8%)
were male. Approximately one-third (31.7%) were current smokers; the remainder were ex-smokers. The
median number of pack-years smoked was 42 (IQR 27.7–56.0 pack-years). The mean BMI was 27.2 kg/m2
(SD 6.1 kg/m2).
The median number of participant-reported exacerbations in the 12 months prior to recruitment was
3 (IQR 2–4) and the mean number of exacerbations was 3.6 (SD 2.2) (Table 8). The majority of participants
(79.9%) were prescribed the ‘triple therapy’ combination of ICS, LABA and LAMA at baseline. Almost
one-fifth (16.7%) were prescribed ICS and LABA. The remainder were prescribed ICS only (2.0%) or ICS
and LAMA (1.5%).
Comorbidities, as reported by participants, were relatively common. Almost one-fifth of participants (18.3%)
had a concurrent diagnosis of asthma. Four per cent of participants reported a diagnosis of bronchiectasis.
Just over one-third of participants (38.2%) reported a diagnosis of hypertension. Thirteen per cent reported
ischaemic heart disease and 6.7% reported a previous cerebrovascular event. Almost one-third (28.0%)
reported anxiety or depression in the previous 5 years. Eleven per cent had a diagnosis of diabetes mellitus
and 12.8% had a diagnosis of osteoporosis.
Measurement of lung function at baseline revealed that the mean FEV1 was 51.7% (SD 20.0%) predicted.
Using the GOLD classification,1 13.6% were classified as having very severe COPD, 37.7% as having severe
COPD, 39.6% as having moderate COPD and 9.2% as having mild COPD.
TABLE 7 Baseline sociodemographic characteristics
Characteristics
Trial arm
OverallTheophylline Placebo
Sex (N, n, %)
Male 788, 425, 53.9 779, 418, 53.7 1567, 843, 53.8
Female 788, 363, 46.1 779, 361, 46.3 1567, 724, 46.2
Age (n, mean, SD) 788, 68.3, 8.2 779, 68.5, 8.6 1567, 68.4, 8.4
Smoking status (N, n, %)
Current smoker 788, 247, 31.3 779, 249, 32.0 1567, 496, 31.7
Ex-smoker 788, 541, 68.7 779, 530, 68.0 1567, 1071, 68.3
Pack-years (n, mean, SD) 785, 47.0, 26.3 775, 47.1, 30.6 1560, 47.1, 28.5
Pack years (n, median, IQR) 785, 43.0, 28.5–57.0 775, 41.0, 27.0–55.0 1560, 42.0, 27.7–56.0
BMI (n, mean, SD) 788, 27.1, 6.2 779, 27.3, 6.0 1567, 27.2, 6.1
BMI group (N, n, %)
Underweight 788, 37, 4.7 779, 38, 4.9 1567, 75, 4.8
Normal 788, 285, 36.2 779, 246, 31.6 1567, 531, 33.9
Overweight 788, 252, 32.0 779, 266, 34.1 1567, 518, 33.1
Obese 788, 214, 27.2 779, 229, 29.4 1567, 443, 28.3
BASELINE CHARACTERISTICS
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TABLE 8 Baseline clinical characteristics
Characteristics
Trial arm
OverallTheophylline Placebo
Exacerbations in the previous 12 months
n, mean, SD 785, 3.6, 2.2 773, 3.5, 2.1 1558, 3.6, 2.2
n, median, IQR 785, 3, 2–4 773, 3, 2–4 1558, 3, 2–4
Exacerbations requiring hospitalisation in the previous 12 months
n, mean, SD 784, 0.4, 0.8 773, 0.4, 1.0 1557, 0.4, 0.9
n, median, IQR 784, 0, 0–1 773, 0, 0–0 1557, 0, 0–0
GOLD 2011 category (N, n, %)
C: two or more exacerbations in the previous year,
mMRC dyspnoea score of 0–1 and CAT score of < 10
779, 37, 4.7 768, 45, 5.9 1547, 82, 5.3
D: two or more exacerbations in the previous year,
mMRC dyspnoea score of ≥ 2 and CAT score of ≥ 10
779, 742, 95.3 768, 723, 94.1 1547, 1465, 94.7
FEV1% predicted (n, mean, SD) 785, 51.3, 20.1 771, 52.2, 19.8 1556, 51.7, 20.0
FEV1% predicted category (N, n, %)
≥ 80% (GOLD mild) 785, 70, 8.9 771, 73, 9.5 1556, 143, 9.2
50–79.9% (GOLD moderate) 785, 308, 39.2 771, 308, 39.9 1556, 616, 39.6
30–49.9% (GOLD severe) 785, 291, 37.1 771, 295, 38.3 1556, 586, 37.7
0–29.9% (GOLD very severe) 785, 116, 14.8 771, 95, 12.3 1556, 211, 13.6
FVC% predicted (n, mean, SD) 783, 84.3, 22.3 770, 86.2, 23.4 1553, 85.2, 22.8
FEV1/FVC ratio (n, mean, SD) 783, 49.0, 19.7 770, 48.5, 14.1 1553, 48.8, 17.1
Current treatment for COPD (N, n, %)
ICS
ICS only 788, 14, 1.8 779, 17, 2.2 1567, 31, 2.0
ICS/LABA 788, 136, 17.3 779, 125, 16.0 1567, 261, 16.7
ICS/LAMA 788, 13, 1.6 779, 10, 1.3 1567, 23, 1.5
ICS/LABA/LAMA 788, 625, 79.3 779, 627, 80.5 1567, 1252, 79.9
Oral mucolytic use 784, 201, 25.6 771, 197, 25.6 1555, 398, 25.6
Long-term antibiotic use 784, 51, 6.5 771, 48, 6.2 1555, 99, 6.4
Comorbidities (N, n, %)
Asthma 782, 138, 17.6 772, 147, 19.0 1554, 285, 18.3
Bronchiectasis 782, 41, 5.2 770, 27, 3.5 1552, 68, 4.4
Ischaemic heart disease 781, 111, 14.2 771, 96, 12.5 1552, 207, 13.3
Hypertension 782, 317, 40.5 772, 277, 35.9 1554, 594, 38.2
Diabetes mellitus 782, 83, 10.6 772, 93, 12.0 1554, 176, 11.3
Osteoporosis 783, 109, 13.9 771, 90, 11.7 1554, 199, 12.8
Anxiety/depression treated in the previous 5 years 782, 222, 28.4 772, 213, 27.6 1554, 435, 28.0
Cerebrovascular event 783, 46, 5.9 772, 58, 7.5 1555, 104, 6.7
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The mean score on the CAT was 22.6 (SD 7.7), indicating that, overall, COPD was having a high impact
on the lives of participants (Table 9). Considering the cut-off points used to interpret the scores derived
from the CAT, COPD was having a low impact on the lives of 5.3% of participants, a medium impact on
the lives of 29.9% of participants, a high impact on the lives of 44.4% of participants and a very high
impact on the lives of 20.4% of participants.
The mean EQ-5D-3L utility score was 0.63 (SD 0.28). The mMRC dyspnoea score revealed that 7.1% of
participants were too breathless to leave the house, 27.6% had to stop for breath after walking ≈100 m,
31.5% walked more slowly than contemporaries on level ground because of breathlessness, 28.3%
became short of breath when hurrying or walking up a slight hill and only 5.5% of participants were not
troubled by breathlessness except on strenuous exercise.
A comparison of the participants recruited in primary and secondary care indicated that those identified in
secondary care were slightly younger, were more likely to be ex-smokers and had experienced a greater
number of exacerbations in the previous 12 months. Furthermore, a higher proportion of those identified
in secondary care had more severe COPD, were on triple (ICS/LAMA/LABA) therapy and long-term
antibiotic use, and had a significantly greater prevalence of comorbidities, such as bronchiectasis, ischaemic
heart disease and osteoporosis (see Appendix 5, Table 35). Participants recruited in secondary care had a
higher CAT score and a slightly lower QoL.
TABLE 9 Baseline patient-reported symptoms and QoL
Symptoms and QoL
Trial arm
OverallTheophylline Placebo
Degree of breathlessness (mMRC dyspnoea)75 [N, n (%)]
Not troubled by breathlessness except on strenuous
exercise
783, 35 (4.5) 772, 50 (6.5) 1555, 85 (5.5)
Short of breath when hurrying or walking up a slight hill 783, 216 (27.6) 772, 224 (29.0) 1555, 440 (28.3)
Walks slower than contemporaries on level ground
because of breathlessness, or has to stop for breath
when walking at own pace
783, 251 (32.1) 772, 239 (31.0) 1555, 490 (31.5)
Stops for breath after walking ≈100m or after a few
minutes on level ground
783, 225 (28.7) 772, 204 (26.4) 1555, 429 (27.6)
Too breathless to leave the house, or breathless when
dressing or undressing
783, 56 (7.2) 772, 55 (7.1) 1555, 111 (7.1)
CAT [N, mean (SD)] 780, 22.8 (7.5) 771, 22.3 (7.9) 1551, 22.6 (7.7)
CAT group [N, n (%)]
Low (score of 0–9) 780, 37 (4.7) 771, 45 (5.8) 1551, 82 (5.3)
Medium (score of 10–19) 780, 219 (28.1) 771, 244 (31.6) 1551, 463 (29.9)
High (score of 20–29) 780, 361 (46.3) 771, 328 (42.5) 1551, 689 (44.4)
Very high (score of 30–40) 780, 163 (20.9) 771, 154 (20.0) 1551, 317 (20.4)
EQ-5D-3L utility [N, mean (SD)] 785, 0.62 (0.28) 772, 0.63 (0.28) 1557, 0.63 (0.28)
EQ-5D-3L VAS [N, mean (SD)] 785, 59.6 (19.0) 770, 60.8 (19.1) 1555, 60.2 (19.1)
VAS, visual analogue scale.
BASELINE CHARACTERISTICS
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Chapter 4 Clinical effectiveness
Clinical effectiveness of low-dose theophylline compared with placebo
In this chapter, we report the results of people with COPD being treated for 1 year with low-dose
theophylline compared with placebo. A total of 1578 participants were randomised to theophylline or
placebo; 11 post-randomisation exclusions resulted in 1567 participants being eligible to initiate trial
medication and for whom baseline characteristics have been reported (see Chapter 3). Follow-up data
were unavailable for 31 (2%) participants (theophylline, n = 16; placebo, n = 15); therefore, the results
presented for the ITT analysis are based on 1536 participants (theophylline, n = 772; placebo, n = 764).
Figure 4 shows the Consolidated Standards of Reporting Trials (CONSORT) flow diagram for the ITT
analysis. In total there were 1489 person-years of follow-up data: 747 person-years in the theophylline
group and 742 person-years in the placebo group (Table 10).
Randomised
(n = 1578)
Screened
(n = 1648)
Allocated theophylline
(n = 791)
Number included
(n = 788)
Post-randomisation
exclusions
(n = 3)
Missing primary
outcome data
(n = 16)
Post-randomisation
exclusions
(n = 8)
Missing primary
outcome data
(n = 15)
Included in ITT 
analysis of
primary outcome
(n = 772)
Allocated placebo
(n = 787)
Number included
(n = 779)
Included in ITT 
analysis of
primary outcome
(n = 764)
• Not eligible,a n = 62
• Eligible, but did not
   consent, n = 8
FIGURE 4 The CONSORT flow diagram for the ITT analysis. a, Reasons for ineligibility were as follows: 16 did not
meet the inclusion criteria for established COPD diagnosis or had a predominant respiratory disease other than
COPD, 10 had not had two exacerbations in the previous year, seven did not meet the smoking history criteria,
seven were taking contraindicated medication, three were not currently using ICSs, one was not clinically stable,
two were participating in another clinical trial, one was currently taking theophylline, one had known or suspected
hypersensitivity to theophylline, one was pregnant, two had severe heart disease and 11 did not meet two or more
of the inclusion criteria.
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TABLE 10 Exacerbation outcomes (ITT analysis)
Exacerbations
Trial arm
Adjusted or
unadjusted Estimate 95% CI p-valueTheophylline Placebo
Primary outcome: exacerbations
Total number included in analysis 772 764
Person-years of follow-up 747.5 742.1
Number with at least one
exacerbation
633 609
Number of exacerbations
Total 1727 1703
Mean 2.24 2.23 Unadjusted IRR 1.00 0.92 to 1.09 0.965
SD 1.99 1.97 Adjusted IRRa 0.99 0.91 to 1.08 0.840
Exacerbations requiring hospital treatment
Total number included in analysis 772 764
Person-years of follow-up 747.5 742.1
Number with at least one
exacerbation
106 130
Number of exacerbations
Total 134 185
Mean 0.17 0.24 Unadjusted IRR 0.72 0.55 to 0.95 0.021
SD 0.49 0.66 Adjusted IRRa 0.72 0.55 to 0.94 0.017
Time to first exacerbation (from randomisation)
Total number included in analysisb 756 753
Number with at least one
exacerbation
617 598
% with at least one exacerbation 81.6 79.4
Median time to first exacerbation
(days)
219 227 Unadjusted HR 1.03 0.92 to 1.14 0.652
25th percentile [time to first
exacerbation (days)]
132 116 Adjusted HRa 1.01 0.90 to 1.13 0.895
75th percentile [time to first
exacerbation (days)]
334 337
a Adjusted for centre (as a random effect), recruiting site (primary or secondary care), age centred on the mean, sex
(male/female), smoking in pack-years, FEV1% predicted, number of COPD exacerbations in the previous year, baseline
COPD treatment and treatment with long-term antibiotics.
b Number in analysis differs to primary outcome as exacerbation onset date was unavailable for 27 participants.
Note
The secondary outcome is the total number of exacerbations of COPD resulting in hospital admission.
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Intention-to-treat analysis
Primary outcome: total number of exacerbations of chronic obstructive pulmonary
disease necessitating a change in management
In total, 633 out of 772 (82.0%) participants allocated to theophylline had at least one exacerbation, with
1727 exacerbations in the group overall. Among participants allocated to placebo, 609 out of 764 (79.7%)
had at least one exacerbation and there were 1703 exacerbations in the group overall. The mean number
of exacerbations per participant was 2.24 (SD 1.99) in those allocated to low-dose theophylline and 2.23
(SD 1.97) in those allocated to placebo. The adjusted IRR for exacerbation was 0.99 (95% CI 0.91 to 1.08),
indicating no difference in the exacerbation rate during the 12-month follow-up period between those on
low-dose theophylline and those on placebo (see Table 10).
The primary outcome was exacerbation treated with antibiotics and/or OCSs, but we also conducted analyses
relating treatment with low-dose theophylline to differing levels of treatment for COPD exacerbations, that is
antibiotics only, OCSs only or antibiotics and OCSs (see Appendix 5, Table 39). In the adjusted model, for
exacerbations treated with antibiotics only, the IRR was 0.94 (95% CI 0.78 to 1.14); for exacerbations treated
with OCSs only, the IRR was 0.88 (95% CI 0.62 to 1.25); and for exacerbations treated with antibiotics and
OCSs, the IRR was 1.02 (95% CI 0.92 to 1.14).
Among participants allocated to low-dose theophylline, 106 (13.7%) had at least one exacerbation
requiring hospital admission, with a total of 134 hospital admissions in the group. Among participants
allocated to placebo, 130 (17.0%) had at least one exacerbation requiring hospital admission, and there
were 185 admissions in total. A comparison of the proportion of participants with at least one exacerbation
requiring hospital admission was not significant at the 5% level (13.7% in the theophylline arm vs. 17.0%
in the placebo arm; p = 0.074). In the adjusted model, the IRR for exacerbations of COPD requiring hospital
treatment was 0.72 (95% CI 0.55 to 0.94), suggesting that low-dose theophylline resulted in a reduction
in the number of exacerbations requiring hospital admission when compared with placebo (see Table 10).
However, further exploration of the data showed that, in the theophylline group, only three participants
had three or more exacerbations necessitating treatment in hospital (12 exacerbations in total), compared
with 13 participants in the placebo group having three or more exacerbations necessitating hospital
treatment (51 exacerbations in total). Therefore, a small excess of participants (n = 10) allocated to placebo
who had three or more exacerbations requiring treatment in hospital accounted for 39 of the 51 excess
admissions in the placebo group (Table 11).
TABLE 11 Number of exacerbations requiring hospital admission
Number of exacerbations
requiring hospital admission
Trial arm, n (%)
Theophylline Placebo
0 666 (86) 634 (83)
1 84 (11) 100 (13)
2 19 (2) 17 (2)
3 0 (0) 5 (1)
4 3 (< 1) 5 (1)
5 0 (0) 2 (< 1)
6 0 (0) 1 (< 1)
Total (n) 772 784
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Secondary outcomes
Time to first exacerbation
The date of onset of the first exacerbation after commencing trial medication was not available for 27 of the
1242 participants who had at least one exacerbation; therefore, this analysis was based on 1509 participants
in the ITT population [294 who had no exacerbation and 1215 (80.5%) who had an exacerbation]. Of the
756 participants allocated to theophylline, 617 (81.6%) had at least one exacerbation, with a median time
to first exacerbation of 219 days (7.2 months) after randomisation. In the placebo group, 598 out of 753
(79.4%) participants had at least one exacerbation, with a median time to first exacerbation of 227 days
(7.5 months). In a Cox regression analysis, the adjusted HR for the time to first exacerbation was 1.01
(95% CI 0.90 to 1.13), suggesting no significant difference between the treatment groups in terms of the
time to first exacerbation (from point of randomisation) during the 12-month follow-up period (see Table 10).
Total number of emergency hospital admissions (including those not related to chronic
obstructive pulmonary disease)
Hospital admission data were available for 1517 of the 1536 participants in the ITT population (theophylline,
n = 762; placebo, n = 755). A similar proportion of participants had at least one hospital admission for
non-COPD-related causes. Among the participants allocated to low-dose theophylline, this proportion
was 10.4% (79/762); among those allocated to placebo, it was 12.2% (92/755). In total, there were
116 hospital admissions among participants allocated to theophylline and 119 among those allocated to
placebo. The adjusted IRR was 0.99 (95% CI 0.71 to 1.38), suggesting no significant difference in the rate
of emergency (unscheduled) hospital admissions between the groups (Table 12).
Mortality (all cause and respiratory related)
There were 33 deaths (from all causes) during the 12-month follow-up period: 19 (2.5%) in the low-dose
theophylline group and 14 (1.8%) in the placebo group. Respiratory-related disease accounted for seven
deaths in theophylline group and eight deaths in the placebo group. Relative to the placebo group, the
adjusted HR for death from all causes in the theophylline group was 1.38 (95% CI 0.69 to 2.76), and
for respiratory-related causes it was 0.85 (95% CI 0.30 to 2.40). Therefore, there was no evidence of a
significant difference between treatment groups for mortality outcomes (see Table 12).
Total number of episodes of pneumonia
In total, there were 23 episodes of pneumonia reported during the follow-up: 14 in participants allocated
to theophylline and nine in participants allocated to placebo (1.8% in the theophylline arm vs. 1.2% in the
placebo arm). The proportion of admissions for pneumonia was not found to significantly differ between
treatment groups (p = 0.307). The unadjusted odds ratio (OR) was 1.55 (95% CI 0.67 to 3.62); however,
in the light of the small event counts, no adjustments were made (see Table 12).
Total dose of inhaled corticosteroids
The total daily dose of ICSs at baseline was available for 1532 of the 1536 members of the ITT population
(two missing from each treatment group). The mean total daily beclomethasone-equivalent ICS dose at
baseline was 1662 µg (SD 677 µg) in those allocated to theophylline and 1680 µg (SD 691 µg) in those
allocated to placebo. During the 12-month follow-up, 215 participants changed their medication: 104
(13.5%) theophylline participants and 111 (14.6%) placebo participants (p = 0.550). The mean total daily
beclomethasone-equivalent dose at the end of follow-up was 1606 µg (SD 694 µg) in those allocated to
theophylline and 1622 µg (SD 714 µg) in those allocated to placebo, resulting in an adjusted difference
of –12.4 µg per day (95% CI –81.4 to 56.6 µg) for theophylline compared with placebo (see Table 12).
This lower dose at the end of follow-up in those taking theophylline was not significantly different from
the dose for those taking placebo. Both groups showed a slight reduction in total daily dose from baseline
to end of follow-up, but a comparison of the adjusted mean dose change between treatment groups was
not significant (p = 0.852).
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TABLE 12 Secondary clinical outcomes (ITT analysis)
Secondary outcome
Trial arm
Adjusted or
unadjusted Estimate 95% CI p-valueTheophylline Placebo
Emergency hospital admissions (non-COPD)
Total number included in analysis 762 755
Number with one or more
emergency hospital admissions
79 92
Total number of admissions 116 119
Mean admission rate 0.15 0.16 Unadjusted IRR 0.96 0.69 to 1.35 0.830
SD admission rate 0.56 0.47 Adjusted IRRa 0.99 0.71 to 1.38 0.952
All-cause mortality
Total number included in analysis 772 764
Number deceased within
12 months
19 14 Unadjusted HR 1.35 0.68 to 2.69 0.398
Percentage deceased within
12 months
2.5 1.8 Adjusted HRa 1.38 0.69 to 2.76 0.369
COPD-/respiratory-related mortality
Total number included in analysis 772 764
Number deceased within
12 months
7 8 Unadjusted HR 0.87 0.31 to 2.39 0.785
Percentage deceased within
12 months
0.9 1.0 Adjusted HRa 0.85 0.30 to 2.40 0.762
Pneumonia
Total number included in analysis 772 764
Number with pneumonia 14 9 Unadjusted OR 1.55 0.67 to 3.62 0.307
Percentage with pneumonia 1.8 1.2
Total daily dose of ICSs
Total number included in analysis 770 762
Number who changed
medication from baseline
104 111
Mean daily dose of ICS at end of
follow-up (µg)
1606 1622 Unadjusted mean
difference
–16.3 –86.8 to 54.2 0.650
SD daily dose of ICS at end of
follow-up (µg)
694 714 Adjusted mean
differencea
–12.4 –81.5 to 56.6 0.724
Change in daily ICS dose from baseline
Total number included in analysis 770 762
Mean change in daily ICS dose
from baseline (µg)
–57 –58 Unadjusted mean
difference
1.4 –36.5 to 39.2 0.943
SD change in daily ICS dose
from baseline (µg)
346 408 Adjusted mean
differencea
3.6 –34.1 to 41.3 0.852
OR, odds ratio.
a Adjusted for centre (as a random effect), recruiting site (primary or secondary care), age centred on the mean, sex
(male/female), smoking in pack-years, FEV1% predicted, the number of COPD exacerbations in the previous year,
baseline COPD treatment and treatment with long-term antibiotics.
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Lung function (% predicted forced expiratory volume in 1 second and forced vital
capacity)
In the ITT analysis, lung function was found to be similar between the treatment groups with mean
% predicted FEV1 (FEV1%) at the end of the 12-month follow-up of 51.5% (SD 20.4%) for participants
allocated to low-dose theophylline (n = 533) and 52.1% (SD 21.7%) for participants allocated to placebo
(n = 489). The overall difference in FEV1% predicted (across the 12-month period) was –0.56% (95% CI
–2.42% to 1.30%) between the groups. A similar pattern was observed for % predicted FVC, with an
overall significant difference of –0.28% (95% CI –2.33% to 1.76%) (Table 13).
TABLE 13 Lung function (ITT analysis)
Outcome
Trial arm
Adjusted or
unadjusted
Overall mean
difference 95% CI p-valueTheophylline Placebo
% predicted FEV1
Baseline
Total (n) 769 757
Mean 51.2 52.3
SD 20.1 19.8
6 months
Total (n) 553 539
Mean 52.2 53.2
SD 20.5 20.9
12 months
Total (n) 533 489
Mean 51.5 52.1 Unadjusted –0.57 –2.51 to 1.36 0.561
SD 20.4 21.7 Adjusteda –0.56 –2.42 to 1.30 0.555
% predicted FVC
Baseline
Total (n) 767 756
Mean 84.3 86.3
SD 22.3 23.4
6 months
Total (n) 548 535
Mean 83.8 84.5
SD 22.8 24.7
12 months
Total (n) 525 486
Mean 83.1 82.3 Unadjusted –0.37 –2.50 to 1.75 0.732
SD 23.8 25.3 Adjusteda –0.28 –2.33 to 1.76 0.788
a Adjusted for centre (as a random effect), recruiting site (primary or secondary care), age centred on the mean, sex
(male/female), smoking in pack-years, FEV1% predicted, the number of COPD exacerbations in the previous year,
baseline COPD treatment and treatment with long-term antibiotics.
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Modified Medical Research Council dyspnoea scale
Table 14 details the responses to the mMRC breathlessness scale at baseline and at 6 and 12 months for
each treatment group. The proportions of participants in each category are relatively similar in both groups
at each time point. The overall adjusted OR (Table 15) from the mixed-effects ordinal logistic regression for
theophylline relative to placebo is 1.20 (95% CI 0.88 to 1.63), indicating a slight increase in odds of higher
mMRC score in theophylline participants than in the placebo participants, but the increase is not significant.
TABLE 14 The mMRC dyspnoea scale (ITT analysis)
mMRC category
Trial arm
Theophylline Placebo
Baseline (N, n, %)
Not troubled by breathlessness except on strenuous exercise 767, 35, 4.6 757, 50, 6.6
Short of breath when hurrying or walking up a slight hill 767, 211, 27.5 757, 218, 28.8
Walks slower than contemporaries on level ground or has to stop for breath when
walking at own pace
767, 248, 32.3 757, 235, 31.0
Stops for breath after walking about 100 m or after a few minutes on level ground 767, 219, 28.6 757, 201, 26.6
Too breathless to leave house, or breathless when dressing/undressing 767, 54, 7.0 757, 53, 7.0
6 months (N, n, %)
Not troubled by breathlessness except on strenuous exercise 676, 42, 6.2 655, 51, 7.8
Short of breath when hurrying or walking up a slight hill 676, 209, 30.9 655, 189, 28.9
Walks slower than contemporaries on level ground or has to stop for breath when
walking at own pace
676, 197, 29.1 655, 179, 27.3
Stops for breath after walking about 100 m or after a few minutes on level ground 676, 178, 26.3 655, 186, 28.4
Too breathless to leave house, or breathless when dressing/undressing 676, 50, 7.4 655, 50, 7.6
12 months (N, n, %)
Not troubled by breathlessness except on strenuous exercise 631, 38, 6.0 615, 52, 8.5
Short of breath when hurrying or walking up a slight hill 631, 186, 29.5 615, 158, 25.7
Walks slower than contemporaries on level ground or has to stop for breath when
walking at own pace
631, 174, 27.6 615, 182, 29.6
Stops for breath after walking about 100 m or after a few minutes on level ground 631, 178, 28.2 615, 167, 27.2
Too breathless to leave house, or breathless when dressing/undressing 631, 55, 8.7 615, 56, 9.1
TABLE 15 The ORs for the mMRC dyspnoea scale (ITT analysis)
OR Estimate 95% CI p-value
Unadjusted OR 1.27 0.91 to 1.76 0.157
Adjusted ORa 1.20 0.88 to 1.63 0.244
a Adjusted for centre (as a random effect), recruiting site (primary or secondary care), age centred on the mean, sex
(male/female), smoking in pack-years, FEV1% predicted, the number of COPD exacerbations in the previous year,
baseline COPD treatment and treatment with long-term antibiotics.
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The COPD Assessment Test
The CAT scores were very similar between groups at baseline (Table 16) and remained similar throughout
the 12-month treatment period, with a mean score of 21.4 (SD 8.2) for participants allocated to low-dose
theophylline (n = 633) and 21.4 (SD 8.6) for participants allocated to placebo (n = 615). A comparison of
the profile of the CAT scores across the three time points (i.e. 0, 6 and 12 months) showed an adjusted
difference of 0.01 (95% CI –0.65 to 0.68), suggesting no significant difference between the groups of the
impact of COPD on the participants’ lives.
TABLE 16 Participant-reported outcomes (ITT analysis)
Outcome
Trial arm
Adjusted or
unadjusted
Overall mean
difference 95% CI p-valueTheophylline Placebo
CAT score
Baseline
Total (n) 764 756
Mean 22.7 22.3
SD 7.5 7.9
6 months
Total (n) 675 657
Mean 21.3 21.1
SD 8.1 8.3
12 months
Total (n) 633 615
Mean 21.4 21.4 Unadjusted 0.13 –0.59 to 0.85 0.715
SD 8.2 8.6 Adjusteda 0.01 –0.65 to 0.68 0.975
HARQ score
Baseline
Total (n) 199 203
Mean 24.9 25.8
SD 16.0 14.8
6 months
Total (n) 191 188
Mean 21.9 22.9
SD 15.1 15.7
12 months
Total (n) 184 172
Mean 24.1 24.2 Unadjusted –0.85 –3.34 to 1.64 0.504
SD 15.7 15.9 Adjusteda –1.10 –3.46 to 1.26 0.359
a Adjusted for centre (as a random effect), recruiting site (primary or secondary care), age centred on the mean, sex
(male/female), smoking in pack-years, FEV1% predicted, the number of COPD exacerbations in the previous year,
baseline COPD treatment and treatment with long-term antibiotics.
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Hull Airways Reflux Questionnaire
The HARQ assesses respiratory symptoms associated with airway reflux, and was completed by a subset of
participants. Participants for whom HARQ data were available were more likely to be female and younger
than those who had no HARQ data (see Appendix 5, Table 37). Data were available for 199 (26.0%)
participants allocated to theophylline and 203 (26.9%) allocated to placebo at baseline. The HARQ scores
were very similar between treatment groups throughout the trial and at the 12-month follow-up; for
participants allocated to low-dose theophylline, the mean HARQ score was 24.1 (SD 15.7), based on
184 participants, and for those allocated to placebo, it was 24.2 (SD 15.9), based on 172 participants. A
comparison of the profiles of HARQ scores across the three time points (i.e. 0, 6 and 12 months) revealed
an adjusted difference of –1.10 (95% CI –3.46 to 1.26), suggesting no significant difference between the
groups in reflux-associated respiratory symptoms measured by the HARQ (see Table 15).
Safety outcomes (safety population)
The safety population comprised all participants who were randomised and included in the trial (n = 1567)
and initiated their trial medication. Five out of 788 (0.6%) participants allocated theophylline did not initiate
medication; 9 out of 779 (1.2%) participants in the placebo group did not initiate placebo. The safety
population consisted of 1553 (99.1%) participants (theophylline, n = 783; placebo, n = 770).
Serious adverse events
Overall, 211 (13.6%) participants had at least one SAE, 103 (out of 783, 13.2%) in the low-dose
theophylline group and 108 (out of 770, 14.0%) in the placebo group. A total of 276 SAEs were reported
in individuals in the safety population. These were balanced between the treatment groups, with 141 in
participants allocated to theophylline and 135 in placebo participants. SAEs were classified using System
Organ Classes (SOCs).95 Table 17 details, for each SOC code and for each treatment group, the number
of participants experiencing at least one SAE of that code, and the total number of SAEs of that SOC
code. No significant differences were observed in the SAE profile of the two treatment groups. The most
common SAE SOC code was for ‘cardiac disorders’ [2.8% (2.3% in the theophylline arm and 3.4%
in the placebo arm)]. SAEs with a coding of ‘respiratory, thoracic and mediastinal’ occurred in 2.5% of
participants (2.3% in the theophylline arm and 2.7% in the placebo arm). A borderline significantly higher
proportion of participants in the theophylline group (2.7%) reported a gastrointestinal SAE than in the
placebo group (1.3%) (p = 0.051). No pregnancies were reported. Line listings are provided in Appendix 6.
Adverse reactions
Information on adverse reactions was available for 1408 participants (theophylline, n = 709; placebo, n = 699),
with 648 (46%) suffering at least one AR (theophylline, n = 341; placebo; n = 307). There were 1701 ARs in
total: 883 in those allocated to low-dose theophylline and 818 in those allocated placebo. Table 18 presents
these ARs in more detail, with total number available for analysis for each AR, number of participants with
at least one AR of that type and the percentage in each group. The five most common ARs were nausea
(10.9% in the theophylline arm and 8.0% in the placebo arm; p = 0.059), insomnia (9.3% in the theophylline
arm and 8.9% in the placebo arm; p = 0.790), dizziness (8.1% in the theophylline arm and 9.6% in the
placebo arm; p = 0.290), gastro-oesophageal reflux (9.4% in the theophylline arm and 7.5% in the placebo
arm; p = 0.217) and headache (9.0% in the theophylline arm and 7.7% in the placebo arm; p = 0.383).
In addition, the proportion reporting tachycardia was slightly higher in the placebo group (3.5%) than in the
theophylline group (1.9%) (p = 0.058). There were no other observed significant differences in ARs between
treatment groups.
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TABLE 17 Serious adverse events (ITT analysis)
SAE
Trial arm
p-valueTheophylline Placebo
Total number included in analysis 783 770
All SAEs
Number of participants with at least one SAE 103 108
Percentage of participants with at least one SAE 13.2 14.0 0.616
Total number of SAEs 141 135
Infection and infestations
Number of participants with at least one SAE of this type 13 9
Percentage of participants with at least one SAE of this type 1.7 1.2 0.413
Total number of SAEs of this type 13 9
Neoplasms: benign, malignant and unspecified
Number of participants with at least one SAE of this type 17 11
Percentage of participants with at least one SAE of this type 2.2 1.4 0.272
Total number of SAEs of this type 18 11
Blood and lymphatic system disorders
Number of participants with at least one SAE of this type 0 2
Percentage of participants with at least one SAE of this type 0 0.3
Total number of SAEs of this type 0 2
Immune system disorders
Number of participants with at least one SAE of this type 0 0
Percentage of participants with at least one SAE of this type 0 0
Total number of SAEs of this type 0 0
Endocrine disorders
Number of participants with at least one SAE of this type 0 0
Percentage of participants with at least one SAE of this type 0 0
Total number of SAEs of this type 0 0
Metabolism and nutrition disorders
Number of participants with at least one SAE of this type 1 0
Percentage of participants with at least one SAE of this type 0.1 0
Total number of SAEs of this type 2 0
Nervous system disorders
Number of participants with at least one SAE of this type 11 7
Percentage of participants with at least one SAE of this type 1.4 0.9 0.361
Total number of SAEs of this type 13 7
Psychiatric disorders
Number of participants with at least one SAE of this type 1 2
Percentage of participants with at least one SAE of this type 0.1 0.3
Total number of SAEs of this type 1 3
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TABLE 17 Serious adverse events (ITT analysis) (continued )
SAE
Trial arm
p-valueTheophylline Placebo
Eye disorders
Number of participants with at least one SAE of this type 0 0
Percentage of participants with at least one SAE of this type 0 0
Total number of SAEs of this type 0 0
Ear and labyrinth disorders
Number of participants with at least one SAE of this type 0 0
Percentage of participants with at least one SAE of this type 0 0
Total number of SAEs of this type 0 0
Cardiac disorders
Number of participants with at least one SAE of this type 18 26
Percentage of participants with at least one SAE of this type 2.3 3.4 0.201
Total number of SAEs of this type 21 29
Vascular disorders
Number of participants with at least one SAE of this type 5 6
Percentage of participants with at least one SAE of this type 0.6 0.8
Total number of SAEs of this type 6 6
Respiratory, thoracic and mediastinal disorders
Number of participants with at least one SAE of this type 18 21
Percentage of participants with at least one SAE of this type 2.3 2.7 0.590
Total number of SAEs of this type 19 22
Hepatobiliary disorders
Number of participants with at least one SAE of this type 2 4
Percentage of participants with at least one SAE of this type 0.3 0.5
Total number of SAEs of this type 2 4
Gastrointestinal disorders
Number of participants with at least one SAE of this type 21 10
Percentage of participants with at least one SAE of this type 2.7 1.3 0.051
Total number of SAEs of this type 22 12
Skin and subcutaneous tissue disorders
Number of participants with at least one SAE of this type 1 0
Percentage of participants with at least one SAE of this type 0.1 0
Total number of SAEs of this type 1 0
Musculoskeletal and connective tissue disorders
Number of participants with at least one SAE of this type 5 9
Percentage of participants with at least one SAE of this type 0.6 1.2
Total number of SAEs of this type 5 11
continued
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TABLE 17 Serious adverse events (ITT analysis) (continued )
SAE
Trial arm
p-valueTheophylline Placebo
Renal and urinary disorders
Number of participants with at least one SAE of this type 6 4
Percentage of participants with at least one SAE of this type 0.8 0.5
Total number of SAEs of this type 6 4
Pregnancy, puerperium and perinatal conditions
Number of participants with at least one SAE of this type 0 0
Percentage of participants with at least one SAE of this type 0 0
Total number of SAEs of this type 0 0
Reproductive system and breast disorders
Number of participants with at least one SAE of this type 0 0
Percentage of participants with at least one SAE of this type 0 0
Total number of SAEs of this type 0 0
Congenital, familial and genetic disorders
Number of participants with at least one SAE of this type 0 0
Percentage of participants with at least one SAE of this type 0 0
Total number of SAEs of this type 0 0
General disorders and administration site disorders
Number of participants with at least one SAE of this type 0 0
Percentage of participants with at least one SAE of this type 0 0
Total number of SAEs of this type 0 0
Investigations
Number of participants with at least one SAE of this type 0 2
Percentage of participants with at least one SAE of this type 0 0.3
Total number of SAEs of this type 0 2
Injury, poisoning and procedural complications
Number of participants with at least one SAE of this type 9 13
Percentage of participants with at least one SAE of this type 1.1 1.7 0.369
Total number of SAEs of this type 11 13
Surgical and medical procedures
Number of participants with at least one SAE of this type 1 0
Percentage of participants with at least one SAE of this type 0.1 0
Total number of SAEs of this type 1 0
Social circumstances
Number of participants with at least one SAE of this type 0 0
Percentage of participants with at least one SAE of this type 0 0
Total number of SAEs of this type 0 0
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TABLE 18 Adverse reactions (ITT analysis)
AR
Trial arm
p-valueTheophylline Placebo
Any AR
Number included in analysis 709 699
Number with at least one AR 341 307
Percentage with at least one AR 48.1 43.9 0.116
Total number of ARs 883 818
Anaphylactic/anaphylactoid reaction
Number included in analysis 692 679
Number with at least one AR of this type 0 1
Percentage with at least one AR of this type 0.0 0.1
Hypersensitivity
Number included in analysis 692 679
Number with at least one AR of this type 5 5
Percentage with at least one AR of this type 0.7 0.7 > 0.999
Nausea
Number included in analysis 695 679
Number with at least one AR of this type 76 54
Percentage with at least one AR of this type 10.9 8.0 0.059
Reflux
Number included in analysis 693 678
Number with at least one AR of this type 65 51
Percentage with at least one AR of this type 9.4 7.5 0.217
Diarrhoea
Number included in analysis 693 680
Number with at least one AR of this type 53 46
Percentage with at least one AR of this type 7.6 6.8 0.527
Abdominal pain
Number included in analysis 692 679
Number with at least one AR of this type 42 34
Percentage with at least one AR of this type 6.1 5.0 0.390
Gastric irritation
Number included in analysis 691 679
Number with at least one AR of this type 38 28
Percentage with at least one AR of this type 5.5 4.1 0.235
Vomiting
Number included in analysis 693 678
Number with at least one AR of this type 28 22
Percentage with at least one AR of this type 4.0 3.2 0.432
continued
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TABLE 18 Adverse reactions (ITT analysis) (continued )
AR
Trial arm
p-valueTheophylline Placebo
Palpitations
Number included in analysis 690 678
Number with at least one AR of this type 29 26
Percentage with at least one AR of this type 4.2 3.8 0.729
Tachycardia
Number included in analysis 691 678
Number with at least one AR of this type 13 24
Percentage with at least one AR of this type 1.9 3.5 0.058
Insomnia
Number included in analysis 691 678
Number with at least one AR of this type 64 60
Percentage with at least one AR of this type 9.3 8.9 0.790
Anxiety
Number included in analysis 691 679
Number with at least one AR of this type 52 42
Percentage with at least one AR of this type 7.5 6.2 0.327
Rash
Number included in analysis 691 679
Number with at least one AR of this type 35 27
Percentage with at least one AR of this type 5.1 4.0 0.332
Pruritus
Number included in analysis 692 679
Number with at least one AR of this type 51 63
Percentage with at least one AR of this type 7.4 9.3 0.201
Tremor
Number included in analysis 691 678
Number with at least one AR of this type 34 38
Percentage with at least one AR of this type 4.9 5.6 0.571
Headache
Number included in analysis 691 678
Number with at least one AR of this type 62 52
Percentage with at least one AR of this type 9.0 7.7 0.383
Dizziness
Number included in analysis 691 678
Number with at least one AR of this type 56 66
Percentage with at least one AR of this type 8.1 9.7 0.290
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Subgroup analysis (intention to treat)
Appendix 5, Table 40 details the results of the subgroup analysis for the prespecified subgroups. Given the
exploratory nature of the analyses, we present 99% CIs. Figure 5 displays this information, alongside the
p-values for the interaction in the adjusted model. There was no evidence at the 1% level of statistical
significance that any effect of low-dose theophylline differed between subgroups of age, sex, smoking
status, BMI, COPD treatments, exacerbation history, COPD severity, baseline ICS dose or use of maintenance
OCSs.
Treatment adherence/compliance
Adherence/compliance was defined as having taken ≥ 70% of expected doses of trial tablets. In the ITT
population (n = 1536), 1180 (76.8%) participants fulfilled the definition of adherent/compliant (and made
up the per-protocol population). In the theophylline-allocated group, 181 out of 772 (23.4%) participants
were classed as non-adherent/non-compliant; three of these never initiated treatment, 171 were non-
persistent with (i.e. ceased) trial medication and seven persisted with trial medication but from returned
TABLE 18 Adverse reactions (ITT analysis) (continued )
AR
Trial arm
p-valueTheophylline Placebo
Agitation
Number included in analysis 691 679
Number with at least one AR of this type 22 18
Percentage with at least one AR of this type 3.2 2.6 0.558
Convulsions
Number included in analysis 691 678
Number with at least one AR of this type 2 4
Percentage with at least one AR of this type 0.3 0.6 0.448
Hyperuricemia
Number included in analysis 691 678
Number with at least one AR of this type 9 7
Percentage with at least one AR of this type 1.3 1.0 0.803
Diuresis
Number included in analysis 691 678
Number with at least one AR of this type 49 48
Percentage with at least one AR of this type 7.1 7.1 0.993
Urinary retention
Number included in analysis 691 677
Number with at least one AR of this type 16 15
Percentage with at least one AR of this type 2.3 2.2 0.901
Other
Number included in analysis 691 677
Number with at least one AR of this type 82 86
Percentage with at least one AR of this type 11.9 12.7 0.638
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medication it was evident that they were non-adherent/non-compliant (Table 19). In addition, 32 out of
591 low-dose theophylline participants fulfilled the adherent/compliant definition despite not persisting
with the trial medication, usually very late in the treatment period (Table 20). In the placebo group, 175 out
of 764 (22.9%) participants were classed as non-adherent/non-compliant; six never initiated medication,
159 were non-persistent with trial medication and 10 persisted with trial medication but medication returns
demonstrated poor implementation (see Table 19). A further 34 participants were non-persistent with
medication but fulfilled the definition of adherent/compliant because they ceased trial medication late into
the treatment period (see Table 20). In summary, the per-protocol population comprises 1180 participants
(591 from the theophylline arm and 589 from the placebo arm) and there were 1146 person-years of
follow-up data (see Table 19). A comparison of the proportion who were non-adherent/non-compliant
(23.4% in the theophylline arm vs. 22.9% in the placebo arm) was not significant (p = 0.802). In total,
203 out of 772 participants in the theophylline arm were non-persistent with medication, compared with
193 out of 764 in the placebo arm (unadjusted IRR 1.05, 95% CI 0.84 to 1.32).
0.642
IRR
0.420
0.849
0.605
0.139
0.785
0.155
0.832
0.478
0.894
0.561
0.637
0.198
0.609
Favours theophylline Favours placebo
Interaction
0.500 0.750 1.000 1.250 1.500
≥ 1600
< 1600 
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IV
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I–II
≥ 5
3 or 4
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ICS onlya
ICS/LABA or ICS/LAMA
ICS/LAMA/LABA
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≥ 70
60 – 69
< 60
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Overall
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Age (years)
Smoking status
BMI
COPD treatment
Number of previous exacerbations
GOLD stage
Oral steroids at baseline?
ICS dose (µg/day)
FIGURE 5 Forest plot of estimates from the subgroups. Vertical dashed line represents no effect (IRR= 1), vertical
solid line indicates the overall treatment effect for exacerbation (IRR = 0.992). a, Upper limit of CI truncated to 1.5,
actual value is 4.09; b, upper limit of CI truncated to 1.5, actual limit is 2.20.
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TABLE 19 Compliance information
Compliance
Trial arm (n)
Theophylline Placebo
Total 772 764
Not adherent/compliant (took < 70% of doses)a 181 175
Did not start medication (non-initiation) 3 6
Actively ceased medication (non-persistence) 171 159
Did not cease (persistent), but adherence/compliance was < 70% 7 10
Compliant (≥ 70%) 591 589
a Unadjusted IRR 1.03, 95% CI 0.81 to 1.31; p = 0.802.
TABLE 20 Reasons for stopping medication (of those who started)
Stopping medication
Trial arm (n)
Theophylline Placebo
Total 772 764
Did not start medication (non-initiation) 3 6
Actively ceased medication (non-persistent) 171 159
Adherent/compliant but ceased medication (non-persistent) 32 34
Total ceasing medication (who started) (non-persistent)a 203 193
Reason for stopping medication
Infections: and infestations 2 1
Neoplasms benign, malignant and unspecified (including cysts and polyps) 7 2
Psychiatric disorders 2 4
Nervous system disorders 19 15
Ear and labyrinth disorders 3 3
Cardiac disorders 7 6
Vascular disorders 1 1
Respiratory, thoracic and mediastinal disorders 10 19
Gastrointestinal disorders 46 32
Hepatobiliary disorders 0 1
Skin and subcutaneous tissue disorders 9 7
Musculoskeletal and connective tissue disorders 4 8
Renal and urinary disorders 5 1
Injury, poisoning and procedural complications 1 1
Surgical and medical procedures 19 21
Social circumstances 15 14
Participant felt no benefit 25 21
No reason given 28 36
a Unadjusted IRR 1.05, 95% CI 0.84 to 1.32; p = 0.676.
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Reasons for stopping medication
Table 20 presents the reasons for stopping medication among the ITT population by SOC code. The most
common reason for stopping medication was gastrointestinal disorders (theophylline, n = 46; placebo,
n = 32), followed by surgical and medical procedures (theophylline, n = 19; placebo, n = 21). Although the
surgical and medical procedures group included some participants who had discontinued ICSs containing
inhalers, the majority of this group comprised participants advised to discontinue the trial drug by a clinician
after presenting with a wide range of illnesses. In total, 46 participants discontinued the trial medication
because they felt no benefit (theophylline, n = 25; placebo, n = 21), and in 64 cases no reason was given
(theophylline, n = 28; placebo, n = 36), with a further 29 ceasing for social circumstances (theophylline,
n = 15; placebo, n = 14). There were no obvious differences between the two treatment groups in the
reasons why trial medication was discontinued, but no formal statistical testing was undertaken.
Per-protocol analysis
The per-protocol population comprised the 1180 participants of the ITT population who met the trial
definition of adherence with the trial medication. The per-protocol analysis comprised 591 participants
allocated to low-dose theophylline and 589 allocated to placebo (Figure 6).
Primary outcome: total number of exacerbations of chronic obstructive
pulmonary disease necessitating a change in management
In the per-protocol population, 591 theophylline-allocated participants had a mean of 2.20 (SD 1.96)
exacerbations, compared with a mean of 2.14 (SD 1.92) exacerbations among the 589 placebo participants.
There were 1298 exacerbations in the theophylline group and 1258 in placebo group. The adjusted IRR
for COPD exacerbation was 1.00 (95% CI 0.91 to 1.10), indicating no difference in the exacerbation rate
during the 12-month follow-up period for those on low-dose theophylline compared with those receiving
placebo who were adherent/compliant with the trial medication (Table 21).
Secondary outcomes
Total number of exacerbations of chronic obstructive pulmonary disease resulting in
hospital admission
In the per-protocol population, 76 out of 591 (13%) participants allocated to theophylline had at least
one COPD exacerbation necessitating hospital admission; there were 92 admissions in the group overall.
Among participants allocated to placebo, 88 out of 589 (15%) had at least one admission and there
were 126 admissions overall. The mean number of COPD exacerbations necessitating hospital admission
was 0.16 (SD 0.45) among the 591 compliant participants in the theophylline group and 0.21 (SD 0.61)
among the 589 compliant participants in the placebo group. In the adjusted model, the IRR for COPD
exacerbations necessitating hospital admission was 0.70 (95% CI 0.50 to 0.97), suggesting a significant
reduction in the number of exacerbations necessitating hospital admission in the low-dose theophylline
group compared with the placebo group (see Table 21).
Time to first exacerbation
The information for the time to first exacerbation was missing for 19 of the 1180 per-protocol participants;
therefore, this analysis was based on 1161 participants. Among participants allocated to theophylline,
468 out of 578 (81.0%) had at least one exacerbation, with a median time to first exacerbation of 221 days
(7.3 months) after randomisation. In the placebo group, 459 out of 583 (78.7%) participants had at least
one exacerbation, with a median time to first exacerbation of 232 days (7.7 months). In a Cox regression
analysis, the adjusted HR for time to first exacerbation was 1.02 (95% CI 0.90 to 1.16), suggesting no
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difference between the treatment groups in terms of time to first exacerbation (from point of
randomisation) during the 12-month follow-up period (see Table 21).
Total number of emergency hospital admissions (non-chronic obstructive pulmonary
disease related)
Hospital admission data were available for 1176 out of 1180 participants in the per-protocol population.
Overall, 111 participants had at least one admission (theophylline, n = 45; placebo, n = 66), with 66
admissions in the theophylline group and 85 admissions in the placebo group. The adjusted IRR for admission
was 0.82 (95% CI 0.54 to 1.24), suggesting no significant difference in the rate of non-COPD-related
emergency hospital admissions between participants compliant with low-dose theophylline and those
compliant with placebo (Table 22).
Randomised
(n = 1578)
Screened
(n = 1648)
Allocated theophylline
(n = 791)
Number included
(n = 788)
Post-randomisation
exclusions
(n = 16)
Missing primary
outcome data
(n = 16)
Post-randomisation
exclusions
(n = 8)
Missing primary
outcome data
(n = 15)
Not eligible, n = 62 
(see Figure 4)
Eligible, but did not
consent, n = 8
• Never initiated
   treatment, n = 3
• Actively ceased
   medication and
   compliance was 
   < 70% over 52 weeks,
   n = 171
• Returns indicated
   that compliance was
   < 70% over 52 weeks,
   n = 7
• Never initiated
   treatment, n = 6
• Actively ceased
   medication and
   compliance was 
   < 70% over 52 weeks,
   n = 159
• Returns indicated
   that compliance was
   < 70% over 52 weeks,
   n = 10
Number included in
per-protocol analysis
of primary outcome
(n = 591)
Allocated placebo
(n = 787)
Number included
(n = 779)
Number included in
per-protocol analysis
of primary outcome
(n = 589)
FIGURE 6 The CONSORT flow diagram for the per-protocol analysis.
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Mortality (all cause and respiratory related)
There were 22 deaths (from all causes) during the 12-month follow-up period in the per-protocol population:
13 (2.2%) in participants taking theophylline and nine (1.5%) in participants taking placebo. These deaths
were respiratory related in five cases in each of the theophylline and placebo groups. The unadjusted HR for
deaths from all causes was 1.45 (95% CI 0.62 to 3.38); for deaths from respiratory-related causes, the HR
was 1.00 (95% CI 0.29 to 3.46) for theophylline relative to placebo (see Table 22). Therefore, there was no
evidence of a significant difference between treatment groups for mortality outcomes in the per-protocol
population. No adjustments were made because of small event counts.
TABLE 21 Exacerbation outcomes (per-protocol analysis)
Exacerbations
Trial arm
Adjusted or
unadjusted Estimate 95% CI p-valueTheophylline Placebo
Primary outcome: exacerbations
Total number included in analysis 591 589
Person-years of follow-up 572.8 573.8
Number with at least one
exacerbation
481 465
Total number of exacerbations 1298 1258
Mean number of exacerbations 2.20 2.14 Unadjusted IRR 1.02 0.92 to 1.13 0.664
SD (number of exacerbations) 1.96 1.92 Adjusted IRRa 1.00 0.91 to 1.10 0.934
Exacerbations requiring hospital admission
Total number included in analysis 591 589
Number with at least one
exacerbation
76 88
Total number of exacerbations 92 126
Mean number of exacerbations 0.16 0.21 Unadjusted IRR 0.74 0.53 to 1.03 0.072
SD (number of exacerbations) 0.45 0.61 Adjusted IRRa 0.70 0.50 to 0.97 0.031
Time to first exacerbation (from randomisation)
Total number included in
analysisb
578 583
Number with at least one
exacerbation
468 459
Percentage with at least one
exacerbation
81.0 78.7
Median time to first exacerbation
(days)
221 232 Unadjusted HR 1.04 0.91 to 1.18 0.576
25th percentile [time to first
exacerbation (days)]
132 126 Adjusted HRa 1.02 0.90 to 1.16 0.733
75th percentile [time to first
exacerbation (days)]
341 339
a Adjusted for centre (as a random effect), recruiting site (primary or secondary care), age centred on the mean, sex
(male/female), smoking in pack-years, FEV1% predicted, number of COPD exacerbations in the previous year, baseline
COPD treatment and treatment with long-term antibiotics.
b Number included is reduced because the date of onset of first exacerbation was missing for 19 participants.
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TABLE 22 Secondary clinical outcomes (per-protocol analysis)
Non-COPD-related hospital
admissions
Trial arm
Adjusted or
unadjusted Estimate 95% CI p-valueTheophylline Placebo
Emergency hospital admissions (non-COPD related)
Total number included in analysis 587 589
Number with at least one
emergency hospital admission
45 66
Total admissions 66 85
Mean admission rate 0.11 0.14 Unadjusted IRR 0.77 0.51 to 1.17 0.220
SD admission rate 0.49 0.45 Adjusted IRRa 0.82 0.54 to 1.24 0.351
All-cause mortality
Total number included in analysis 591 589
Number deceased within
12 months
13 9 Unadjusted HR 1.45 0.62 to 3.38 0.394
% deceased within 12 months 2.2 1.5
Respiratory related mortality
Total number included in analysis 591 589
Number deceased within
12 months
5 5 Unadjusted HR 1.00 0.29 to 3.46 0.998
Percentage deceased within
12 months
0.9 0.9
Pneumonia
Total number included in analysis 591 589
Number with pneumonia 9 5 Unadjusted OR 1.81 0.60 to 5.44 0.291
Percentage with pneumonia 1.5 0.9
Total daily dose ICS
Total number included in analysis 589 588
Number changed medication
from baseline
78 93
Mean ICS daily dose at end of
follow-up (µg)
1617 1605 Unadjusted
mean difference
12.2 –67.6 to 92.1 0.764
SD (ICS daily dose at end of
follow-up) (µg)
693 704 Adjusted mean
differencea
12.5 –65.9 to 90.9 0.754
Change in daily ICS dose from baseline
Total number included in analysis 589 588
Mean change in daily ICS dose
from baseline (µg)
–62 –60 Unadjusted
mean difference
–1.60 –45.4 to 42.3 0.943
SD (change in daily ICS dose
from baseline) (µg)
347 417 Adjusted mean
differencea
–0.58 –44.3 to 43.1 0.979
a Adjusted for centre (as a random effect), recruiting site (primary or secondary care), age centred on the mean, sex
(male/female), smoking in pack-years, FEV1% predicted, number of COPD exacerbations in the previous year, baseline
COPD treatment and treatment with long-term antibiotics.
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Total number of episodes of pneumonia
There were 14 episodes of pneumonia: nine (out of 591, 1.5%) among low-dose theophylline-adherent/
compliant participants and five (out of 589, 0.9%) among placebo-compliant participants. The unadjusted
IRR was 1.81 (95% CI 0.60 to 5.44) and no adjustments were made because of small event counts (see
Table 22).
Total dose of inhaled corticosteroids
The total daily dose of ICS at baseline was available for 1176 of the 1180 members of the per-protocol
population. During the 12-month follow-up, 171 participants changed their medication: 78 (13.2%)
theophylline participants and 93 (15.8%) placebo participants (p = 0.210). The mean total daily
beclomethasone-equivalent dose at the end of follow-up was 1617 µg (SD 693 µg) in those allocated
to theophylline and 1605 µg (SD 704 µg) in those allocated to placebo, resulting in an adjusted daily
beclomethasone-equivalent difference of 12.5 µg (95% CI –65.9 to 90.9 µg) between theophylline
and placebo (see Table 22); this difference was not significantly different. Both groups showed a slight
reduction in total daily dose from baseline to end of follow-up, but a comparison of the adjusted mean
dose change between treatment groups revealed that the difference was not significant (p = 0.979).
Lung function (% predicted forced expiratory volume in 1 second and forced
vital capacity)
In the per-protocol analysis, lung function profile was similar in both treatment groups. The mean %
predicted FEV1 at the end of the 12-month follow-up period was slightly lower in the compliant/adherent
theophylline group than in the placebo group [51.3% (SD 20.3%) (n = 455) vs. 52.6% (SD 21.8%) (n = 432)],
giving an overall difference between the groups of –1.33% (95% CI –3.47% to 0.80%) (Table 23). A similar
pattern was observed for % predicted FVC, with an overall difference of –0.65% (95% CI –2.96% to
1.67%). This was a larger reduction than that observed in the ITT analysis, but remained non-significant.
Modified Medical Research Council dyspnoea scale
Tables 24 and 25 detail the responses to the mMRC dyspnoea scale at baseline, 6 months and 12 months
for each treatment group in the per-protocol population. In the unadjusted model, the OR for higher
mMRC dyspnoea score in theophylline participants compared with placebo participants is 1.54 (95% CI
1.05 to 2.26); the adjusted OR is 1.39 (95% CI 0.97 to 1.98).
The COPD Assessment Test
The CAT scores were very similar between treatment groups at baseline (Table 26) and remained similar
through to 12 months, with a mean score of 21.0 (SD 8.2) for theophylline-adherent/compliant participants
(n = 534) and 20.9 (SD 8.7) for placebo participants (n = 527) in the per-protocol population. A comparison
of the profile of the CAT scores across the three time points (0, 6 and 12 months) showed an adjusted
difference of 0.29 (95% CI –0.45 to 1.04), suggesting that the impact of COPD on participants’ lives did
not significantly different between the groups of the per-protocol population.
Hull Airway Reflux Questionnaire
At 12 months, the mean HARQ score was 23.0 (SD 15.6) among 153 theophylline-adherent/compliant
participants and 24.4 (SD 15.8) among 141 placebo-adherent/compliant participants. A comparison of the
profile of the HARQ scores across the three time points (0, 6 and 12 months) showed an adjusted difference
of –1.62 (95% CI –4.25 to 1.01), suggesting no significant difference between the per-protocol treatment
groups in reflux-associated respiratory symptoms measured by the HARQ (see Table 26).
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TABLE 23 Lung function (per-protocol analysis)
Outcome
Trial arm
Adjusted or
unadjusted Overall mean difference 95% CI p-valueTheophylline Placebo
FEV1% predicted
Baseline
Total (n) 588 583
Mean 50.7 52.8
SD 20.5 20.0
6 months
Total (n) 471 471
Mean 52.0 53.7
SD 20.8 20.8
12 months
Total (n) 455 432
Mean 51.3 52.6 Unadjusted –1.41 –3.65 to 0.82 0.215
SD 20.3 21.8 Adjusteda –1.33 –3.47 to 0.80 0.221
FVC% predicted
Baseline
Total (n) 586 582
Mean 84.2 86.6
SD 22.9 23.5
6 months
Total (n) 467 467
Mean 84.3 84.6
SD 23.0 24.3
12 months
Total (n) 449 431
Mean 83.3 82.6 Unadjusted –0.84 –3.25 to 1.56 0.492
SD 23.2 25.3 Adjusteda –0.65 –2.96 to 1.67 0.584
a Adjusted for centre (as a random effect), recruiting site (primary or secondary care), age centred on the mean, sex
(male/female), smoking in pack-years, FEV1% predicted, number of COPD exacerbations in the previous year, baseline
COPD treatment and treatment with long-term antibiotics.
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TABLE 24 The mMRC dyspnoea scale (per-protocol analysis)
Time
point mMRC category75
Trial arm (N, n %)
Theophylline Placebo
Baseline Not troubled by breathlessness except on strenuous exercise 586, 26, 4.4 584, 44, 7.5
Short of breath when hurrying or walking up a slight hill 586, 160, 27.3 584, 176, 30.1
Walks slower than contemporaries on level ground or has to stop for
breath when walking at own pace
586, 198, 33.8 584, 181, 31.0
Stops for breath after walking about 100 m or after a few minutes on
level ground
586, 157, 26.8 584, 149, 25.5
Too breathless to leave house, or breathless when dressing/
undressing
586, 45, 7.7 584, 34, 5.8
6 months Not troubled by breathlessness except on strenuous exercise 560, 34, 6.1 552, 46, 8.3
Short of breath when hurrying or walking up a slight hill 560, 182, 32.5 552, 160, 29.0
Walks slower than contemporaries on level ground or has to stop for
breath when walking at own pace
560, 161, 28.8 552, 155, 28.1
Stops for breath after walking about 100 m or after a few minutes on
level ground
560, 142, 25.4 552, 153, 27.7
Too breathless to leave house, or breathless when dressing/
undressing
560, 41, 7.3 552, 38, 6.9
12 months Not troubled by breathlessness except on strenuous exercise 535, 32, 6.0 527, 47, 8.9
Short of breath when hurrying or walking up a slight hill 535, 167, 31.2 527, 149, 28.3
Walks slower than contemporaries on level ground or has to stop for
breath when walking at own pace
535, 146, 27.3 527, 153, 29.0
Stops for breath after walking about 100 m or after a few minutes on
level ground
535, 147, 27.5 527, 135, 25.6
Too breathless to leave house, or breathless when dressing/
undressing
535, 43, 8.0 527, 43, 8.2
TABLE 25 The ORs for the mMRC dyspnoea scale (per-protocol analysis)
OR Estimate 95% CI p-value
Unadjusted 1.54 1.05 to 2.26 0.028
Adjusteda 1.39 0.97 to 1.98 0.074
a Adjusted for centre (as a random effect), recruiting site (primary or secondary care), age centred on the mean, sex
(male/female), smoking in pack-years, FEV1% predicted, number of COPD exacerbations in the previous year, baseline
COPD treatment and treatment with long-term antibiotics.
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TABLE 26 Patient-reported outcomes (per-protocol analysis)
Time point
Trial arm
Adjusted or
unadjusted
Overall mean
difference 95% CI p-valueTheophylline Placebo
CAT score
Baseline
Total (n) 584 583
Mean 22.7 21.8
SD 7.5 7.9
6 months
Total (n) 560 555
Mean 21.0 20.5
SD 8.2 8.2
12 months
Total (n) 534 527
Mean 21.0 20.9 Unadjusted 0.52 –0.29 to 1.33 0.212
SD 8.2 8.7 Adjusteda 0.29 –0.45 to 1.04 0.444
HARQ score
Baseline
Total (n) 153 152
Mean 25.2 26.8
SD 15.9 14.7
6 months
Total (n) 160 151
Mean 21.2 22.5
SD 14.8 15.6
12 months
Total (n) 153 141
Mean 22.9 24.4 Unadjusted –1.39 –4.17 to 1.40 0.329
SD 15.6 15.8 Adjusteda –1.62 –4.25 to 1.01 0.227
a Adjusted for centre (as a random effect), recruiting site (primary or secondary care), age centred on the mean, sex
(male/female), smoking in pack-years, FEV1% predicted, number of COPD exacerbations in the previous year, baseline
COPD treatment and treatment with long-term antibiotics.
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Sensitivity analysis
We undertook a sensitivity analysis for the primary outcome and a number of secondary outcomes that
excluded the 33 participants who died during the 12-month follow-up period. This left 1503 participants in
the ITT population (753 theophylline and 750 placebo). Appendix 5, Tables 41 and 42, give the details of
these analyses.
Primary outcome
After excluding participants who died, the adjusted IRR for COPD exacerbations was 0.99 (95% CI 0.91 to
1.07) (see Appendix 5, Table 41), indicating that restricting the result to those who were alive for the full
12-month follow-up did not change the result of the original ITT analysis (IRR 0.99, 95% CI 0.91 to 1.08).
Secondary outcomes
Hospital admissions
Excluding the 33 deaths from the analysis of COPD exacerbations necessitating hospital admission, the
adjusted IRR was 0.73 (95% CI 0.55 to 0.97) in the remaining 1503 members of the ITT population, which
is very similar to the treatment estimate observed for all 1536 members of the ITT population (IRR 0.72,
95% CI 0.55 to 0.94). Data on admission to hospital for non-COPD reasons were available for 1485 people,
after excluding those who died. The adjusted IRR for admission for theophylline relative to placebo was
1.03 (95% CI 0.73 to 1.43), compared with 0.99 (95% CI 0.71 to 1.38) in the full ITT population.
Other
Excluding the 33 deaths made very little difference to the estimates of treatment effect on lung function
(FEV1 or FVC) or to the patient-reported outcomes of CAT and HARQ scores (see Appendix 5, Table 42).
For FEV1, the adjusted difference was –0.58% (95% CI –2.46% to 1.29%) compared with –0.56%
(95% CI –2.42% to 1.30%). For FVC, the adjusted difference was –0.37% (95% CI –2.43% to 1.69%)
compared with –0.28% (95% CI –2.33% to 1.76%) for the ITT population. For the CAT score, the
treatment difference was 0.02 (95% CI –0.65 to 0.69) compared with 0.01 (95% CI –0.65 to 0.69) in the
original ITT population. The HARQ analysis gave an adjusted difference of –0.89 (95% CI –3.27 to 1.50)
compared with –1.10 (95% CI –3.46 to 1.26) of the original ITT population. In summary, excluding the
33 deaths made little or no difference to the estimates of treatment effect in the ITT population.
Summary
There was no evidence that, overall, low-dose theophylline significantly reduced the number of COPD
exacerbations requiring treatment compared with placebo. There was some evidence that low-dose
theophylline reduced exacerbations that necessitated hospital admission, with most benefit being evident
in a small [1% (13/1556)] subgroup of patients frequently hospitalised with COPD. The total number of
emergency hospital admissions (non-COPD related) did not significantly differ between groups, and nor did
total episodes of pneumonia or mortality. Lung function was similar across the 12-month follow-up in the
two groups. The impact of the disease on patients was measured by the CAT, mMRC dyspnoea scale and
HARQ; no significant differences were found. The safety profile of low-dose theophylline was similar to
placebo. There was no evidence that the treatment effect differed in any of the prespecified subgroups.
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Chapter 5 Cost-effectiveness
This chapter reports the health economics results from the trial. The objective of the health economicsstudy was to determine the cost-effectiveness of adding low-dose theophylline to ICS therapy over a
12-month period. Mean resource use per participant is presented, along with levels of missing data and
mean unadjusted and adjusted costs.
Baseline resource use and costs
Baseline resource use and costs are presented in Table 27.
There is no significant difference between the arms for any of these baseline resources.
TABLE 27 Baseline resource use and costs (per participant)
Resource use
Trial arm, mean (SD)
Theophylline Placebo
Resource use
Exacerbations
Exacerbations requiring treatment in the previous 12 months 3.63 (2.22); n = 772 3.52 (2.08); n = 764
Exacerbations resulting in hospitalisation in the previous 12 months 0.404 (0.840); n = 768 0.358 (0.918); n = 758
Non-exacerbation resource use (mean number of uses per participant in the 6 months prior to randomisation)
COPD maintenance treatment at baseline n = 769 n = 758
Inhaled SABA 0.967 (0.177) 0.972 (0.164)
Inhaled combined ICS LABA 0.966 (0.181) 0.960 (0.195)
Inhaled short-acting muscarinic antagonist 0.068 (0.251) 0.065 (0.246)
Inhaled ICS 0.043 (0.203) 0.040 (0.195)
Inhaled non-combination LABA 0.018 (0.134) 0.029 (0.168)
Inhaled LAMA 0.805 (0.397) 0.817 (0.387)
Nebulised ipratropium 0.051 (0.291) 0.041 (0.246)
Nebulised SABA 0.204 (0.536) 0.185 (0.491)
Oral mucolytics 0.247 (0.432) 0.248 (0.432)
Oral leukotriene antagonists 0.042 (0.200) 0.041 (0.198)
Long-term antibiotics 0.066 (0.249) 0.059 (0.236)
Regular medication
Counta 4.65 (3.64); n = 772 4.41 (3.54); n = 764
Costsb (£)
Baseline COPD maintenance treatment costsc n = 769 n = 758
Inhaled SABA 17.50 (3.20) 17.60 (3.00)
Inhaled combined ICS and LABA 325.00 (1897) 247.00 (486)
Inhaled short-acting muscarinic antagonist 2.77 (10.30) 2.64 (10.10)
continued
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Resource use
Table 28 reports the mean resource use per participant for complete cases, during the 12-month follow-up
period.
As discussed in Chapter 4, the treatment of exacerbations at hospital was significantly different between
groups: more exacerbations were treated in hospital in the placebo group than in the theophylline group
(p = 0.02).
TABLE 27 Baseline resource use and costs (per participant) (continued )
Resource use
Trial arm, mean (SD)
Theophylline Placebo
Inhaled ICS 7.28 (50.80) 8.27 (71.20)
Inhaled non-combination LABA 3.89 (28.60) 6.20 (35.90)
Inhaled LAMA 164.00 (80.90) 167.00 (79.00)
Nebulised ipratropium 4.78 (26.30) 4.19 (24.00)
Nebulised SABA 8.55 (21.30) 8.14 (20.40)
Oral mucolytics 34.70 (60.70) 34.90 (60.80)
Oral leukotriene antagonists 0.44 (2.10) 0.43 (2.08)
Long-term antibiotics 21.00 (88.00) 25.70 (275)
Total baseline COPD maintenance treatment costs 590.00 (1904) 522.00 (571)
a Count (medication); mean number of non-COPD medications taken by each participant.
b Baseline resource use was collected for current use of COPD maintenance treatment and regular medication. For
calculating baseline resource use and costs, we have assumed this usage to be for the 6 months prior to baseline.
c Baseline costs are calculated for the previous 6 months, based on the medications used at baseline.
TABLE 28 Twelve-month resource use for complete cases (per participant)
Resource use
Trial arm, mean (SD)
Theophylline (n= 743) Placebo (n= 727)
Exacerbation resource usea (mean number of uses per participant in the 12-month follow-up period)
Increased use of SABA 1.01 (1.51) 1.04 (1.60)
Increased/started nebulised bronchodilator 0.288 (0.836) 0.318 (0.910)
OCS 1.72 (1.87) 1.68 (1.79)
Antibiotics 2.01 (1.83) 2.01 (1.84)
Oxygen 0.129 (0.511) 0.142 (0.541)
Other 0.075 (0.320) 0.076 (0.354)
Treated at home 2.08 (1.92) 2.10 (1.90)
Care by services to prevent hospitalisation 0.086 (0.379) 0.100 (0.416)
Admitted to hospital 0.179 (0.497) 0.253 (0.676)
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TABLE 28 Twelve-month resource use for complete cases (per participant) (continued )
Resource use
Trial arm, mean (SD)
Theophylline (n= 743) Placebo (n= 727)
Non-exacerbation resource use
COPD maintenance treatment (mean number of uses per participant in the 12-month follow-up period)
Inhaled SABA 0.926 (0.262) 0.934 (0.248)
Inhaled combined ICS LABA 0.918 (0.275) 0.922 (0.269)
Inhaled short-acting muscarinic antagonists 0.069 (0.253) 0.062 (0.241)
Inhaled ICS 0.039 (0.194) 0.044 (0.205)
Inhaled non-combination LABA 0.032 (0.177) 0.047 (0.211)
Inhaled LAMA 0.817 (0.387) 0.824 (0.381)
Nebulised ipratropium 0.046 (0.209) 0.037 (0.189)
Nebulised SABA 0.157 (0.364) 0.176 (0.381)
Oral mucolytics 0.285 (0.452) 0.294 (0.456)
Oral leukotriene antagonists 0.046 (0.209) 0.044 (0.205)
Long-term antibiotics 0.092 (0.289) 0.085 (0.279)
Non-exacerbation health services use
Inpatient
General medical ward stays (number of stays) 0.059 (0.263) 0.084 (0.406)
Long-stay ward stays (number of stays) 0.004 (0.063) 0 (0)
Other inpatient services (number of contacts) 0.027 (0.192) 0.022 (0.173)
Outpatient
Hospital day-case admissions (number of admissions) 0.187 (0.900) 0.169 (0.530)
Hospital outpatient appointments (number of appointments) 1.68 (2.63) 1.58 (2.66)
Accident and emergency (no overnight admission; number of visits) 0.137 (0.490) 0.128 (0.513)
Other inpatient services (number of admissions) 0.514 (2.87) 0.476 (2.23)
Primary care services
Emergency GP visit 1.03 (1.97) 1.01 (2.10)
Routine GP visit 3.18 (4.33) 2.84 (3.83)
Community district nurse (number of appointments) 0.801 (9.64) 0.631 (3.50)
Hospital at home team (number of contacts) 0.101 (1.01) 0.158 (2.92)
Other primary care services (number of contacts) 2.16 (5.37) 1.77 (3.68)
Non-COPD emergency hospital admissions
Emergency hospital admissions 0.150 (0.555) 0.158 (0.468)
Regular medication count
Regular medication countb 4.34 (3.55) 4.32 (3.51)
a Mean number of times each treatment was used for exacerbations per participant.
b Count (medication); mean number of non-COPD medications taken by each participant.
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Missing data
The disaggregated level of missing data affecting resource use is reported below; these are broken down
into exacerbations, COPD maintenance treatment and non-COPD emergency hospital admissions.
Exacerbations (length of exacerbation, treatment costs and location of treatment)
A total of 3430 exacerbations were recorded:
l In 329 participants, data on length of exacerbation were missing (5.9% missing data points).
l In 210 recorded exacerbations, the location of treatment marker was missing (3.4% missing
data points).
l In 46 participants with exacerbations treated in hospital, length of stay data were missing.
l In 171 recorded exacerbations, treatment cost was missing (1% missing data points).
Maintenance chronic obstructive pulmonary disease treatment
A total of 82 participants had missing total COPD maintenance costs (5.6% missing data points); these
missing data were replaced with a treatment-specific mean.
Non-chronic obstructive pulmonary disease emergency hospital admissions
A total of 235 non-COPD emergency hospital admissions were recorded:
l Nine participants had missing length of stay data for emergency hospital admissions (2.8% missing
data points).
All missing resource data were replaced using pragmatic, naive methods suitable for use when < 10% of
data are missing.
Table 29 presents the missing economic data for resource use and EQ-5D-3L completion.
Resource use data were available for 743 participants in the theophylline arm and 727 in the placebo arm;
resource use data during the follow-up period were not captured for 29 (3.8%) participants in the
theophylline arm and 37 (4.8%) participants in the placebo arm. Overall, 66 (4.3%) participants were
missing resource use data for the whole 12-month follow-up period.
The number of participants with missing EQ-5D-3L data was 137 (17.7%) in the theophylline arm and 156
(20.4%) in the placebo arm. Overall, 293 (19.1%) EQ-5D-3L questionnaires were missing.
TABLE 29 Missing resource use and EQ-5D-3L data
Data
Trial arm, n (%)
Total, n (%)Theophylline Placebo
Cost
ITT population 772 (100) 764 (100) 1536 (100)
No resource use captured during follow-up 29 (3.8) 37 (4.8) 66 (4.3)
Complete cases 743 (96.2) 727 (95.2) 1470 (95.7)
EQ-5D-3L
ITT population 772 (100) 764 (100) 1536 (100)
Missing EQ-5D-3L data at baseline/6 months or 12 months 137 (17.7) 156 (20.4) 293 (19.1)
Complete cases 635 (82.3) 608 (79.6) 1243 (80.9)
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Costs
Table 30 reports complete-case costs (unadjusted). Differences between arms are calculated using a GLM
with identity link, gamma family and a cluster for centre number. Regular medication was not included in
these costs because there was no significant difference between arms in regular medication count.
There is a significant difference of £452 (95% CI £133 to £771) in the mean total costs between arms,
with placebo being more costly than theophylline. This difference is driven by the difference in exacerbation
mean costs between arms: £447 (95% CI £186 to £709) higher in the placebo arm. The difference in
exacerbation costs is driven by the location of the treatment of an exacerbation. The mean ‘location of
exacerbation treatment’ cost is £422 (95% CI £171 to £673) higher in the placebo arm than in the
theophylline arm. As presented in Chapter 4, this is driven by a higher number of exacerbations treated in
hospital in the placebo arm than in the theophylline arm. This is reflected in the health economics analysis
for which the location of treatment costs are further broken down into ‘treatment at home’, ‘care by
services to prevent hospitalisation’ and ‘admitted to hospital’. The ‘treatment at home’ and ‘care by services
to prevent hospitalisation’ resource use costs show no significant differences between arms; however,
the ‘admitted to hospital’ cost is £416 (95% CI £177 to £655) higher in the placebo arm than in the
theophylline arm, which is a statistically significant result.
At a per-exacerbation level, this difference can be explored further. The mean cost per exacerbation
treated in hospital is £3613 [standard error (SE) £342] in the placebo arm and £2671 (SE £220) in the
theophylline arm, a significant difference of £941 (SE £386) (95% CI £140 to £1743). The 10 most costly
observations (> £10,000) were all in the placebo arm, and were the result of hospital stays of > 40 days.
Because of the lack of treatment effect, we believe this difference to be a chance finding and not a real
result of the trial. The distribution for length of hospital stay is similar for both arms apart from a small
excess of participants in the placebo arm with longer stays. It is important to note that the proxy for
hospital length of stay is length of exacerbation and that this is likely to overestimate length of stay in
hospital. In total, 319 exacerbations were treated in hospital: 185 in the placebo arm and 134 in the
theophylline arm.
TABLE 30 Complete-case costs (unadjusted)
Costs
Trial arm, mean (SD) (£)
Difference (£) 95% CI (£)Theophylline Placebo
Intervention costs 22 (0.24) 0 (0) 22 22 to 22
Exacerbation costs
Total exacerbation costs 585 (1682) 1033 (3383) –447 –709 to –186
Total location costs 535 (1594) 958 (3185) –422 –673 to –171
Location
Home 67 (61) 68 (60) –1 –6 to 4
Services 33 (145) 38 (159) –5 –23 to 12
Hospital 436 (1538) 852 (3142) –416 –655 to –177
Treatment 50 (167) 75 (296) –25 –41 to –8
Non-exacerbation costs
COPD maintenance treatment 974 (379) 978 (416) –4 –45 to 38
Health services resource use (not exacerbation related) 819 (1,224) 862 (1812) –43 –175 to 89
Non-COPD-related emergency hospital admissions 282 (1529) 262 (1136) 20 –102 to 143
Total costs 2684 (2882) 3136 (4851) –452 –771 to –133
Non-intervention, non-exacerbation costs 2075 (2079) 2101 (2528) –26 –234 to 181
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The cost of treatment of exacerbations differed significantly between arms, the mean cost per participant
being £25 lower in the theophylline arm. At a per-exacerbation level, this is driven by treatment with
oxygen. The mean cost of oxygen use per exacerbation treated with oxygen was £141 (SE £52) (95% CI
£40 to £243) lower in the theophylline arm than in the placebo arm. The difference in oxygen treatment
is driven by the fact that seven participants, six of whom were in the placebo group, were treated with
oxygen for > 51 days, at a cost per exacerbation of > £1000.
The wide SDs for hospitalised exacerbations, treatment of exacerbations, non-COPD emergency hospital
admissions and other health services use indicate a wide range of individual participants’ costs in these
resource groups.
No other resource use costs are significantly different between arms, which is reflected in the fact that
there was no difference between arms for the non-intervention, non-exacerbation costs presented in
Table 30.
Economic outcome
Complete-case EQ-5D-3L data and QALYs are reported in Table 31.
Utilities from the EQ-5D-3L data at baseline and the 6- and 12-month follow-ups and QALYs are higher in
the placebo arm than in the theophylline arm; however, these differences are not significant.
Multiple imputation
Multiple imputation results are presented in Table 32 for costs and QALYs.
TABLE 32 Multiple imputation results (unadjusted)
Costs and QALYs
Trial arm, mean (SE)
Difference (95% CI)Theophylline Placebo
Total costs (£) 2702 (110) 3141 (148) –439 (–846 to –32)
Total QALYs 0.617 (0.010) 0.621 (0.010) –0.004 (–0.031 to 0.024)
TABLE 31 Complete-case EQ-5D-3L utilities and QALYs for the 12-month trial period
Time point
Trial arm, mean (SD)
Difference (95% CI)Theophylline Placebo
Baseline 0.629 (0.280) 0.643 (0.279) –0.014 (–0.045 to 0.017)
6 months 0.630 (0.296) 0.642 (0.295) –0.012 (–0.045 to 0.021)
12 months 0.622 (0.292) 0.623 (0.308) –0.001 (–0.034 to 0.032)
QALYs over 12 monthsa 0.626 (0.259) 0.637 (0.263) –0.011 (–0.040 to 0.018)
a There were 33 deaths in the ITT population; these participants had QALYs allocated to them for the period they were
alive, on a monthly basis.
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Multiple imputation results mirror the complete-case results, with costs significantly higher in the placebo
arm (a difference of £439). Total QALYs are higher in the placebo arm; however, this is not a statistically
significant result (a difference of 0.004).
Bootstrapping
To explore the robustness of these results, 1000 non-parametric bootstrapped samples were taken from
the observed data. The results were plotted using a cost-effectiveness plane to illustrate the mean
differences between the arms in incremental costs and QALYs.
Non-adjusted bootstrapped results are presented in Figure 7. This cost-effectiveness plane clearly illustrates
that the majority of total mean costs are lower in the theophylline arm than the placebo arm, with the
majority of incremental samples falling in the south-east and south-west quadrants of the cost-effectiveness
plane (below the horizontal axis of £0). The majority of total mean QALYs are lower in the theophylline arm
than in the placebo arm, represented by the majority of bootstrapping samples falling in the south-west
quadrant where the placebo arm has higher mean QALYs than the theophylline arm. The cost-effectiveness
plane includes an ellipse to illustrate the 95% confidence level.
This uncertainty is explored further using cost-effectiveness acceptability curves.
The unadjusted bootstrapped results are presented in Figure 8. At a willingness-to-pay threshold of £20,000,
there is a 75% chance of theophylline being cost-effective. At £30,000, there is a 64% chance of theophylline
being cost-effective. However, these results should be viewed with caution as there is no significant difference
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FIGURE 7 Cost-effectiveness plane (unadjusted).
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FIGURE 8 Cost-effectiveness acceptability curve (unadjusted).
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in QALYs or clinical effect, and the difference in costs is driven by a very small number of participants with
prolonged hospital admissions and the likelihood that the finding of a difference between arms for
exacerbations treated in hospital is a chance finding. Moreover, as discussed in Adjusted analysis, the cost
benefits of theophylline are not evident in multivariate models.
Adjusted analysis
Multiple imputation total mean costs were adjusted for baseline variables that were significant predictors of
cost. These were medication count at baseline, EQ-5D-3L data at baseline, offset time (time spent in the trial),
age, number of hospitalisations for exacerbations in the 12 months prior to randomisation and number of
exacerbations in the 12 months prior to randomisation. A cluster command was used for centre number.
Multiple imputation total mean QALYs were adjusted for baseline variables that were significant predictors of
QALYs. These were baseline EQ-5D-3L data, medication count at baseline, offset time, age, sex, hospitalisation
for exacerbations in the 12 months prior to randomisation and exacerbations in the 12 months prior to
randomisation. A cluster command was used for centre number. These results are presented in Table 33.
When multiple imputation total costs are adjusted, there is a trend towards higher costs in the placebo
arm; however, this difference is not significant.
Adjusting QALYs for baseline characteristics results in theophylline having higher QALYs than placebo;
however, this difference is not significant.
Figure 9 illustrates that, when the results are adjusted for baseline characteristics, the results are more
uncertain: the majority of total mean costs in the theophylline arm are still lower than in the placebo
arm, although this is now not a significant result. In addition, the QALYs are marginally higher in the
theophylline arm, again not a significant result. The ellipse represents the 95% confidence levels.
The adjusted bootstrapped results are presented in a cost-effectiveness acceptability curve in Figure 10.
At a willingness-to-pay threshold of £20,000, there is a 90% chance of theophylline being cost-effective.
At £30,000, there is an 85% chance of theophylline being cost-effective. Again, these results should be
viewed with caution as there was no significant difference between arms for QALYs or treatment effect.
Exacerbation costs were also adjusted separately to explore the adjustment on the significant difference in
exacerbation costs between arms. Strong predictors of exacerbation costs were offset time, hospitalisation
for exacerbations in the 12 months prior to randomisation and exacerbations in the 12 months prior to
randomisation. A cluster command was used for centre number. These results are presented in Table 34
and show that, for adjusted exacerbation costs, although there is a trend for higher costs in the placebo
arm, this difference is not significant. The mean cost difference has decreased from £447 to £67.
TABLE 33 Multiple imputation results (adjusted)
Costs and QALYs
Trial arm, mean (SE)
Difference (95% CI) Cost-effectivenessTheophylline Placebo
Total costs (£) 2784 (125) 3006 (167) –222 (–472 to 27) Theophylline dominates:
fewer costs and higher QALYs
Total QALYs 0.621 (0.006) 0.616 (0.007) 0.005 (–0.015 to 0.025)
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FIGURE 10 Cost-effectiveness acceptability curve (adjusted).
TABLE 34 Complete-case adjusted exacerbation costs
Costs
Trial arm, mean (SE) (£)
Difference (£) 95% CI (£)Theophylline Placebo
Total exacerbation cost 732 (96) 799 (71) –67 –196 to 61
Location costs 675 (98) 735 (72) –60 –190 to 68
Treatment costs 58 (11) 64 (8) –6 –19 to 7
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FIGURE 9 Cost-effectiveness plane (adjusted).
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Cost-effectiveness
For cost per QALY, the unadjusted results suggest that, although theophylline is cheaper than placebo
(significant result), the QALY gain is higher in the placebo arm than in the theophylline arm (non-significant
result). The adjusted results suggest that theophylline dominates: it is cheaper than placebo and results in a
higher QALY gain. However, this result should be interpreted with caution because the difference in QALYs
is not significant. This is mirrored by the trial primary outcome: theophylline is not clinically effective in terms
of reducing exacerbations.
COST-EFFECTIVENESS
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Chapter 6 Discussion
Main results
The results of this trial show that, for people with COPD at high risk of exacerbation, the addition of
low-dose oral theophylline to a drug regimen that includes an ICS confers no overall clinical or health economic
benefit. This result was evident from both the ITT and the per-protocol analyses. The primary outcome measure
for this trial was the total number of exacerbations of COPD requiring changes in management (minimum
management change: use of OCSs and/or antibiotics) during the 1-year treatment period, as reported by the
participant. For the 11 prespecified secondary outcome measures, the addition of low-dose theophylline had
no clinical or health economic benefit in 10 of these measures. The addition of low-dose theophylline did reduce
the number of COPD exacerbations necessitating hospital admission (often classified as ‘severe’)68 (adjusted
IRR 0.72, 95% CI 0.55 to 0.94); however, further inspection of the data indicated that this difference was the
consequence of a small excess of participants allocated to placebo (n = 10) having three or more hospital-treated
exacerbations, which accounted for 39 of the extra 51 hospital-treated exacerbations in the placebo arm. This
effect on hospital admissions was also evident in the per-protocol analysis. Given that adjustments for multiple
comparisons were not performed, it is possible that this finding could be due to type I error. However, in the
light of a 2018 report96 showing that another PDE inhibitor (roflumilast) is most beneficial in people with prior
COPD hospitalisation for exacerbation and greater exacerbation frequency, this finding warrants further
investigation. The safety data demonstrated that the addition of low-dose theophylline was not associated
with an increase in SAEs or ARs.
Relevance to existing literature
Oral theophylline has been used in the treatment of COPD and asthma for > 70 years. Conventionally, oral
theophylline has been used as a bronchodilator in COPD, this effect being mediated by inhibition of PDE.
However, in order to achieve modest clinical effects, relatively high blood concentrations (of 10–20mg/l) are
required, but, at these concentrations, non-specific inhibition of PDE is also associated with a wide range of
well-recognised side effects, for example nausea, palpitations and headaches. A Cochrane review published
in 2002 and updated in 201083 identified 20 randomised placebo-controlled trials of theophylline in COPD,
all of crossover design, using dosing schedules to obtain conventional plasma theophylline levels in the
therapeutic range (10–20 mg/l), that is conventional high-dose theophylline. The number of participants in
these trials ranged from 8 to 60; the total number of participants in the 20 trials was 488. The duration of the
studies was 9–90 days, the mean age of participants ranged from 58 to 69 years and four of the studies were
graded as being of high quality. The systematic review demonstrated that use of high-dose conventional
theophylline resulted in a small but significant increase in FEV1 of 100 ml (95% CI 40 to 160ml). This was
derived from 13 studies with 244 participants. Two studies with a total of 45 participants reported on the
incidence of exacerbations, concluding that high-dose conventional theophylline had no effect on the
incidence of exacerbations. Three studies with a total of 64 participants reported data on nausea, with the
risk of experiencing nausea when on theophylline treatment being significantly increased (RR 7.67, 95% CI
1.47 to 39.94). When compared with previous trials of conventional high-dose theophylline in COPD, the
current trial of low-dose theophylline that recruited 1578 participants is clearly somewhat larger and the
treatment period is longer in duration. Moreover, in contrast to conventional high-dose theophylline trials
with their focus on lung function, the primary outcome of the current study was exacerbations of COPD
and the study population comprised participants at high risk of exacerbating. When compared with these
trials of high-dose conventional theophylline, the current trial, as expected, showed no effect of low-dose
theophylline on lung function (FEV1) and, reassuringly, no increase in side effects. One of the findings from
the Cochrane review83 was that very few participants withdrew from intervention trials of high-dose
conventional theophylline for any reason. In the review,83 nine studies reported no dropouts, and in the
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remaining studies the dropout rate was generally very low; the only exception to this low dropout rate was
the study of Guyatt et al.,97 who reported eight withdrawals out of 27 recruited participants (30%).
The sample size of the current trial included an estimate of 6% of participants ceasing taking their trial
medication, based on the four high-quality studies reported in the Cochrane review,83 in which three out of
51 (6%) participants dropped out. The 26% of participants ceasing trial medication in the current study is
greater than anticipated (although balanced across the arms) and more in keeping with the study of Guyatt
et al.,97 probably reflecting the pragmatic nature of the current trial, the fact that participants in the current
trial were older than those in the Cochrane review and that the trial lasted longer.83
The use of high-dose conventional theophylline has declined over the years because of its narrow therapeutic
index, modest clinical effect, side effect profile, drug interactions, the need for blood concentration monitoring
and the availability of more effective inhaled therapies.98 High-dose conventional theophylline is now included
in current COPD guidelines as a third-line therapy.1
The concept of using low-dose theophylline to augment the anti-inflammatory effects of corticosteroids on
the airway inflammatory processes in COPD originated from in vitro and animal studies investigating the
molecular mechanisms contributing to the reduced corticosteroid sensitivity of COPD.32,38–40,43,46 The key
observation was that the reduced HDAC2 activity of COPD can be reversed by low concentrations (1–5 mg/l)
of theophylline; moreover, theophylline reduces corticosteroid insensitivity in COPD, such that there is a
marked synergistic interaction between theophylline and corticosteroids in suppressing the release of
inflammatory mediators from alveolar macrophages obtained from COPD patients.43,44 These basic research
studies suggest that low-dose (i.e. 1–5 mg/l) theophylline could increase HDAC activity and, hence, reduce
corticosteroid resistance in COPD patients, thereby enabling ICSs to switch off inflammation and potentially
more effectively reduce exacerbation rates.
Prior to commencing the current study, the concept of using low-dose theophylline in conjunction with
corticosteroids in COPD had been explored in two small RCTs. The first RCT was in 35 patients admitted
to a Spanish hospital with an acute exacerbation of COPD who were treated with a regime that included
systemic corticosteroids.48 Participants were randomised to receive additional low-dose theophylline or
nothing in a single-blind design; participants not on ICSs at admission were commenced on ICSs. After
3 months of treatment, low-dose theophylline increased sputum macrophage HDAC activity and reduced
sputum concentrations of the pro-inflammatory mediators IL-8 and tumour necrosis factor alpha (TNF-α).
There were no clinically significant effects in this small study,48 although fewer participants in the
theophylline group than in the control group had a subsequent exacerbation (12.5% vs. 26%). This
study48 differed from the current study in the following ways: small sample size, single blinded, no placebo
control, 3-month follow-up, participants were recruited only during hospitalisation with exacerbations of
COPD, all were male and only 14% had experienced two or more exacerbations in the previous year.
Notably, 26% of participants were not followed up at 3 months.
The second small (n = 30) RCT of COPD patients was a double-dummy (low-dose theophylline vs. placebo,
standardised dose of ICS vs. placebo), randomised, double-blind, parallel study, based in the UK.49 After
4 weeks of low-dose theophylline, there was no effect on the primary outcome of absolute number of
sputum neutrophils. The combination of low-dose theophylline/ICS significantly reduced a number of
secondary end points (e.g. sputum percentage neutrophils, sputum total eosinophil count). In an open-label
extension of the trial, the combination of low-dose theophylline/ICS increased peripheral blood mononuclear
cell HDAC activity ninefold. The study concluded that the combination of ICS and low-dose theophylline
may attenuate airway inflammation in patients with COPD. One of the limitations of this study was that
the significant findings were for low-dose theophylline/ICS versus theophylline, rather than low-dose
theophylline/ICS versus ICS, suggesting perhaps that the observed effects were a consequence of the ICS
and not the low-dose theophylline. This study49 differs from the current study in the following ways: 4-week
duration, small numbers, 83% male and younger average age (61 years). Lung function (mean FEV1 54%)
was similar.
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While the current trial was being conducted, two trials investigating the therapeutic consequences of
low-dose theophylline were published.52,99 The first study,99 from India, was a hospital-based, single-blinded,
prospective, randomised, placebo-controlled study that investigated the effects of adding low-dose
theophylline to the combination of formoterol plus budesonide. A total of 58 patients with moderate/severe
COPD were commenced on a standardised ICS/LABA therapy (budesonide and formoterol) and were
randomised to receive in addition either low-dose theophylline or placebo for 60 days. Fifty participants
completed the trial and their data were presented.99 The addition of low-dose theophylline resulted in a
greater improvement in total symptom scores, a greater increase in FEV1 and a greater increase in 6-minute
walking distance than did the addition of placebo. Of note, however, is that the method of randomisation
was not described, the actual number of participants randomised to each treatment group was not presented,
the nature of the ‘single blind’ was not explained and there was no ITT analysis. The randomisation appeared
not to have eliminated potential sources of bias, as the participants allocated to low-dose theophylline were
clearly more severely affected by COPD: their respiratory rate was greater (20.7 vs. 18.7 breathes per minute;
p = 0.003), their FEV1 values were lower (49% vs. 57% predicted; p = 0.05), their symptom scores were
greater (10.17 vs. 8.37; p = 0.003), their 6-minute walking distance was shorter (373 m vs. 409m; p = 0.07)
and more were classified as having severe COPD (54% vs. 27%; p = 0.09).99 Moreover, the placebo tablets
were described as similar rather than identical. These differences could reflect a bias for the more severely
affected participants to be preferentially allocated to the low-dose theophylline arm of the trial. This study99
differs from the current study in the following ways: the sample size was much smaller and hospital based,
92% of participants were male, participants were younger (≈55 years), BMI was lower (≈17 kg/m2), there was
a 60-day treatment period and the trial was single blinded. In addition to the issues regarding blinding and
randomisation, the results of the trial99 also raise the possibility that, although the intention was to investigate
low-dose theophylline, in reality, conventional high-dose theophylline was being tested: an improvement
in FEV1 was described with theophylline treatment and the dosing regimen for this study was 400mg of
theophylline for a weight of > 50 kg, 300mg for a weight of 40–50 kg and 200 mg for a weight of < 40 kg.
However, a significant proportion of participants appeared to be underweight, with a mean BMI of ≈17 kg/m2,
and theophylline treatment resulted in higher incidences of typical high-dose theophylline toxicity symptoms
such as nausea, vomiting, headache, palpitation and insomnia. In the current study, this was avoided by basing
theophylline dose on IBW and smoking status.
The second study, the Spanish ASSET trial,52 was a multicentre, randomised, double-blind, placebo-controlled
trial that recruited patients with COPD while they were hospitalised for a COPD exacerbation. Participants
were randomised to low-dose theophylline (100 mg twice a day) or matched placebo in addition to ICS/LABA
treatment; participants not routinely taking ICS/LABA were established on ICS/LABA. In total, 70 patients were
randomised (theophylline, n = 36; placebo, n = 34) and 46 completed the year of treatment (theophylline,
n = 23; placebo, n = 23). The co-primary outcomes were change in HDAC and exacerbation frequency
during the 1-year treatment period. The addition of low-dose theophylline had no effect on plasma/sputum
HDAC concentrations and no effect on COPD exacerbation rate [theophylline 0.97 (SD 0.94) vs. placebo
0.88 (SD 0.89)]. This trial52 has some similarities with the current trial: primary outcome of exacerbation,
same definition of exacerbation, 1-year treatment period, similar participant age, CAT score and levels of
cardiovascular comorbidity at baseline, and no significant difference in ARs between groups. However, there
are some important differences between the ASSET trial52 and the current trial (TWICS). The current trial
is much larger (n = 1578) than the ASSET trial (n = 70), being designed to detect a 15% reduction in
exacerbations with 90% power, whereas the ASSET trial was designed to detect an arguably implausibly large
50% reduction in exacerbations with 80% power. The exacerbation rate in the ASSET trial was about half
that observed for the TWICS trial (0.92 vs. 2.23 per year). Perhaps the most plausible explanation for this is
that all participants in the ASSET trial were recruited while hospitalised with an exacerbation of COPD,
irrespective of exacerbation history, whereas participants in the TWICS trial were clinically stable; 60% were
identified from primary care and all had a history of two or more exacerbations in the previous year requiring
treatment with antibiotics and/or corticosteroids. The proportion of participants ceasing trial medication
was higher in the ASSET trial than in the TWICS trial (34% vs. 26%); however, it should be noted that 14%
of participants in the ASSET trial ceased trial medication because their FEV1 improved to > 50% predicted
during the 1-year treatment period. This is most likely to be a consequence of the ASSET trial recruiting in the
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peri-exacerbation period and the TWICS trial recruiting when participants were clinically stable. When
compared with the TWICS trial, participants in the ASSET trial were more likely to be male, had more severe
COPD (lower FEV1) and were more likely to be hospitalised during the treatment period, but were less likely to
be diabetic [probably reflecting the higher mean BMI of the TWICS trial participants (27 vs. 22 kg/m2)].
The GOLD management strategy guideline1 highlights that the clinical relevance of low-dose theophylline
has not been fully established and that clinical evidence for an effect of low-dose theophylline, particularly
on exacerbations, is limited and contradictory. The TWICS trial is the first large, pragmatic, community-
based trial to investigate the effect of adding low-dose theophylline to the treatment regimen of people
with COPD who are at a high risk of exacerbating despite a treatment regime that includes maintenance
ICSs in COPD.
Pre-clinical work convincingly demonstrates that the combination of low-dose theophylline and
corticosteroids has a strong biological effect, increasing HDAC and inhibiting the release of pro-inflammatory
mediators.38,39,41–44 The trials conducted to date have been small (n = 30–70), hospital based and have tended
to focus on biological outcomes with short treatment periods.48,49,52,99 The largest trial52 to date in this field
has reported that low-dose theophylline had no effect on HDAC or exacerbations; however, as the authors
of the ASSET trial acknowledge, ‘we might have overestimated the potential clinical benefit when we
calculated the sample size, which may have precluded us from identifying a clear-cut clinical effect’.52
The TWICS trial avoids many of the limitations of previous studies and clearly demonstrates that, in a NHS
setting, the addition of low-dose oral theophylline to a drug regimen that includes an ICS confers no overall
clinical benefit for people with COPD. The participants in the TWICS trial were a group of people with COPD
who were at high risk of experiencing an exacerbation based on their history of exacerbating in the previous
year. This group was deliberately chosen because of their impact on the NHS and it enabled us to design a
trial of realistic (but ambitious) sample size. Although the TWICS trial did not investigate whether or not
people with COPD who are at low risk of exacerbation would benefit from low-dose theophylline, the
combination of the findings of the TWICS trial and the absence of a biological effect (HDAC concentrations)
in the ASSET trial, despite a sample size that was ‘more than enough to demonstrate a biological effect of
the intervention’,52 make it highly unlikely that low-dose theophylline would be beneficial in COPD patients
who are at low risk of exacerbation. A possible explanation for the disparity between the biological effects
observed in previous studies, with short treatment periods, and the absence of beneficial effects in the
TWICS trial, with a year-long treatment period, is that any biologically beneficial effect of low-dose
theophylline is not sustained in the long term.
Cost-effectiveness
The health economics results indicate that, after adjustment for baseline characteristics, there was no
significant difference between the total health economic costs associated with treatment with low-dose
theophylline and the costs associated with placebo treatment: adjusted mean difference £222 (95% CI
–£27 to £472). With unadjusted complete-case data, the total costs are higher in the placebo arm than in
the theophylline arm: a significant difference of £452 (95% CI £132 to £771). This difference was driven
by the fact that more participants in the placebo arm than in the theophylline arm received treatment for
exacerbations in hospital. The 10 most costly observations (> £10,000) were all in the placebo arm, and
were the result of hospital stays of > 40 days. The multiple imputation results mirror the complete-case
results with a significant difference in unadjusted costs of £439 (95% CI £32 to £846) higher in the
placebo arm.
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The difference between arms in total costs is driven solely by the hospital-treated exacerbations and
exacerbations treated with oxygen; no other resource group differs significantly between arms. The
difference in the number of exacerbations necessitating hospital treatment is likely to be the result of a
small number of participants in the placebo arm having very frequent hospital admissions. Therefore, these
results should be interpreted with caution.
Exacerbation costs are 22% and 33% of the total costs (theophylline and placebo, respectively), somewhat
less than the 60% reported by Britton et al.27 in 2003, perhaps reflecting differences in management
between 2003 and 2015/6, particularly in increased use of preventative drugs, pulmonary rehabilitation
and more structured chronic disease management in primary care.
In the unadjusted complete-case analysis, QALY gain was higher in the placebo arm than in the theophylline
arm (difference 0.011 QALYs, 95% CI –0.018 to 0.040 QALYs); however, the difference is not significant.
Multiple imputation results mirrored the complete-case results; there were no significant differences,
with unadjusted results favouring the placebo arm and adjusted results favouring the theophylline arm.
These results reflect the primary outcome of number of exacerbations needing treatment during the
12-month follow-up period; there was no significant difference between arms.
Hettle et al.100 reported 4-year UK costs in their paper on tiotropium versus usual care in the UK and Belgium.
Exacerbation costs ranged from £2295 to £2744 (£574–686 per year) and maintenance costs ranged from
£2935 to £3937 (£737–984 per year). This compares to the 1-year costs from this research of exacerbations,
ranging from £585 to £1033, and maintenance costs ranging from £2074 to £2101. Although the annual
exacerbation costs in the current trial are similar to those of Hettle et al.,100 the maintenance costs are somewhat
higher, reflecting the older average age of participants in the current study (68.4 years vs. 64 years), and
the facts that, in the current study, 80% of the participants were prescribed LAMAs (none for the usual
care group in the Hettle et al.100 study), participants with COPD using long-term oxygen were included
and participants were more likely to be in the severest GOLD category (14% vs. 8%). Hettle et al.100 also
reported that in Belgium the cost of exacerbations resulting in hospitalisation was 33 times higher than
the cost of exacerbations not necessitating hospitalisation, substantiating the increased cost of hospital
treatment compared with non-hospital treatment of exacerbations that we found in this research.
The strengths of this research include the fact that there were few participants with no outcome or
resource use (low proportion of missing cases: 4.3%), that uncertainty was explored using non-parametric
bootstrapping and that, when there was a significant difference in exacerbation costs, this was explored
further to identify what was driving this difference.
The two main limitations to the cost-effectiveness analysis are the large number of missing EQ-5D-3L
questionnaires (19.1%) and the fact that small numbers of missing data were imputed using naive
methods at a disaggregated level.
Strengths and limitations
The main strength of the TWICS trial is that it was a large, pragmatic, predominantly community-based,
suitably powered, double-blind, randomised, placebo-controlled, UK multicentre clinical trial with a high
follow-up rate for the primary clinical outcome. A total of 1578 individuals were recruited in 121 UK
sites; 60% of these were identified in primary care, making it highly likely that the TWICS trial participants
reflected normal clinical practice across both primary and secondary care in the UK. The 1-year treatment
period allowed for capture of the seasonality of exacerbations.101
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Originally, the TWICS trial aimed to recruit 1424 participants, the sample size being primarily based on the
findings of the observational ECLIPSE cohort study of 2138 COPD patients recruited in 46 centres from
12 countries.21 The ECLIPSE study demonstrated that the best predictor of an exacerbation in a year was
a treated exacerbation in the previous year. The ECLIPSE study also identified a frequent exacerbator
phenotype, defined as two or more exacerbations in the previous year; moreover, this frequent exacerbator
phenotype was relatively stable for 3 years and could be reliably identified by patient report. For the patients
experiencing frequent exacerbations recruited into the TWICS trial, data from the ECLIPSE study predicted a
mean of 2.22 (SD 1.86) exacerbations in the year of treatment; the sample size for the TWICS trial was based
on this. This prediction proved to be remarkably close to what we observed, increasing confidence in the
findings, with a mean number of exacerbations in the theophylline arm of 2.24 (SD 1.99) and in the placebo
arm of 2.23 (SD 1.97). A notable finding of the TWICS trial was an apparent disparity between the number
of exacerbations reported by participants in the year prior to the trial [mean 3.59 (SD 2.15)] and the number
of self-reported exacerbations in the treatment year, which was somewhat lower [mean 2.23 (SD 1.99)].
The most likely explanation for this disparity is that we did not ask for dates for the reported exacerbations
in the year prior to the trial, whereas, during the trial, we asked for dates and the conventional minimum of
2 weeks between consecutive exacerbation episodes was necessary to consider exacerbations as separate.68
This resulted in exacerbations that were separated by < 2 weeks being merged. Although further factors
contributing to the disparity in exacerbations before and during the trial may include an over-reporting bias
by participants and regression to the mean, the exacerbation frequency during the treatment period was
remarkably consistent with that predicted by the ECLIPSE study. Although the exacerbation rate observed in
the current trial is somewhat higher than in recent explanatory trials,102,103 it is entirely consistent with the
recent pragmatic UK Salford Lung Study.104 The Salford Lung Study, with an inclusion criterion of one or
more exacerbations in the previous year, reported exacerbation rates of 1.74–1.90 per year. The slightly
higher exacerbation rate in the current trial most probably reflects the participants’ increased propensity to
exacerbate (two or more exacerbations in the previous year), as well as the lack of requirement to withhold
therapy other than theophylline, meaning that investigators were happier to recruit patients at a higher
risk of exacerbation. Although the diagnosis of COPD was confirmed by post-bronchodilator FEV1/FVC of
< 0.7, 18.3% of participants reported a concurrent/previous diagnosis of asthma. This may, in part, reflect
a diagnostic bias towards the more socially acceptable diagnosis of asthma in the past, but it is possible
that the current trial included up to 18% of participants with asthma–COPD overlap syndrome. Although
it is possible that these patients may respond differently to the theophylline, whether or not people with
asthma–COPD overlap syndrome responded differently to theophylline was not one of the trial objectives.
By recruiting 1578 individuals, 60% of whom were identified in primary care, the TWICS trial exceeded
its original recruitment target of 1424 with at least 50% being recruited in primary care. It was initially
envisaged that the TWICS trial would recruit from a limited number (seven) of secondary care sites, with
primary care sites acting as PIC sites for these secondary care centres. Recruitment to the TWICS trial
was delayed by 5 months because of a worldwide shortage of bottle tops for the drug bottles. Initially,
recruitment in 16 primary and six secondary care sites was on target and the TWICS trial achieved its
recruitment targets for the feasibility phase by recruiting 100 participants in months 7, 8 and 9, with 55%
identified in primary care. Within 4 months, it became apparent that it would not be possible to sustain
recruitment, with recruitment falling below the required 59 participants per month to a nadir of 26 in
month 15 (October 2014). To address this, a change in recruitment strategy was implemented in month
12 (July 2014), with rapid increases in the number and rate of opening up of primary and secondary care
sites. Ultimately, 121 recruiting sites were opened up, comprising 88 primary care sites and 33 secondary
care sites. Other primary care practices acted as PICs for primary and secondary care sites. In total, 477
participants were recruited and followed up entirely in primary care, 464 participants were identified in
primary care but recruited and followed up in secondary care (this was particularly the case in Scotland)
and 637 participants were identified, recruited and followed up in secondary care. This change in recruitment
strategy was successful, with monthly recruitment remaining above 50 per month from month 19 and reaching
a peak of 81 in month 35.
DISCUSSION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
72
Primary outcome data (number of COPD exacerbations) were collected on 98% of the 1567 participants
who commenced the 1-year treatment period (1578 recruited minus 11 post-randomisation exclusions).
Several factors contributed to the high follow-up rate. The TWICS trial was designed to be as inclusive
as possible by facilitating participation of people with COPD who would normally find it too difficult to
participate in a trial because of their ill health. The trial was designed to be relatively ‘light touch’, with
three study visits to a local study centre. If participants were unable to attend for assessment, they were
visited at home, contacted by telephone or sent the questionnaires to complete at home. Participation and
remote follow-up were further facilitated by delivering the trial drug to participants’ homes using a third-
party distributor. All participants who ceased taking the trial drug were invited to remain in the trial for
follow-up, by face-to-face assessment, telephone assessment or postal questionnaire. If participants could
not be followed up directly, for example if they failed to attend follow-up, various methods of follow-up,
independent of participant involvement, were used. In the first instance, the participant’s GP was sent a
questionnaire enquiring about exacerbations (number, dates, how and where treated); the minimum
information requested was the number of exacerbations in the treatment period. Failing this, GP surgeries
were contacted by telephone or a request was made for a redacted copy of patient encounter summaries
from which the co-chief investigator extracted exacerbation data. The combination of follow-up methods
enabled the ITT analysis to include 1489 years of participant follow-up data. Inevitably, there were some
participants who did not provide a full 12 months of follow-up data, for example because they died, or for
whom 12 months of follow-up data were not available even using a remote follow-up method. A strength
of the TWICS trial was that the statistical analytical methods used enabled inclusion of these participants
up to the point at which they were lost to follow-up, with their time in study utilised in the offset variable
during analysis.
Previous studies investigating the potential anti-inflammatory effects of low-dose theophylline in COPD and
asthma (not in conjunction with ICS) have used a ‘one size fits all’ dosing approach, that is all participants
received 100 mg bd or 200 mg bd.43,44,48,99,105–107 In contrast, one of the strengths of the TWICS trial was
that theophylline dosing was somewhat personalised, being determined by IBW and smoking status. As
noted in the protocol paper,55 population studies have demonstrated that theophylline pharmacokinetics are
influenced by weight, COPD disease status (reduced clearance) and smoking (increased clearance).57–66,108
Smoking increases theophylline clearance by ≈60%, but the plasma theophylline level gradually returns
to normal following smoking cessation. This was incorporated into the definition of a non-smoker in the
TWICS trial and procedures were implemented to modify, when necessary, the dose of the trial drug in a
timely manner if participants changed their smoking status during the treatment period. The use of IBW in
preference to actual weight avoided the potential for giving an inappropriately high dose of theophylline
to obese participants. In the TWICS trial, theophylline dosing was based on pharmacokinetic modelling,
incorporating the major determinants of theophylline Css, namely weight, smoking status and clearance
of theophylline (low, normal or high), and was designed to achieve a steady-state plasma theophylline
concentration of 1–5 mg/l and certainly < 10 mg/l.55 Theophylline is metabolised in the liver by the enzyme
CYP1A2, which is induced by smoking and inhibited by a number of medications, with a consequent
increase in plasma theophylline concentration. For this reason, the exclusion criteria included long-term
use of drugs with the potential to increase plasma theophylline concentration;94 conversely, concomitant
use of drugs with the potential to lower plasma theophylline concentration was permitted in the trial.
Reassuringly, the dosing regimen used for the TWICS trial appeared to be effective in establishing low-dose
plasma theophylline concentrations of 1–5 mg/l because there was no evidence of the typical sequelae of
conventional high-dose theophylline, such as an improvement in FEV1. In addition, when compared with
the placebo group, there was no evidence that participants allocated to low-dose theophylline experienced
more SAEs or ARs, nor did they report SAEs or ARs typical of theophylline toxicity, namely gastrointestinal,
cardiac, psychological or neurological symptoms. Furthermore, when the reasons for ceasing trial medication
were analysed, there were no significant differences between the arms, notably for gastrointestinal, cardiac,
psychological or neurological symptoms typical of theophylline toxicity. A consequence of the personalised
dosing of the trial drug to achieve a low-dose plasma theophylline concentration well below that associated
with typical side effects was that there was no need for blood sampling to monitor plasma theophylline,
a necessity that would have greatly increased the complexity of the trial and increased the likelihood of
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unblinding the participant and/or investigator. The absence of blood testing reduced costs and was extremely
popular with primary care sites and contributed to the willingness of many primary care sites to participate
in the TWICS trial. The potential limitation of relying on participant-reported smoking status is perhaps less
important in this trial, as any smoker claiming to be a non-smoker would have been prescribed the lower
dose of theophylline, thereby ensuring that plasma theophylline remained in the low-dose range of 1–5 mg/l.
As with all studies, there are limitations associated with the TWICS trial. The primary outcome for the trial
was the number of participant-reported exacerbations during the 1-year treatment period; to facilitate
recall, participants were given a diary card to make notes on exacerbations, treatment and health-care
usage. The definition of an exacerbation was the widely used ATS/ERS guideline recommendation of a
worsening of a patient’s dyspnoea, cough or sputum beyond day-to-day variability sufficient to warrant
a change in management.68 The minimum management change was treatment with antibiotics or OCSs;
consequently, the TWICS trial quantified only moderate and severe exacerbations. However, these
exacerbations are the ones that are the most burdensome to patients and health-care services. A limitation
of the TWICS trial is that the relatively conservative definition of exacerbation probably underestimates the
frequency of symptom-defined mild exacerbations that are short-lived and treated by a patient with a
temporary increase in bronchodilator therapy.109 The identification of such mild exacerbations would have
required participants to complete daily symptom diary cards, adding to the intrusiveness of the trial and
considerably adding to the data-entry burden of research staff. Although the TWICS trial did not quantify
mild exacerbations, there were no significant differences between the treatment and placebo arms in
QoL/impact on health status as quantified by EQ-5D-3L/CAT, suggesting that either low-dose theophylline
had no effect on mild exacerbations or, if there was an effect, it did not impact on health status/health-care
usage.
A possible limitation of participant-reported exacerbations is the accuracy of such a report over a 6-month
period. Although it would have been possible to obtain such exacerbation data from health-care records,
it is well documented that people with COPD do not report all of their exacerbations to health-care
professionals.18,110–112 Patient recall of COPD exacerbations has been shown to be highly reliable over a
year: in the London COPD cohort study,112 there was no significant difference between the number of
exacerbations recorded on diary cards and patient estimates of their exacerbation number over the
same 1-year period [mean 2.4 (SD 2.2) vs. mean 2.3 (SD 2.1)] and there was 93% agreement between
patient-recalled and diary-recorded exacerbations. There was, however, a difference between the number
of treated exacerbations recorded on diary cards and the number of treated exacerbations remembered
by the patient over the same 1-year period [mean 2.3 (SD 2.1) vs. mean 1.8 (SD 1.8)] and there was
88.6% agreement between patient-recalled and diary-recorded treated exacerbations.112 The patient
representatives helping with the TWICS trial were adamant that it was fairly straightforward to recall the
number of exacerbations over a 6-month period. A small validation exercise was conducted at two of the
largest sites (Aberdeen and Aintree) during the TWICS trial to confirm that participant recall was indeed
valid. The validation was done by requesting a care/encounter summary from the GP and comparing this
with the participant report. In Aberdeen, 43 records (a 20% sample) were checked; in 37 there was
complete agreement between the participant and GP reports. In Aintree, 24 records were checked and
in 16 there was complete agreement between the patient and GP reports. Therefore, in a 4% sample of
participants, there was 80% agreement. This rate of agreement was slightly lower than that reported by
Quint et al.;112 however, current GP records may not be as reliable a source of exacerbation data as in the
past, given that patients have rescue packs at home and can access help for their exacerbations through
many non-GP sources, for example pharmacies, emergency and walk-in centres, and accident and
emergency departments.
A limitation of the TWICS trial was the proportion of participants who ceased taking their trial drugs (26%)
was higher than anticipated (6%), although this was somewhat offset by 10% over-recruitment (n = 154).
There was no evidence of bias in ceasing trial medication, with the proportion and the reasons given for
ceasing trial medication being equally distributed between those allocated to low-dose theophylline and
those allocated to placebo. The original sample size for the TWICS trial (n = 1424) accounted for 6% of
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participants ceasing their trial medication based on the four high-quality studies reported in a Cochrane
review83 of theophylline in COPD, in which 3 out of 51 (6%) participants dropped out. In reality, 413 of
the 1578 participants either never started/initiated medication (post-randomisation exclusions, n = 11;
non-initiation, n = 8) or ceased taking the trial medication (non-persistence, n = 393). This 26% rate of
ceasing trial medication is greater than anticipated, but in keeping with the ASSET trial of low-dose theophylline,
which reported a 34% rate of ceasing trial medication.44 The higher than anticipated rate of ceasing trial
medication in the TWICS trial was most likely the consequence of the relatively high rates of comorbidities
in participants, giving rise to symptoms that were attributed to the trial medication and a heightened
awareness of ARs listed in the PIL and the package insert accompanying the trial medication. This is
consistent with 46% of participants reporting ARs typical of high-dose theophylline (but equally distributed
between the two trial arms) and why 20% of those ceasing trial medication gave gastrointestinal symptoms
as the reason for ceasing trial medication, although there was no significant difference in the incidence
of such symptoms in those ceasing low-dose theophylline and those ceasing placebo. Some participants
were asked to discontinue trial medication because they had stopped taking an ICS. During the trial, there
was an emergent change in prescribing practice away from ICS-containing preparations to LABA/LAMA
inhalers; however, this had minimal impact on the trial (certainly < 20 participants), most probably because
the participants in this trial were at high risk of exacerbation and were participants in whom there is still a
role for ICSs. Although 413 participants ceased trial medication during the TWICS trial, a review of the
medication returns indicated that 66 of these participants had > 70% adherence while taking the trial
medication when averaged over the 12-month treatment period; for example, they ceased trial medication
at 11 months. These individuals were included in the per-protocol analysis. Although per-protocol analyses
are biased by their very nature, the per-protocol analysis for this trial included 1142 years of participant data
(85% of the 1338 years indicated by the power calculation); therefore, it is not surprising that the results of
the per-protocol analysis were almost identical to those of the ITT analysis. Although adherence to the trial
medication was quantified through pill counting, it was not practicable to assess adherence to the ICS, as
this would have entailed use of non-routine care methodologies such as diaries cards, metered inhalers, etc.
The rationale for the use of low-dose theophylline is as an adjunct to ICS therapy; that we were unable to
verify adherence to ICS therapy is a limitation of this trial.
Generalisability
This trial has good external validity as it was of a pragmatic design that reflected normal clinical practice
across both primary and secondary care in the UK. Participants remained on their existing COPD medications,
they were managed in the normal way by their usual health-care teams and the trial recruited from 121 sites
(88 primary care and 33 secondary care) that spanned the UK; many of the secondary care sites were district
general hospitals. We consider it to be highly probable that the TWICS trial participants are typical of COPD
patients in normal clinical practice across both primary and secondary care in the UK and that the findings
are generalisable to clinical practice in the UK.
The TWICS trial recruited participants who were highly likely to experience an exacerbation during the 1-year
treatment period, as evidenced by the fact that they had experienced two or more treated exacerbations
in the previous year. In contrast to many COPD trials, we did not exclude potential participants with mild
COPD, as evidenced by FEV1 of > 80% predicted; 9% of the TWICS trial participants had mild COPD based
on spirometry criteria, but fulfilled the frequent exacerbator phenotype,21 enhancing the generalisability of
the trial. Recruitment to the TWICS trial was limited to frequent exacerbators because, in clinical practice,
these are the patients who are usually commenced on this ‘third-line’ therapy;24 moreover, a trial of
participants less likely to experience exacerbation (e.g. those experiencing one exacerbation in the previous
year) would have been much larger (n =≈3000) and somewhat more costly. Although we did not test whether
or not the addition of low-dose theophylline to ICSs had an effect on people who experienced less frequent
exacerbations, there is no scientific or clinical reason why low-dose theophylline should have a differential
effect according to the frequency of exacerbations. Therefore, it would seem reasonable to extend the
findings of the current study to people with COPD who are at a low risk of experiencing an exacerbation.
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Although the results of this trial are generalisable to the UK and probably to other high-income countries,
the findings may not be applicable to low- or medium-income countries, with differing pharmacogenetic
profiles, where theophylline remains a frequently used therapy in COPD, most probably because it is
inexpensive compared with inhaled therapies.113–116 The randomised, double-blind, placebo-controlled trial
of Zhou et al.117 raises the possibility that, in China at least, there is a therapeutic response to low-dose
theophylline in the absence of ICS. In that trial,117 the addition of low-dose theophylline to usual COPD
treatment in 110 people with COPD (theophylline, n = 57; placebo, n = 53) for a year significantly reduced
the frequency of exacerbations when compared with placebo [mean 0.79 (SD 1.16) vs. 1.70 (SD 2.61);
p = 0.047]. The participants in that trial117 differed considerably from those taking part in the TWICS trial:
only 30% were taking regular medication prior to the trial, and this was restricted to inhaled salbutamol;
use of ICS, LABA and LAMA was excluded; and the target plasma theophylline concentration (5–10 mg/l)
was also somewhat higher than the target range (1–5mg/l) identified for optimum synergistic interaction
between corticosteroids and low-dose theophylline. The use of low-dose theophylline in conjunction with
corticosteroids in China is being addressed by the ongoing Theophylline And Steroids in COPD Study (TASCS),
which is recruiting 2400 people with COPD in China.118 They are being randomly allocated to low-dose
prednisolone (5 mg od) or low-dose theophylline (100 mg bd) with low-dose prednisolone (5 mg od) for
48 weeks. The primary outcome is exacerbation rate over the 48-week treatment period. This study has
been presented in abstract form119 and demonstrated that the combination of low-dose theophylline and
prednisolone did not reduce the annualised rate of exacerbations. It will be interesting to compare the results
of TASCS with the TWICS trial, although it should be noted that the routine use of OCSs as a maintenance
treatment for COPD, even though they are cheaper than ICS, would never be contemplated in developed
countries for clinical and ethical reasons.
Patient and public involvement
Patient and public involvement in this trial was limited, but effective, and lessons were learnt that have
been implemented in a subsequent study funded by the NIHR Health Technology Assessment (HTA)
programme (reference 15/130/20),120 for example a person with COPD is a joint grant holder in that study.
A patient with COPD was a voting member of the TWICS trial TSC; recruitment and retention of a patient
representative was hindered by ill health. The first patient approached declined because of ill health.
The patient representative nominated by CHSS as part of their Voices Scotland initiative had to resign
because of ill health. A third patient representative was identified and he made an active contribution to
the TWICS trial. Support of the TSC patient representative was actively undertaken by several members
of the local study team. In the subsequent trial funded by the NIHR HTA programme,120 we have a patient
representative who is supported by CHSS’s Voices Scotland lead who is not only a voting member of the
TSC, but also co-ordinator and representative of a panel of 15 COPD patients (as they like to be called).
A representative of the British Lung Foundation and a person with COPD made important contributions to
trial design procedures [what was acceptable (e.g. spirometry) and what was not acceptable (e.g. daily diary
cards)]. Perhaps the most important suggestions were to deliver trial medication to home addresses and
to facilitate follow-up for ill participants by way of home visits and telephone and postal questionnaires.
PPI resulted in many changes to the design and content of the ‘short’ PIL (a one-page summary PIL) and the
‘long’ PIL (a more detailed PIL). The importance of these changes is evidenced by the success in recruitment,
and there were no changes to the PIL throughout the trial. PPI was particularly insightful during TSC
deliberations concerning the validity of patient recall of COPD exacerbations.
The support of the British Lung Foundation and CHSS has been invaluable throughout the trial, identifying
volunteers for PPI and publicising the trial.
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Conclusions
Main conclusions
To our knowledge, this is the first adequately powered, multicentre, pragmatic, double-blind, randomised,
placebo-controlled trial to assess the effectiveness of adding low-dose theophylline to a drug regimen
containing ICSs in people with COPD who are at a high risk of exacerbation. The analyses demonstrated
that low-dose theophylline has no overall clinical or health economic benefit.
Implications for practice
The trial has shown that low-dose theophylline has no overall clinical impact when added to ICSs in COPD.
We anticipate that the results of the trial will be incorporated in an ongoing systematic review of theophylline
in COPD.121 Given that the TWICS trial is one of the largest trials of theophylline to date, we anticipate that it
will have a major influence on the meta-analyses and conclusions. National and international COPD guidelines
should take the results of the TWICS trial into account when making recommendations on the treatment of
COPD and the prevention of exacerbations of COPD. In the meantime, clinical commissioners can now be
encouraged to make informed decisions regarding the use theophylline in COPD.
Recommendations for research
The findings from one of the planned secondary analyses was that low-dose theophylline reduces the
rate of admission to hospital due to severe COPD exacerbation. Although it is possible that this may be a
chance finding, it is consistent with a recent report96 that roflumilast is most beneficial in people with prior
COPD hospitalisation for exacerbation and greater exacerbation frequency. A further study investigating
the effect of low-dose theophylline in people with COPD who frequently exacerbate and are admitted
to hospital is justifiable, given the disproportionate impact on NHS resources of such exacerbations.
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Appendix 1 Rationale for the low-dose
theophylline strategy
Population theophylline pharmacokinetic studies during the 1970s and 1980s demonstrated that diseasestatus, weight and smoking decrease the half-life of theophylline and increase its clearance.57–62 It has
been shown that theophylline clearance is lower in COPD patients who do not smoke than in healthy
volunteers.60 Based on these data and our publications,63–66 an average population clearance value of
theophylline in non-smokers is 40 ml/hour/kg, which is reduced to 32 ml/hour/kg in a patient with COPD,
and by a further 20% if they have another related disease (e.g. severe congestive heart failure). This
corresponds to the fast, normal and slow categories of plasma theophylline pharmacokinetic modelling for
COPD patients provided in Table 35. Smoking increases theophylline clearance by ≈60%, and the plasma
theophylline level gradually returns to normal levels when a person stops smoking. Another relevant population
pharmacokinetic value that is useful for loading doses is a volume of distribution for theophylline of 0.5 l/kg.57–66
TABLE 35 The results of pharmacokinetic modelling for theophylline doses of 200mg bd and od for current
smoking/non-smoking participants by weight and theophylline clearance
IBW (kg)
Theophylline 200mg bd Theophylline 200mg od
Steady-state plasma theophylline concentration (Css) (mg/l)
Participant theophylline clearance
Slow Normal Fast Slow Normal Fast
Not current smoker
40.1–50 17.4 13.0 10.4 8.7 6.5 5.2
50.1–60 13.9 10.4 8.3 6.9 5.2 4.2
60.1–70 11.6 8.7 6.9 5.8 4.3 3.5
70.1–80 9.9 7.4 6.0 5.0 3.7 3.0
80.1–90 8.7 6.5 5.2 4.3 3.3 2.6
90.1–100 7.7 5.8 4.6 3.9 2.9 2.3
100.1–110 6.9 5.2 4.2 3.5 2.6 2.1
110.1–120 6.3 4.7 3.8 3.2 2.4 1.9
> 120 5.8 4.3 3.5 2.9 2.2 1.7
Current smoker
40.1–50 10.9 8.1 6.5 5.4 4.1 3.3
50.1–60 8.7 6.5 5.2 4.3 3.3 2.6
60.1–70 7.2 5.4 4.3 3.6 2.7 2.2
70.1–80 6.2 4.7 3.7 3.1 2.3 1.9
80.1–90 5.4 4.1 3.3 2.7 2.0 1.6
90.1–100 4.8 3.6 2.9 2.4 1.8 1.4
100.1–110 4.3 3.3 2.6 2.2 1.5 1.2
110.1–120 3.9 3.0 2.4 2.0 1.5 1.2
> 120 3.6 2.7 2.2 1.8 1.4 1.1
Note
The plasma theophylline concentrations using the dosing schedule are shaded mediun green (Professor Henry Chrystyn,
Inhalation Consultancy Ltd, 2014, personal communication).
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The use of actual weight or IBW has been shown to have an effect on the clearance of theophylline in
young adults who smoke.122 If a patient is obese, they may be given a high dose when their actual weight is
used. It is good practice to assume that this occurs in all patients and thus use IBW. IBW can be calculated
using the following equations:67
IBWfemale = 45 + ½0.9(height in cm – 152) kg, (3)
IBWmale = 50 + ½0.9(height in cm – 152) kg: (4)
The IBW is used unless the actual weight is lower than the IBW.
For oral theophylline dosing, the pharmacokinetic model is:
Css =
F × D
Cl × τ
, (5)
where Css is the steady-state theophylline concentration, F is the bioavailability of theophylline (F = 1 for
theophylline preparations), D is the dose, Cl is the clearance and τ is the dosage interval (either 12 or
24 hours). Using this model and the population theophylline clearance values for COPD patients described
above, in smokers and non-smokers, predicted Css values are as shown in Table 35.
Confidence that plasma theophylline in the low-dose range can be achieved using the above dosing strategy
is provided from a detailed analysis of a COPD study that measured theophylline concentrations at three
different theophylline dosing regimens.63 In 33 COPD patients [who had a mean weight of 64.6 (SD 14.3) kg
and a mean age of 61.2 (SD 5.8) years], we found that the mean plasma theophylline concentration at
steady state when they received a mean of 252 (SD 87) mg bd was 6.3 (SD 2.1) mg/l. This represents a
clearance value of 51.6 ml/hour/kg. When the theophylline dose was increased to 430 mg bd and then to
597 (SD 153) mg bd, mean steady-state plasma theophylline concentrations rose to 12.1 (SD 1.9) mg/l and
18.3 (SD 3.0) mg/l, respectively. This represents clearance values of 45.8 ml/hour/kg and 42.1 ml/hour/kg,
respectively. This will include smokers and non-smokers (numbers of each not recorded) and the latter
clearance value is similar to the 40 ml/hour/kg used in the population pharmacokinetics modelling for the
‘fast’ category. Our other publications64,65 (n = 83 patients64 and n = 15 patients65) on plasma theophylline
highlight our confidence of using low-dose theophylline in the TWICS trial.
In the clinical situation in which a clinician wished to use intravenous aminophylline to treat a patient
participating in the TWICS trial with an acute exacerbation of COPD, the BNF recommends a loading dose
of intravenous aminophylline of 5 mg/kg (typically 250 mg); this is usually omitted if the patient is already
taking theophylline. This is then followed by an intravenous infusion of aminophylline of 0.5 mg/kg.86 It is
recommended that plasma theophylline be measured after 24 hours to direct the rate of further dosing.
The pharmacokinetic model for a loading dose is:
Co =
F × D
V
, (6)
where Co is the concentration immediately after the slow intravenous bolus dose of aminophylline, F is the
bioavailability (F = 0.8 for aminophylline) and V is the volume of distribution. A loading dose of 5 mg/kg
would provide a Co of:
Co =
0.8 × 5mg/kg
0.5 l/kg
= 8mg/l. (7)
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Because the predicted Css shown in Table 35 ranges from 2.2 to 8.7 mg/l, the maximum theophylline
concentration would be 16.7 mg/l. Alternatively, a loading dose of 250 mg of aminophylline could be
given, rather than a dose based on weight. A loading dose of 250 mg of aminophylline in COPD patients
weighing 40–100 kg would provide a Co ranging from 4 to 10 mg/l. There is a linear relationship between
Css and weight. Similarly, if the loading dose was 500 mg of aminophylline, then the predicted Css would
be double that for the 250-mg dose.
For an aminophylline infusion of 0.5 mg/kg/hour86 and based on a clearance of 40 ml/hour/kg and the
following pharmacokinetic model:
Css =
F × D
Cl × τ
, (8)
where Css is the steady-state theophylline concentration, F is the bioavailability of theophylline (F = 0.8 for
aminophylline preparations), D is the dose, Cl is the clearance (using a clearance of 40 ml/hour/kg) and τ is
the dosage interval (1 hour for an intravenous infusion). In this case the predicted Css would be:
Css =
0.8 × 0.5 mg/hour/kg
0.04 l/hour/kg × 1
= 10mg/l: (9)
Note that the predicted Css is independent of weight (see Equation 9). The predicted Css in non-smokers
with COPD with slow, normal or fast theophylline clearance given an infusion of 0.5 mg/hour/kg would be
10.0, 12.5 and 16.7 mg/l, respectively. In smokers, the corresponding predicted Css values would be 6.3,
7.8 and 10.4 mg/l.
Importantly for the TWICS trial, it was safe for participants to receive a 5-mg/kg loading infusion of
aminophylline followed by an infusion of 0.5 mg/kg/hour as the plasma concentration would exceed the
target 10–20 mg/l range required for conventional theophylline dosing.
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Appendix 2 Validation of patient-reported
exacerbations
Initially, we planned to validate the total number of COPD exacerbations for ≈20% of participants byexamination of general practice records.
At the TSC meeting of 20 March 2017, the validation exercise comparing the number of exacerbations as
recorded in general practice records and reported by the participant was discussed. At that time, the focus
of this validation had been in two of the largest sites: Aberdeen and Aintree. The validation was done by
requesting a care/encounter summary from the GP and comparing this against the patient report. In
Aberdeen, 43 records had been checked; in 37 there was complete agreement between patient report and
GP report. In Aintree, 24 records had been checked; in 16 there was complete agreement between patient
report and GP report. Therefore, 4% of participants had undergone validation, and there was ≈80%
concordance. Concerns were raised that there is no ‘gold standard’ for the reporting of exacerbations, and
that current general practice records may not be as reliable a source of exacerbation data as in the past,
given that patients have rescue packs at home and can access help for their exacerbations through many
non-GP sources, for example pharmacies, emergency and walk-in centres, and accident and emergency
departments. The published evidence is that patients are able to reliably report the number of exacerbations
experienced in the previous year.112 Furthermore, the patient representatives for the TWICS trial are
adamant that it is fairly straightforward to remember the number of exacerbations over this time period.
It was also noted that the primary outcome of this trial is patient-reported exacerbations and it is this
outcome that drives demand for NHS services. The TSC, therefore, recommended that we completed the
validation exercise for the participants for whom we had data, but that the validation exercise did not need
to be extended beyond these two sites or to include further participants.
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Appendix 3 Breaches
Site affected
(site number) Description of breach Assessment
36 The site consented a patient into the trial on 28 April 2014, before the site agreement
had been signed by all parties. The trial processes in place prevented the site from
randomising the patient on the live randomisation system and also meant that a drug
pack could not be dispensed
Non-serious
18 Participant had rescue medication, including erythromycin (one of the drugs that can
increase serum theophylline), and, in response to an exacerbation, the participant started
to take the rescue medication without stopping the trial medication. The patient came to
no harm, and did not suffer any adverse effects
Non-serious
11 The chief investigator raised concerns about the monitoring process following a routine
trial monitoring visit carried out by R&D monitors at the site. For two patients, the
monitors recorded amber findings relating to the recording of comorbities and
concomitant medication in the case report form, and for one patient indicated that there
was contraindicated medication. However, the data recorded in both case report forms
were accurate and both patients were eligible. The breach related to the monitors
incorrectly noting amber findings and making the research nurses modify the case report
form by entering incorrect information
Non-serious
12 Participant was admitted to hospital. Prior to the admission, the participant had been
prescribed clarithromycin (one of the drugs that can increase serum theophylline). His trial
medication was stopped by the hospital pharmacist. The symptoms experienced by the
participant (gastro-oesophageal reflux) may have resulted from clarithromycin per se,
and/or an interaction between clarithromycin and theophylline. Gastro-oesophageal reflux
is a side effect of both clarithromycin and theophylline
Non-serious
11 The third-party distributor identified that it had despatched a shipment to a participant
that contained drug pack numbers 40167 (correctly) and 40166 (in error) on 5 November
2014. The participant was contacted on 29 January 2015 and indicated that he had
started using kit number 40167 and that he had not opened kit number 40166. He
returned kit number 40166 to the research nurse later that day and it was destroyed.
The participant was resupplied with an appropriate box of medication
Non-serious
27 At the point of randomisation (20 April 2014), the participant had been randomised as a
smoker (rather than as an ex-smoker) and was allocated and received a dose of twice-
daily trial medication (he should have received a once-daily dose). On 5 November 2014,
the patient was diagnosed with atrial fibrillation. No palpitations were noted. Atrial
tachycardias are a known side effect of theophylline. The patient was unblinded so he
could be managed appropriately. The atrial fibrillation experienced by the patient may
have been caused by the theophylline. The participant was seen on 6 January 2015 for
a routine appointment, and his pulse was noted to be regular, that is spontaneously
reverted to sinus rhythm
Serious
12 Noted at the 12-month follow-up, the participant had been on diltiazem hydrochloride
(Tildiem LA, Sanofi-Aventis) (300mg od) since recruitment into the study (26 February 2014).
Tildiem LA is a form of diltiazem (diltiazem is one of the drugs listed in the trial protocol
as known to interact with theophylline). Although this medication had been recorded
on the baseline case report form, the patient was assessed as being eligible for the trial.
The patient was well throughout the trial. No AEs were noted
Non-serious
11 During the 12-month follow-up appointment (19 May 2015), the participant mentioned
that the community pharmacist had been supplying Uniphyllin 200 mg (theophylline) in
his dosette box. After taking the Uniphyllin included in the dosette box for 2 or 3 days,
the participant realised that he may be taking theophylline as both the TWICS trial
medication and as prescribed medication. He therefore ceased taking the TWICS trial
medication. The participant has noted no adverse effects as a result of this
Non-serious
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Site affected
(site number) Description of breach Assessment
78 Participant was randomised to twice-daily trial medication – dosing instruction ‘Take ONE
tablet every morning and ONE tablet every evening’, but took two tablets each morning
and two each evening. After 10 days of taking the trial medication, the participant noted
that he was experiencing nausea, tremors and disturbed sleep (which, in part, may have
been anxiety related because of a forthcoming bypass operation); his dose was reduced
by the trial team to one tablet per day and his symptoms settled. At the 6-month follow-up
appointment, the participant noted that he was still taking ‘one tablet’, but as he was
feeling well, wished to start taking two tablets again. The trial team agreed that he could
increase his dose to two tablets per day (the recommended ‘low dose’ for a smoker of his
height and weight). He did this for 3 days and symptoms of nausea/sickness returned.
The participant therefore reduced his dose to ‘one tablet’ and the symptoms settled.
In subsequent discussion with the participant, it became clear that he had misinterpreted
the initial instruction on medication use as two tablets twice a day, and had been taking
this dose rather than one tablet twice a day. For approximately 10 days between
3 December 2014 and 17 December 2014, he had therefore been taking a dose in the
normal therapeutic range (400 mg twice daily) rather than a low dose (200mg twice
daily). For the period between 17 December 2014 and 10 June 2015 he had been taking
one tablet twice a day; this was the appropriate ‘low dose’ used in the trial. For a further
3 days from 10 June 2015, the participant again misinterpreted the instruction on the
medication bottle and took two tablets twice a day (i.e. the normal therapeutic range
rather than a low dose)
Non-serious
12 Participant was prescribed Elleste Duet (Piramal Healthcare UK Ltd, Morpeth, UK) (which
is an oestrogen; oestrogens may raise theophylline levels to within the normal therapeutic
range rather than a low dose) by her GP between being recruited into the study and her
6-month follow-up. At the 6-month follow-up (18 June 2015), she was advised to cease
taking trial medication. The interaction between Elleste Duet and theophylline is such that
the serum levels of theophylline may be raised into the normal therapeutic range, and not
to toxic levels. Thus any interaction does not raise safety concerns
Non-serious
Across sites Following review of emergency hospital admissions captured at follow-up, we identified a
number of admissions that should have been captured as SAEs. None was related to trial
medication
Non-serious
12 The participant failed to attend for the 12-month follow-up. Follow-up data were sought
from his GP, and during this data-collection exercise, it was noted that the participant had
been prescribed Uniphyllin on repeat prescription since 8 May 2012. He had not disclosed
this at recruitment or the 6-month follow-up, or during any telephone calls. The prescription
he brought to the recruitment appointment did not include the Uniphyllin. No AEs were
noted during follow-up (last contact with participant was at the 46-week call)
Non-serious
12 Late reporting of a SAE in this participant (strangulated small bowel secondary to hernia,
not related to trial medication), who had ceased trial medication prior to the event
Non-serious
125 Participant was randomised on 12 January 2016 (200 mg od); on 26 January it was noted
that he was already taking aminophylline (225 mg bd). The participant had taken trial
medication as well as routine aminophylline for 8 days. The participant did not experience
any ARs. The GP confirmed that the aminophylline (225mg bd) plus trial medication
(if active; 200 mg od) would not have taken the participant over the maximum daily dose
Non-serious
12 The trial office prepared a waybill for the dispatch of trial medication with the house
number transposed (so the trial medication was delivered to house number 35 rather
than house number 53). The participant was resupplied, and the incorrect delivery was
retrieved from house number 35
Non-serious
78 The third-party distributor picked the wrong kit and this was dispatched to the
participant. The wrong kit was retrieved from the participant and she was resupplied with
the correct kit
Non-serious
14 Participant was recruited into the TWICS trial while participating in another drug study
(in breach of the TWICS trial eligibility criteria). There was no documentation in the
medical notes in relation to the other study and the participant did not mention it at
recruitment. The participant came to no harm
Non-serious
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Site affected
(site number) Description of breach Assessment
145 Participant randomised on 23 June 2016 to once-daily trial medication, and was allocated
an appropriate labelled bottle. The participant took the trial medication twice daily for
approximately 7 days after commencing medication (this would have brought her into the
normal therapeutic range for theophylline rather than a low dose). The participant came
to no harm (she noted some initial constipation, which resolved)
Non-serious
122 Participant was randomised to od study medication. The bottle was correctly labelled, but
a dispensing label was added at the time the medication was dispensed that indicated a
two-a-day dosing regimen. The error was noted and corrected. The participant took twice
daily study medication for approximately 10 days (this would have brought him into the
normal therapeutic range for theophylline rather than a low dose) and came to no harm
Non-serious
159 In an attempt to prevent medication being prescribed that may interact with theophylline,
the practice added theophylline to the repeat prescription as a trial drug. The pharmacist
dispensed liquid theophylline as part of the repeat prescription; for a period of 7 days, the
participant took a dose of liquid theophylline three times per day and also took their trial
medication three times per day. This would have brought the participant into the normal
therapeutic range for theophylline rather than a low dose. The participant came to no
harm
Non-serious
141 The third-party distributor picked the wrong kit and this was dispatched to the
participant. The wrong kit was retrieved from the participant and she was resupplied with
the correct kit
Non-serious
115 Participant was recruited to the trial in October 2015. During data checking in January
2017, it was noted that the participant was already taking Phyllocontin (Napp
Pharmaceuticals Ltd). The participant took trial medication for a full 12 months, and no
AEs were noted. Subsequent data checking identified five other participants who had
been recruited while on a medication that may interact with theophylline:
l Site 32 – febuxostat; participant took trial medication for 12 months; non-serious
gastrointestinal symptoms noted (abdominal pain, two episodes of reflux)
l Site 80 – estradiol valerate; participant took trial medication for 2 weeks and
experienced non-serious side effects likely to be related to theophylline (nausea,
headache, dizziness)
l Site 102 – roflumilast; participant took study medication for 12 months; no ARs noted
during the 12-month follow-up
l Site 131 – elleste duet; participant continues on trial medication (due to complete
12-month follow-up); no ARs noted
l Site 131 – estradiol; participant continues on trial medication (due to complete
12-month follow-up); no ARs noted
Non-serious
LA, long acting; R&D, research and development.
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Appendix 4 Recruitment by site
Site
Participants
recruited (n)
Secondary care sites (N = 33) 1101
Aberdeen Royal Infirmary 212
Aintree University Hospital NHS Foundation Trust 127
Belfast City Hospital 6
Queen Elizabeth Hospital Birmingham 54
Blackpool Victoria Hospital 57
Bradford Royal Infirmary 9
Queen’s Hospital, Burton Hospitals NHS Foundation Trust 4
Calderdale Royal Hospital, Huddersfield Royal Infirmary, Calderdale & Huddersfield NHS Foundation
Trust
4
University Hospital of North Durham 9
Lister Hospital, East and North Hertfordshire NHS Trust 20
Victoria Hospital, Kirkcaldy 29
Freeman Hospital, Newcastle 45
Glasgow Hospitals (Gartnavel, Glasgow Royal, Southern General, Victoria Infirmary, Western Infirmary) 115
Castle Hill Hospital, Hull 114
Raigmore Hospital, Inverness 31
University Hospital Wishaw 12
Royal Lancaster Infirmary 19
Leighton Hospital, Crewe 13
Musgrove Park Hospital 6
Norfolk and Norwich University Hospital 80
University Hospital of North Tees 6
City Hospital, Nottingham 11
Derriford Hospital, Plymouth 4
South Tyneside District Hospital 44
Torbay Hospital 12
New Cross Hospital, Wolverhampton 33
Worcestershire Royal Hospital 11
Yeovil District Hospital 8
York Hospital, York Teaching Hospital NHS Foundation Trust 6
East of England primary care (N = 48) 242
Alconbury and Brampton Surgeries 6
Alexandra and Crestview Surgeries 5
Andaman Surgery 7
Attleborough Surgeries 7
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Site
Participants
recruited (n)
Beccles Medical Centre 7
Bridge Road Surgery 4
Bridge Street Medical Centre, Cambridge 2
Bridge Street Surgery, Downham Market 8
Campingland Surgery 2
Castle Partnership 8
Coltishall Medical Practice 4
Comberton and Eversden Surgeries 3
Cutlers Hill Surgery 2
Davenport House 3
De Parys Medical Centre 5
East Norfolk Medical Practice 1
Elizabeth Courtauld Surgery 1
Gorleston Medical Centre 3
Greyfriars Medical Centre 6
Harvey Group Practice 6
Holt Medical Practice 2
Hoveton and Wroxham Medical Centre 6
Linton Health Centre 5
Long Stratton Medical Partnership 4
Ludham & Stalham Green Surgeries 12
Mount Farm Surgery 3
Mundesley Medical Centre 14
Nuffield Road Medical Centre 4
Orchard Surgery, Dereham 3
Peninsula Practice 6
Portmill Surgery 4
Rosedale Surgery 3
Roundwell Medical Centre 5
Salisbury House Surgery 3
Sheringham Medical Practice 5
Spinney Surgery 4
St Stephens Gate Medical Practice 12
St Johns Surgery, Terrington 5
Staithe Surgery 4
The Over Surgery 1
Trinity and Bowthorpe Medical Practice 2
Vida Healthcare 11
Wells Health Centre 3
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Site
Participants
recruited (n)
Wellside Surgery 3
Woodhall Farm Medical Centre 3
Woolpit Health Centre 19
Wymondham Medical Practice 1
York Street Medical Practice 5
North of England primary care (N = 26) 131
Beacon View Medical Centre 8
Beaumont Park Medical Group 4
Belford Medical Practice 8
Bellingham Practice 1
Benfield Park Medical Centre 6
Burn Brae Medical Group 1
Castlegate & Derwent Surgery 29
Corbridge Medical Group 6
Elvaston Road Surgery 1
Fell Cottage Surgery 2
Grove Medical Group 1
Guidepost Medical Group 7
Haltwhistle Medical Group 2
Haydon and Allendale Medical Practice 1
Hetton Group Practice 4
Humshaugh and Wark Medical Group 3
Marine Avenue Surgery 2
Maryport Health Services 9
Priory Medical Group 2
Prudhoe Medical Group 4
Seaton Park Medical Group 2
Sele Medical Group 6
Temple Sowerby Medical Group 5
The Village Surgery 4
Waterloo Medical Group 11
West Farm Surgery 2
South West England primary care (N = 11) 95
Barton Surgery 6
Bovey Tracey and Chudleigh Practice 9
Brunel Medical Practice 20
Claremont Medical Practice 4
Coleridge Medical Centre 3
Helston Medical Centre 2
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Site
Participants
recruited (n)
Ide Lane Surgery 2
Petroc Group Practice 11
Richmond House Surgery 5
Rolle Medical Partnership 4
Westlake Surgery 29
Wessex primary care (N = 3) 9
Friarsgate Practice 1
Park and St Francis Surgery 1
Swanage Medical Centre 7
Total recruitment 1578
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Appendix 5 Supplementary tables
TABLE 36 Baseline sociodemographic characteristics by location of recruitment
Characteristic
Primary care
(N= 917)
Secondary care
(N= 619) p-value
Sex
Male, n (%) 498 (54.3) 330 (53.3) 0.701
Female, n (%) 419 (45.7) 289 (46.7)
Age (years), mean (SD) 68.9 (8.2) 67.7 (8.5) 0.006
Smoking status
Current smoker, n (%) 322 (35.1) 164 (26.5) < 0.001
Ex-smoker, n (%) 595 (64.9) 455 (73.5)
Pack-years, mean (SD); n 46.1 (29.5); 910 48.4 (27.1); 619 0.113
BMI (kg/m2), mean (SD) 27.4 (6.1) 27.0 (6.1) 0.284
BMI group, n (%)
Underweight 41 (4.5) 29 (4.7) 0.463
Normal 306 (33.4) 214 (34.6)
Overweight 296 (32.3) 214 (36.6)
Obese 274 (29.9) 162 (26.2)
Number of exacerbations in the previous 12 months, mean (SD); n 3.35 (1.8); 908 3.92 (2.5); 619 < 0.001
Number of exacerbations requiring hospitalisation in the previous
12 months, mean (SD); n
0.22 (0.6); 907 0.61 (1.1); 619 < 0.001
GOLD 2011 category
N 901 615 0.006
C: two or more exacerbations in the previous year, mMRC dyspnoea
score of 0–1 and CAT score of < 10, n (%)
60 (6.7) 21 (3.4)
D: two or more exacerbations in the previous year, mMRC dyspnoea
score of ≥ 2 and CAT score of ≥ 10, n (%)
841 (93.3) 594 (96.6)
FEV1% predicted, mean (SD); n 54.5 (19.6); 907 47.7 (19.9); 619 < 0.001
FEV1% predicted category
N 907 619 < 0.001
≥ 80% (GOLD mild), n (%) 100 (11.0) 40 (6.5)
50–79.9% (GOLD moderate), n (%) 399 (44.0) 207 (33.4)
30–49.9% (GOLD severe), n (%) 320 (35.3) 255 (41.2)
0–29.9% (GOLD very severe), n (%) 88 (9.7) 117 (18.9)
FVC% predicted, mean (SD); n 86.4 (23.3); 904 83.7 (22.1); 619 0.022
FEV1/FVC ratio, mean (SD); n 50.8 (14.2); 904 45.8 (20.4); 619 < 0.001
continued
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TABLE 36 Baseline sociodemographic characteristics by location of recruitment (continued )
Characteristic
Primary care
(N= 917)
Secondary care
(N= 619) p-value
Current treatment for COPD
ICS, n (%)
ICS only 26 (2.8) 5 (0.8) 0.001
ICS/LABA 176 (19.2) 84 (13.6)
ICS/LAMA 12 (1.3) 10 (1.6)
ICS/LABA/LAMA 703 (76.7) 520 (84.0)
Oral mucolytic use, n (%); N 162 (17.9); 905 222 (35.9); 619 < 0.001
Long-term antibiotic use, n (%); N 34 (3.8); 905 62 (10.0); 619 < 0.001
Comorbidities
Asthma, n (%); N 186 (20.6); 905 93 (15.1); 618 0.006
Bronchiectasis, n (%); N 22 (2.4); 905 43 (7.0); 617 < 0.001
Ischaemic heart disease, n (%); N 107 (11.9); 903 97 (15.7); 618 0.031
Hypertension, n (%); N 351 (38.8); 905 231 (37.4); 618 0.579
Diabetes mellitus, n (%); N 102 (11.3); 905 72 (11.7); 618 0.819
Osteoporosis, n (%); N 99 (10.9); 905 96 (15.5); 318 0.008
Anxiety/depression treated in the previous 5 years, n (%); N 231 (25.5); 905 195 (31.6); 618 0.010
Cerebrovascular event, n (%); N 58 (6.4); 905 45 (7.3); 619 0.511
TABLE 37 Baseline patient-reported symptoms and QoL by location of recruitment
Patient-reported outcome Primary care Secondary care p-value
Degree of breathlessness (mMRC dyspnoea)
N 907 617 < 0.001
Not troubled by breathlessness except on strenuous exercise, n (%) 65 (7.2) 20 (3.2)
Short of breath when hurrying or walking up a slight hill, n (%) 286 (31.5) 143 (23.2)
Walks slower than contemporaries on level ground because of
breathlessness, or has to stop for breath when walking at own pace, n (%)
267 (29.4) 216 (35.0)
Stops for breath after walking about 100 m or after a few minutes on
level ground, n (%)
234 (25.8) 186 (30.2)
Too breathless to leave the house, or breathless when dressing or
undressing, n (%)
55 (6.1) 52 (8.4)
CAT (N, mean, SD) 21.6 (7.6); 905 23.9 (7.6); 615 < 0.001
CAT group
N 905 615 < 0.001
Low (score of 0–9), n (%) 60 (6.6) 21 (3.4)
Medium (score of 10–19), n (%) 295 (32.6) 159 (25.9)
High (score of 20–29), n (%) 391 (43.2) 285 (46.3)
Very high (score of 30–40), n (%) 159 (17.6) 150 (24.4)
EQ-5D-3L utility (N, mean, SD) 0.66 (0.28); 908 0.58 (0.29); 619 < 0.001
EQ-5D-3L VAS (N, mean, SD) 61.7 (19.3); 907 59.1 (18.9); 617 < 0.001
VAS, visual analogue scale.
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TABLE 38 Baseline sociodemographic characteristics comparing those with and those without HARQ data
Characteristic HARQ not completed (N= 1134) HARQ completed (N= 402) p-value
Sex (male), n (%) 629 (55.5) 199 (49.5) 0.039a
Age, mean (SD) 68.9 (8.3) 66.8 (8.2) < 0.001a
Smoking status, n (%)
Current smoker 352 (31.0) 134 (33.3) 0.396a
Ex-smoker 782 (69.0) 268 (66.7)
Pack-years, mean (SD); N 46.3 (26.8); 1128 49.2 (33.2); 401 0.076b
BMI, mean (SD) 27.2 (6.01) 27.4 (6.4) 0.689b
a Chi-squared test.
b Independent samples t-test.
TABLE 39 Additional outcomes for the ITT population for treatment of exacerbation
Exacerbations
Trial arm
Model Estimate 95% CI p-valueTheophylline Placebo
Exacerbations treated with antibiotics only
Total number included in analysis 772 764
Number with at least one
exacerbation
230 227
Total number of exacerbations 338 368
Mean number of exacerbations 0.44 0.48 Unadjusted IRR 0.94 0.78 to 1.13 0.484
SD (number of exacerbations) 0.82 0.97 Adjusted IRRa 0.94 0.78 to 1.14 0.541
Exacerbations treated with steroids only
Total number included in analysis 772 764
Number with at least one
exacerbation
77 88
Total number of exacerbations 117 124
Mean number of exacerbations 0.15 0.16 Unadjusted IRR 0.93 0.66 to 1.32 0.697
SD (number of exacerbations) 0.60 0.58 Adjusted IRRa 0.88 0.62 to 1.25 0.476
Exacerbations treated with antibiotics and steroids
Total number included in analysis 772 764
Number with at least one
exacerbation
487 479
Total number of exacerbations 1171 1106
Mean number of exacerbations 1.52 1.45 Unadjusted IRR 1.05 0.93 to 1.17 0.446
SD (number of exacerbations) 1.72 1.65 Adjusted IRRa 1.02 0.92 to 1.14 0.725
a Adjusted for centre (as a random effect), recruiting site (primary or secondary care), age centred on the mean, sex
(male/female), smoking in pack-years, FEV1% predicted, number of COPD exacerbations in the previous year, baseline
COPD treatment and treatment with long-term antibiotics.
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TABLE 40 Subgroup analysis for primary outcome (ITT analysis)
Category
Trial arm
IRRa 95% CI Interaction p-valueTheophylline Placebo
All participants
n 772 764
Mean 2.24 2.23
SD 1.99 1.97 0.99 0.91 to 1.08
Sex
Male
n 418 410
Mean 2.23 2.18 1.01 0.87 to 1.17
SD 2.04 1.92
Female
n 354 354
Mean 2.25 2.28 0.97 0.83 to 1.14 0.609
SD 1.93 2.03
Age group (years)
< 60
n 115 131
Mean 2.33 2.46 0.91 0.70 to 1.19
SD 2.01 1.81
60–69
n 313 284
Mean 2.27 2.13 1.07 0.89 to 1.28 0.198
SD 2.06 1.81
≥ 70
n 344 349
Mean 2.18 2.23 0.96 0.82 to 1.13 0.637
SD 1.92 2.01
Smoking status
Current
n 241 245
Mean 2.40 2.47 0.96 0.80 to 1.16
SD 2.01 2.07
Ex-smoker
n 531 519
Mean 2.16 2.11 1.01 0.89 to 1.16 0.561
SD 1.97 1.92
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TABLE 40 Subgroup analysis for primary outcome (ITT analysis) (continued )
Category
Trial arm
IRRa 95% CI Interaction p-valueTheophylline Placebo
BMI category
Underweight
n 37 33
Mean 2.51 2.45 0.93 0.57 to 1.52 0.894
SD 2.34 1.72
Normal
n 277 243
Mean 2.29 2.41 0.95 0.79 to 1.15
SD 1.91 1.72
Overweight/obese
n 458 488
Mean 2.18 2.13 1.02 0.88 to 1.17 0.478
SD 2.01 1.96
COPD treatment at baseline
ICS/LAMA/LABA
n 610 613
Mean 2.33 2.36 0.98 0.87 to 1.10
SD 2.05 1.87
ICS/LABA or ICS/LAMA
n 148 134
Mean 1.89 1.78 1.00 0.76 to 1.32 0.832
SD 1.70 1.87
ICS only
n 14 17
Mean 1.86 1.06 1.63 0.65 to 4.09 0.155
SD 1.92 1.43
Number of exacerbations in the 12 months prior to baseline
2
n 286 308
Mean 1.61 1.53 1.05 0.86 to 1.28
SD 1.66 1.85
3 or 4
n 317 298
Mean 2.31 2.25 1.02 0.86 to 1.21 0.785
SD 1.93 1.85
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TABLE 40 Subgroup analysis for primary outcome (ITT analysis) (continued )
Category
Trial arm
IRRa 95% CI Interaction p-valueTheophylline Placebo
≥ 5
n 169 158
Mean 3.16 3.55 0.89 0.73 to 1.09 0.139
SD 2.21 2.38
GOLD stage
I–II
n 370 376
Mean 1.93 2.03 0.97 0.82 to 1.14
SD 1.89 1.99
III
n 286 289
Mean 2.38 2.40 1.02 0.85 to 1.21 0.605
SD 2.03 1.99
IV
n 113 92
Mean 2.90 2.58 0.99 0.75 to 1.32 0.849
SD 2.03 2.04
OCSs at baseline
No
n 418 410
Mean 2.23 2.18 0.99 0.88 to 1.10
SD 2.04 1.92
Yes
n 354 354
Mean 2.25 2.28 1.20 0.65 to 2.20 0.420
SD 1.93 2.03
ICS dose at baseline
≥ 1600 µg per day
n 549 547
Mean 2.38 2.31 0.98 0.87 to 1.12 0.642
SD 1.98 2.03
< 1600 µg per day
n 221 215
Mean 1.91 2.01 1.03 0.83 to 1.27
SD 1.98 1.80
a Adjusted for centre (as a random effect), recruiting site (primary or secondary care), age centred on the mean, sex
(male/female), smoking in pack-years, FEV1% predicted, number of COPD exacerbations in the previous year, baseline
COPD treatment and treatment with long-term antibiotics.
APPENDIX 5
NIHR Journals Library www.journalslibrary.nihr.ac.uk
114
TABLE 41 Sensitivity analysis for the ITT population excluding the 33 participants who died during the 12-month
follow-up: exacerbations and hospital admissions
Exacerbations and hospital
admissions
Trial arm
Model Estimate 95% CI p-valueTheophylline Placebo
Total exacerbations
Total number included in analysis 753 750
Person-years of follow-up 738.6 735.1
Number with at least one
exacerbation
619 596
Total number of exacerbations 1690 1678
Mean number of exacerbations 2.24 2.24 Unadjusted IRR 1.00 0.91 to 1.09 0.934
SD (number of exacerbations) 1.99 1.98 Adjusted IRRa 0.99 0.91 to 1.07 0.729
Exacerbations requiring hospital treatment
Total number included in analysis 753 750
Person-years follow-up 738.6 735.1
Number with at least one
exacerbation
99 118
Total number of exacerbations 126 172
Mean number of exacerbations 0.17 0.23 Unadjusted IRR 0.73 0.55 to 0.97 0.032
SD (number of exacerbations) 0.49 0.66 Adjusted IRRa 0.73 0.55 to 0.97 0.031
Non-COPD hospital admissions
Total number included in analysis 744 741
Number with at least one admission 77 87
Total number of admissions 111 111
Mean admission rate 0.15 0.15 Unadjusted IRR 0.99 0.71 to 1.38 0.949
SD (admission rate) 0.54 0.45 Adjusted IRRa 1.03 0.74 to 1.43 0.875
a Adjusted for centre (as a random effect), recruiting site (primary or secondary care), age centred on the mean, sex
(male/female), smoking in pack-years, FEV1% predicted, number of COPD exacerbations in the previous year, baseline
COPD treatment and treatment with long-term antibiotics.
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TABLE 42 Sensitivity analysis for the ITT population excluding the 33 participants who died during the 12-month
follow-up: lung function and patient-reported outcomes
Outcome
Trial arm
Model Overall mean difference 95% CI p-valueTheophylline Placebo
% predicted FEV1
Baseline
Total n 750 743
Mean 51.4 52.4
SD 20.0 19.8
6 months
Total n 548 535
Mean 52.4 53.2
SD 20.4 20.9
12 months
Total n 533 488
Mean 51.5 52.2 Unadjusted –0.59 –2.54 to 1.36 0.551
SD 20.4 21.6 Adjusteda –0.58 –2.46 to 1.29 0.543
% predicted FVC
Baseline
Total n 748 742
Mean 84.5 86.5
SD 22.2 23.5
6 months
Total n 543 531
Mean 84.0 84.6
SD 22.74 24.8
12 months
Total n 525 485
Mean 83.1 82.5 Unadjusted –0.45 –2.59 to 1.69 0.678
SD 23.8 25.1 Adjusteda –0.37 –2.43 to 1.69 0.723
CAT score
Baseline
Total n 745 742
Mean 22.7 22.3
SD 7.6 7.9
6 months
Total n 668 653
Mean 21.2 21.1
SD 8.1 8.3
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TABLE 42 Sensitivity analysis for the ITT population excluding the 33 participants who died during the 12-month
follow-up: lung function and patient-reported outcomes (continued )
Outcome
Trial arm
Model Overall mean difference 95% CI p-valueTheophylline Placebo
12 months
Total n 633 615
Mean 21.4 21.4 Unadjusted 0.16 –0.56 to 0.89 0.661
SD 8.2 8.6 Adjusteda 0.02 –0.65 to 0.69 0.950
HARQ score
Baseline
Total n 193 197
Mean 25.2 25.8
SD 16.1 14.9
6 months
Total n 189 187
Mean 21.9 22.8
SD 15.13 15.7
12 months
Total n 184 172
Mean 24.1 24.2 Unadjusted –0.62 –3.15 to 1.91 0.631
SD 15.70 15.94 Adjusteda –0.89 –3.27 to 1.50 0.468
a Adjusted for centre (as a random effect), recruiting site (primary or secondary care), age centred on the mean, sex
(male/female), smoking in pack-years, FEV1% predicted, number of COPD exacerbations in the previous year, baseline
COPD treatment and treatment with long-term antibiotics.
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Appendix 6 Line listings of serious adverse events
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TABLE 43 Events recorded as suspected unexpected serious adverse reactions
Case ID
Country, sex,
age (years) Event Outcome Date of onset
Assessment of
relatedness to
trial drug
Daily dose route
formulation
Dates of
treatment Comments
System Organ Class: cardiac disorders
ID 070 UK, female,
72
2 : 1 AV block Recovered
with sequelae
April 2015 Possible 200 mg of
theophylline od
4 March–12
April 2015
PI disputed diagnosis of AV block
made by cardiology team. Chief
investigator noted normal ECG
after discontinuing study drug prior
to development of AV block, also
noted that theophylline increased
heart rate rather than to slow it
and therefore unlikely to be related
to study drug
ID 143 UK, female,
59
STEMI, PCI to LCx and
OM arteries, cor
pulmonale, mild to
moderate LVSD on
ventriculogram
Recovered 30 March 2016 Possible 200 mg of
theophylline od
21–27 March
2016
PI suggested that there was
possible association with study
drug. Chief investigator noted that
the participant had ceased study
medication 3 days prior to the
cardiac event and therefore highly
unlikely to be related to study drug
AV, atrioventricular; ECG, electrocardiogram; ID, identification; LCx, left circumflex; LVSD, left ventricular systolic dysfunction; OM, obtuse marginal; PCI, percutaneous coronary intervention;
PI, principal investigator; STEMI, ST elevation myocardial infarction.
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TABLE 44 Events recorded as possible serious adverse reactions
Case ID
Country, sex,
age (years) SAE Outcome Date of onset
Assessment of
relatedness to
trial drug
Daily dose route
formulation Dates of treatment Comments
System Organ Class: cardiac disorders
007 UK, male, 66 Atypical atrial flutter/atrial
tachycardia
Recovered 25 August 2014 Possible 200mg theophylline bd 6–12 August 2014
and 19–25 August
2014
018 UK, male, 79 Syncopal episode resulting in
fracture to right fourth metacarpal
Recovered 8 November 2014 Possible 200mg theophylline od 30 March 2014–
31 March 2015
029 UK, male, 81 Atrial fibrillation Not
recovered
31 October 2014 Possible 200mg theophylline bd 30 April 2014–
26 January 2015
072 UK, male, 82 Non-sustained ventricular
tachycardia
Recovered
with
sequelae
14 August 2015 Possible 200mg theophylline od 25 August 2014–
14 August 2015
186 UK, male, 76 Palpitations Not
recovered
11 August 2016 Possible 200mg placebo od 4–11 August 2016
189 UK, female, 73 Palpitations and tachycardia Not
recovered
16 August 2016 Possible 200mg theophylline od 16 February–
5 September 2016
213 UK, female, 54 Palpitations Unknown 12 October 2016 Probable 200mg placebo od 27 May–17 October
2016
233 UK, male, 73 Sinus tachycardia Recovered 18 November 2016 Possible 200mg placebo od 25 November 2015–
ongoing at time of
event
System Organ Class: gastrointestinal disorders
103 UK, female, 71 Dyspeptic pain Recovered 22 October 2015 Possible 200mg placebo od 12–27 October 2015
System Organ Class: investigations
268 UK, male, 76 Weight loss, lethargy Unknown 19 April 2017 Possible 200mg placebo od 9 June 2016–ongoing
at time of event
ID, identification.
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TABLE 45 Events recorded as SAEsa
Case ID
Country, sex,
age (years) SAE Outcome Date of onset
Daily dose
route
formulation Dates of treatment Comments
System Organ Class: infections and infestations
012 UK, male, 74 Infected elbow Recovering 30 September 2014 200mg of
placebo od
12 September 2014–
ongoing
055 UK, female, 54 Right leg cellulitis Recovered 10 June 2015 200mg of
theophylline od
9–11 December 2014
060b UK, female, 82 UTI Unknown 9 July 2015 200mg of
placebo od
Never commenced trial
medication (trial
medication not
dispensed)
Did not start/initiate study medication
071 UK, female, 76 Sepsis Recovered with
sequelae
19 August 2015 200mg of
placebo od
1 July 2015–ongoing at
time of event
081 UK, male, 70 Left arm cellulitis Recovered 16 September 2015 200mg of
placebo od
3 April–16 September
2015
110 UK, female, 75 Cellulitis lower leg
secondary to cat bite
Unknown 13 December 2015 200mg of
theophylline od
2 December 2015–
ongoing at time of
event
120 UK, female, 77 Cellulitis, delirium Recovered 13 December 2015 200mg of
theophylline od
13 February 2015–
ongoing at time of
event
127 UK, female, 82 UTI Recovered 29 December 2015 200mg of
theophylline od
27 February–
29 December 2015
128 UK, female, 71 Sepsis Unknown 8 February 2016 200mg of
placebo od
26 January 2016–
ongoing at time of
event
134 UK, male, 79 UTI and reduced mobility Recovered 26 November 2015 200mg of
theophylline bd
16 September 2015–
25 January 2016
174 UK, female, 64 Infection, unknown
source
Recovered 28 May 2016 200mg of
theophylline od
23 June 2015–ongoing
at time of event
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Case ID
Country, sex,
age (years) SAE Outcome Date of onset
Daily dose
route
formulation Dates of treatment Comments
181 UK, female, 76 Atrial flutter secondary
to sepsis from lower-limb
cellulitis
Recovering 4 August 2016 200mg of
theophylline od
19 May 2016–ongoing
at time of event
Recorded as infection as this was the
primary driver of atrial flutter
201 UK, male, 57 Exacerbation of COPD,
leading to type 2
respiratory failure,
bilateral leg swelling and
also became infected
Clostridium difficile while
in hospital
Unknown 13 June 2016 200mg of
placebo od
19 April 2016–13 July
2017
Recorded as infection because of
clostridium difficile infection. The
exacerbation of COPD captured as
primary outcome
203 UK, female, 78 Gram-negative
bacteraemia
Recovered 20 August 2016 200mg of
placebo od
15 July–5 September
2016
217 UK, male, 69 Cellulitis Recovered 12 February 2015 200mg of
theophylline od
7 July–24 November
2014
220 UK, female, 77 Infective gastroenteritis Recovered 4 May 2016 200mg of
theophylline od
Never commenced trial
medication
Did not start/initiate study medication
221 UK, female, 77 Cellulitis Recovered 10 July 2016 200mg of
theophylline od
Never commenced trial
medication
Did not start/initiate study medication
222 UK, female, 77 Confusion, possible
secondary to cellulitis
Recovered 2 October 2016 200mg of
theophylline od
Never commenced trial
medication
l Did not start/initiate study
medication
l Recorded as infection as this was
the primary driver of confusion
225 UK, male, 78 Sepsis Recovered 13 November 2016 200mg of
placebo od
14 June 2016–ongoing
at time of event
239 UK, male, 74 Fall/possible sepsis Unknown 28 December 2016 200mg of
theophylline od
2 August 2016 ongoing
at time of event
Recorded as infection as this was the
primary driver of falls
244 UK, male, 66 Ankle joint infection Recovering 7 January 2017 200mg of
placebo od
22 January 2016–
ongoing at time of
event
247 UK, female, 65 UTI Recovered 10 October 2016 200mg of
placebo od
3 August 2016–ongoing
at time of event
continued
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TABLE 45 Events recorded as SAEsa (continued )
Case ID
Country, sex,
age (years) SAE Outcome Date of onset
Daily dose
route
formulation Dates of treatment Comments
249 UK, male, 77 UTI Recovered 19 January 2017 200mg of
theophylline od
9 February 2016–
ongoing at time of
event
251 UK, female, 71 Periumbilical abscess Recovered 6 October 2016 200mg of
theophylline od
27 November 2015–
ongoing at time of
event
253 UK, female, 60 UTI and possible viral
gastroenteritis
Recovered 10 December 2016 200mg of
theophylline od
21–29 March 2016
281 UK, male, 71 Gastroenteritis Recovered 6 February 2017 200mg of
theophylline od
9 June–20 July 2016
System Organ Class: neoplasm (benign, malignant and unspecified)
010 UK, female, 74 Moderately differentiated
squamous cell carcinoma
of supraglottic
submucosal T3 N2c M0
Recovered Unknown: reported
29 September 2014
200mg of
theophylline od
14 April 2014–
28 February 2015
011 UK, male, 68 Lung cancer Not recovered Unknown: reported
30 September 2014
200mg of
placebo od
19 May–30 September
2014
017 UK, female, 71 Left lower lobe lesion
with pleural effusion
Unknown 29 October 2014 200mg of
theophylline od
19 May–13 November
2014
019 UK, male, 68 Metastatic lung cancer
stage T2a N3 M1b
Fatal 18 November 2014 200mg of
theophylline od
7 July–27 August 2014
021 UK, female, 85 Metastatic bladder
cancer
Fatal 7 October 2014 200mg of
placebo od
2 April–2 June 2014
022 UK, male, 70 Perforated caecal tumour Fatal 24 November 2014 200mg of
theophylline od
24 July–November 2014
039 UK, female, 70 Intermediate-grade
neuroendocrine tumour/
atypical carcinoid
Recovering 16 January 2015 200mg of
placebo od
7 March–3 June 2015
040 UK, female, 77 Large pelvic mass/
sigmoid carcinoma
Not recovered 12 April 2014 200mg of
theophylline od
21 May 2014–25 April
2015
A
PPEN
D
IX
6
N
IH
R
Journals
Library
w
w
w
.journalslibrary.nihr.ac.uk
124
Case ID
Country, sex,
age (years) SAE Outcome Date of onset
Daily dose
route
formulation Dates of treatment Comments
059 UK, female, 79 Lung malignancy Unknown 6 June 2015 200mg of
theophylline od
17 July 2014–July 2015
068 UK, male, 83 Lung cancer Fatal 12 August 2015 200mg of
theophylline od
18 August 2014–
27 May 2015
078 UK, female, 66 Metastatic colonic
malignancy
Fatal 16 July 2015 200mg of
placebo od
16 December 2014–
19 January 2015
109 UK, male, 63 Left breast cancer Recovering 4 November 2015 200mg of
theophylline
twice daily
24 June 2015–ongoing
at time of event
112 UK, male, 61 Laryngeal cancer Fatal 11 September 2015 200mg of
placebo od
Never commenced trial
medication
Did not start/initiate study medication
117 UK, female, 64 Right hilar mass Not recovered 15 December 2015 200mg of
theophylline od
5–25 August 2015
123 UK, male, 80 Metastatic disease in the
liver with no obvious
primary
Unknown 11 December 2015 200mg of
placebo od
21 July–31 August 2015
132 UK, female, 67 Central tumour,
mediastinal
lymphadenopathy,
cerebral metastases
Not recovered 12 February 2016 200mg of
theophylline od
4–19 February 2016
141 UK, male, 67 Metastatic cancer Unknown 17 March 2016 200mg of
placebo od
14 April 2015–13 April
2016
147 UK, female, 72 Lung cancer Not recovered 1 April 2016 200mg of
theophylline od
15 October 2015–
ongoing at time of
event
148 UK, female, 72 Haemoptysis secondary
to lung cancer
Recovering 1 April 2016 200mg of
theophylline od
15 October 2015–
ongoing at time of
event
160 UK, female, 76 Pancreatic malignancy
with biliary obstruction
Fatal 3 May 2016 200mg of
theophylline od
17 March–17 May 2016
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TABLE 45 Events recorded as SAEsa (continued )
Case ID
Country, sex,
age (years) SAE Outcome Date of onset
Daily dose
route
formulation Dates of treatment Comments
202 UK, male, 61 T2 N2b squamous cell
carcinoma of his right
pyriform fossa
Unknown 8 March 2016 200mg of
placebo od
28 August 2015–
ongoing at time of
event
219 UK, female, 68 Lung neoplasm Not recovered Unknown 200mg of
theophylline od
19 July 2016–3 January
2017
228 UK, female, 59 Investigation following CT
scan showing nodule –
primary lung tumour
Unknown 15 November 2016 200mg of
placebo od
1 June 2016–ongoing at
time of event
231 UK, male, 70 Lung cancer Not recovered 4 November 2016 200mg of
placebo twice
daily
3 December 2015–
ongoing at time of
event
238 UK, male, 70 Grade 2 prostate cancer Unknown 22 December 2016 200mg of
placebo od
28 July 2016–ongoing
at time of event
241 UK, female, 58 Mastectomy for breast
cancer
Recovering 19 December 2016 200mg of
theophylline od
18 February 2016–
ongoing at time of
event
254 UK, female, 67 Right breast cancer Unknown 2 March 2017 200mg of
theophylline od
27 May 2016–ongoing
at time of event
260 UK, female, 81 Uterine cancer Recovering 27 February 2017 200mg of
theophylline od
3 March 2016–ongoing
at time of event
263 UK, female, 64 Chronic lymphocytic
leukaemia
Not recovered 5 April 2017 200mg of
placebo od
25 August 2016–
ongoing at time of
event
286 UK, male, 70 Hepatic flexure cancer
(Dukes’ B)
Recovering 20 July 2017 200mg of
theophylline od
4 August 2016–ongoing
at time of event
289 UK, female, 82 Classification of death:
Ia metastatic
cholangiocarcinoma,
II COPD
Fatal 8 November 2017 200mg of
placebo od
Never commenced trial
medication
Did not start/initiate study medication
A
PPEN
D
IX
6
N
IH
R
Journals
Library
w
w
w
.journalslibrary.nihr.ac.uk
126
Case ID
Country, sex,
age (years) SAE Outcome Date of onset
Daily dose
route
formulation Dates of treatment Comments
System Organ Class: blood and lymphatic system disorders
173 UK, male, 71 Iron deficiency anaemia Recovered 18 February 2016 200mg of
placebo od
29 June 2015–ongoing
at time of event
184 UK, female, 72 Abdominal haematoma Recovering 3 May 2016 200mg of
placebo od
7 August 2015–ongoing
at time of event
System Organ Class: immune system disorders
None
System Organ Class: endocrine disorders
None
System Organ Class: metabolism and nutrition disorders
245 UK, male, 79 Dysphagia Unknown 27 January 2017 200mg of
theophylline od
14 July 2016–31 January
2017
246 UK, male, 79 Refeeding syndrome Unknown 28 January 2017 200mg of
theophylline od
14 July 2016–31 January
2017
System Organ Class: psychiatric disorders
073 UK, male, 57 Overdose of amitriptyline
and alcohol
Recovering 1 September 2015 200mg of
placebo od
4 August–2 September
2015
098 UK, male, 58 Overdose of amitriptyline
and alcohol
Not recovered 8 November 2015 200mg of
placebo od
4 August–2 September
2015
146 UK, male, 59 Admission to psychiatric
ward with a depressive
episode
Recovered 24 July 2015 200mg of
placebo bd
8 April–30 June 2015
183 UK, male, 73 Death (suicide) as a
result of asphyxiation
Fatal 13 July 2016 200mg of
theophylline od
9 September 2015–
13 July 2016
System Organ Class: nervous system disorders
014 UK, male, 76 TIA, atrial fibrillation Recovered with
sequelae
1 September 2014 200mg of
theophylline bd
3 June 2014–9 January
2015
continued
D
O
I:10.3310/hta23370
H
EA
LTH
TECH
N
O
LO
G
Y
A
SSESSM
EN
T
2019
VO
L.23
N
O
.37
©
Q
ueen
’s
Printer
and
C
ontroller
of
H
M
SO
2019.
This
w
ork
w
as
produced
by
D
evereux
et
al.
under
the
term
s
of
a
com
m
issioning
contract
issued
by
the
Secretary
of
State
for
H
ealth
and
SocialC
are.
This
issue
m
ay
be
freely
reproduced
for
the
purposes
of
private
research
and
study
and
extracts
(or
indeed,
the
fullreport)
m
ay
be
included
in
professional
journals
provided
that
suitable
acknow
ledgem
ent
is
m
ade
and
the
reproduction
is
not
associated
w
ith
any
form
of
advertising.
A
pplications
for
com
m
ercialreproduction
should
be
addressed
to:
N
IH
R
Journals
Library,
N
ationalInstitute
for
H
ealth
Research,
Evaluation,
Trials
and
Studies
C
oordinating
C
entre,
A
lpha
H
ouse,
U
niversity
of
Southam
pton
Science
Park,
Southam
pton
SO
16
7N
S,
U
K
.
127
TABLE 45 Events recorded as SAEsa (continued )
Case ID
Country, sex,
age (years) SAE Outcome Date of onset
Daily dose
route
formulation Dates of treatment Comments
025 UK, male, 76 Stroke Recovering 11 November 2014 200mg of
theophylline bd
3 June 2014–November
2014, restarted briefly at
start of January 2015
027 UK, male, 66 Seizure secondary to
intracerebral
haemorrhage
Recovered 13 January 2015 200mg of
theophylline od
31 March 2014–
26 March 2015
033 UK, female, 44 Headache Recovered 19 February 2015 200mg of
theophylline od
7 January 2015–ongoing
at time of event
043 UK, male, 65 Subdural bleed/
haematoma as result of
fall prior to trial inclusion
Unknown 1 April 2015 200mg of
theophylline od
23 April 2015–ongoing
at time of event
050 UK, female, 78 Suspected cerebral
infarct
Recovering 23 May 2015 200mg of
placebo od
30 April–21 May 2015
064 UK, male, 78 Subdural haemorrhage Fatal 20 June 2015 200mg of
theophylline od
23 April–23 July 2015
077 UK, male, 73 Spinal canal stenosis Recovered 10 September 2015 200mg of
theophylline od
21 April–9 September
2015
080 UK, female, 82 Partial anterior circulation
infarct
Recovered 7 September 2015 200mg of
theophylline od
27 February–
7 September 2015
085 UK, male, 73 Chest pain/spinal
stenosis
Recovered 20 July 2015 200mg of
theophylline od
13 October 2014–
12 October 2015
099 UK, male, 78 Lewy body dementia Recovered 6 November 2015 200mg of
placebo od
1 December 2014–
ongoing at time of
event
107 UK, female, 82 Right total anterior
circulation stroke
syndrome or Todd’s palsy
Recovered 21 October 2015 200mg of
theophylline od
27 February 2015–
ongoing at time of
event
114 UK, male, 76 Bilateral thalamic infarct Not recovered 31 December 2015 200mg of
theophylline od
15 September 2015–
ongoing at time of
event
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Case ID
Country, sex,
age (years) SAE Outcome Date of onset
Daily dose
route
formulation Dates of treatment Comments
118 UK, male, 81 CVA Recovering 31 December 2015 200mg of
placebo od
30 January 2015, then
stopped trial drugs as
soon as admitted
131 UK, female, 58 Possible TIA Recovering 18 January 2016 200mg of
placebo od
24 March–18 August
2015
140 UK, female, 72 Dizziness and vomiting Recovered with
sequelae
22 March 2016 200mg of
theophylline od
1 April 2015–ongoing at
time of event
151 UK, male, 62 Confusion with
worsening headache
Recovered 16 December 2015 200mg of
placebo od
10 April 2015–15 April
2016
172 UK, male, 72 Ischaemic stroke,
community-acquired
pneumonia
Recovering 1 July 2016 200mg of
theophylline od
2 February 2016–
ongoing at time of
event
176 UK, female, 79 Subarachnoid
haemorrhage
Unknown 6 June 2016 200mg of
placebo od
15 September 2015–
6 June 2016
269 UK, male, 68 Frontal lobe dementia Fatal Unknown 200mg of
placebo od
12 April–18 October
2016
System Organ Class: eye disorders
None
System Organ Class: ear and labyrinth disorders
None
System Organ Class: cardiac disorders
004 UK, female, 84 Pulmonary oedema Recovered 24 June 2014 200mg of
placebo od
9 April–20 June 2014
013 UK, male, 72 Death: cause of death –
myocardial infarction,
infective exacerbation of
COPD, atrial fibrillation
Fatal 1 October 2014 200mg of
placebo od
30 May–13 August
2014
026 UK, male, 90 Orthostatic hypotension Recovered with
sequelae
28 December 2014 200mg of
theophylline od
7 May–6 June 2014
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TABLE 45 Events recorded as SAEsa (continued )
Case ID
Country, sex,
age (years) SAE Outcome Date of onset
Daily dose
route
formulation Dates of treatment Comments
031 UK, male, 75 Out-of-hospital cardiac
arrest; end-stage COPD;
mitral valve prolapse
Fatal 8 January 2015 200mg of
theophylline od
21 June–4 September
2014
032 UK, male, 57 Chest pain Recovered 1 December 2014 200mg of
placebo od
31 March 2014–2 April
2015
036 UK, male, 71 Anterolateral NSTEMI
(myocardial infarction)
Recovered 26 February 2015 200mg of
placebo od
13 March 2014–
26 February 2015
042 UK, male, 75 Cardiac arrest at home;
carcinoma of the right
upper lobe and COPD
Fatal 28 April 2015 200mg of
placebo od
18 August 2014–April
2015
052 UK, female, 76 Angina Recovered with
sequelae
11 July 2014 200mg of
theophylline od
3 April 2014–2 April
2015
053 UK, female, 76 Angina Recovered with
sequelae
31 July 2014 200mg of
theophylline od
3 April 2014–2 April
2015
056 UK, male, 65 Atrial fibrillation/flutter Recovered with
sequelae
16 June 2014 200mg of
placebo od
1–16 June 2015 Initially reported as possibly related
to the study medication; at SAE
follow-up, reported as having no
relationship to study medication
062 UK, female, 78 Carotid vascular disease Recovered with
sequelae
4 June 2015 200mg of
placebo od
29 April–12 May 2015
063 UK, female, 78 Angina Recovered with
sequelae
5 June 2015 200mg of
placebo od
29 April–12 May 2015
079 UK, female, 82 Missed STEMI versus
broken heart syndrome
Recovered 16 August 2015 200mg of
theophylline od
27 February–16 August
2015
082 UK, female, 70 Fast atrial fibrillation Recovering 2 October 2015 200mg of
placebo od
25 November 2014–
28 July 2015
086 UK, male, 59 Unstable angina Recovered 9 September 2015 200mg of
placebo od
8 April–30 June 2015
097 UK, female, 74 Left ventricular failure Recovered 1 November 2015 200mg of
placebo od
6 January 2015–ongoing
at time of event
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Case ID
Country, sex,
age (years) SAE Outcome Date of onset
Daily dose
route
formulation Dates of treatment Comments
102 UK, male, 82 Collapse not otherwise
specified
Unknown 25 November 2015 200mg of
placebo od
21 May 2015–ongoing
at time of event
119 UK, female, 77 Exacerbation of COPD;
pulmonary congestion
Recovered 4 December 2015 200mg of
theophylline od
13 February 2015–
ongoing at time of
event
122 UK, female, 77 Left ventricular failure,
secondary to acute MI,
secondary sepsis,
secondary to pneumonia
Fatal 17 January 2016 200mg of
theophylline od
14 February 2015–
18 January 2016
Recorded as cardiac because of
pulmonary congestion, the
exacerbation of COPD was captured
as primary outcome
126 UK, female, 82 Congestive cardiac
failure
Recovered 16 December 2015 200mg of
theophylline od
27 February–
16 December 2015
133 UK, male, 69 Cardiac arrest Fatal 26 January 2016 200mg of
placebo od
21 October 2015–
26 January 2016
149 UK, female, 62 Heart failure Recovered 1 February 2016 200mg of
placebo od
14 April 2015–ongoing
at time of event
164 UK, male, 79 Cardiac arrest Fatal 12 May 2016 200mg of
theophylline od
31 October–
19 December 2015
178 UK, male, 78 Heart failure, acute
kidney injury
Fatal 21 July 2016 200mg of
theophylline od
1 June–21 July 2016
179 UK, male, 68 Cardiac arrest Fatal 9 July 2016 200mg of
theophylline od
27 November 2015–
8 July 2016
185 UK, male, 76 Possible heart attack Not recovered 12 August 2016 200mg of
placebo od
3 June–23 September
2016
192 UK, female, 64 Narrow complex
tachycardia, exacerbation
of COPD
Recovering 29 June 2016 200mg of
theophylline od
26 August 2015–
ongoing at time of
event
195 UK, male, 86 Chest pain – probably
angina
Recovered 11 February 2015 200mg of
placebo od
5–11 September 2014
196 UK, male, 86 Unstable angina Recovered 9 June 2015 200mg of
placebo od
5–11 September 2014
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TABLE 45 Events recorded as SAEsa (continued )
Case ID
Country, sex,
age (years) SAE Outcome Date of onset
Daily dose
route
formulation Dates of treatment Comments
205 UK, male, 55 Acute coronary
syndrome
Unknown 14 September 2016 200mg of
placebo twice
daily
5 February 2016–
ongoing at time of
event
223 UK, male, 73 Acute myocardial
infarction
Unknown 24 October 2016 200mg of
placebo od
7 June 2016–ongoing at
time of event
240 UK, female, 78 Heart failure, moderate
to severe aortic stenosis
Unknown 29 November 2016 200mg of
placebo od
15 July–5 September
2016
242 UK, male, 73 NSTEMI Recovered with
sequelae
15 October 2016 200mg of
theophylline od
1 February 2016–
9 January 2017
243 UK, male, 63 Congestive heart failure Recovering 21 December 2016 200mg of
placebo twice
daily
26 July 2016–ongoing
at time of event
250 UK, female, 69 STEMI Recovered 23 February 2016 200mg of
placebo od
27 February–30 July
2015
258 UK, male, 88 NSTEMI Recovered 9 October 2016 200mg of
placebo od
13 November 2015–
ongoing at time of
event
265 UK, male, 64 End-stage congestive
cardiac failure
Fatal 12 April 2017 200mg of
placebo twice
daily
26 July 2016–30 April
2017
276 UK, male, 68 Acute pulmonary
oedema
Fatal 1 June 2017 200mg of
theophylline od
14 July 2016–1 June
2017
282 UK, female, 65 Atrial fibrillation and
heart failure
Recovered 10 June 2016 200mg of
placebo od
11 May 2016–ongoing
at time of event
284 UK, female, 69 Postural hypotension Recovered 31 May 2017 200mg of
placebo od
11 August 2016–
ongoing at time of
event
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Case ID
Country, sex,
age (years) SAE Outcome Date of onset
Daily dose
route
formulation Dates of treatment Comments
System Organ Class: vascular disorder
001 UK, male, 57 Old cerebellar gliosis/
stroke
Recovered 25 April 2014 200mg of
placebo od
31 March 2014–
ongoing at time of
event
066 UK, male, 62 COPD with lower
respiratory tract infection
and DVT
Recovered 20 June 2015 200mg of
placebo od
18 September–October
2014 (18 doses in total)
Recorded as vascular because
exacerbation of COPD captured as
primary outcome
105 UK, male, 75 Ruptured abdominal
aortic aneurysm
Fatal 29 November 2015 200mg of
theophylline
twice daily
14 October–29
November 2015
168 UK, female, 76 Right leg DVT Recovering 14 June 2016 200mg of
theophylline od
2 December 2015–
ongoing at time of
event
182 UK, female, 72 Collapse Unknown 5 August 2016 200mg of
placebo od
26 January 2016–
ongoing at time of
event
224 UK, male, 78 Intracerebral
haemorrhage
Recovered 6 November 2016 200mg of
placebo od
14 June 2016–ongoing
at time of event
252 UK, male, 69 Right ICA occlusion Recovering 26 December 2016 200mg of
placebo od
1 March 2016–
17 February 2017
255 UK, male, 74 Bilateral subdural
haematomas
Recovered with
sequelae
28 December 2015 200mg of
theophylline od
21 April–17 September
2015
256 UK, male, 74 DVT/pulmonary
embolism
Recovered with
sequelae
28 December 2015 200mg of
theophylline od
21 April–17 September
2015
267 UK, female, 73 Uncontrolled
hypertension
Recovered 13 April 2017 200mg of
theophylline od
13 April 2016–ongoing
at time of event
270 UK, male, 68 Collapse, cause
unknown
Recovered 17 June 2016 200mg of
placebo od
12 April–18 October
2016
285 UK, male, 77 Ruptured abdominal
aortic aneurysm
Fatal 7 August 2017 200mg of
theophylline od
17 August–9 October
2016
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TABLE 45 Events recorded as SAEsa (continued )
Case ID
Country, sex,
age (years) SAE Outcome Date of onset
Daily dose
route
formulation Dates of treatment Comments
System Organ Class: respiratory, thoracic and mediastinal disorders
002 UK, male, 70 Death: pneumonia,
diabetic hypoglycaemia
Fatal 12 May 2014 200mg of
theophylline od
24 April–11 May 2014
003 UK, female, 74 Pulmonary embolism Recovered 24 June 2014 200mg of
placebo od
16 June 2014–ongoing
at time of event
015 UK, female, 65 Death: exacerbation of
COPD
Fatal 30 October 2014 200mg of
placebo od
24 June–30 October
2014
023 UK, female, 69 Chest infection/chest
pain/left upper rib
fracture
Recovered 17 October 2014 200mg of
placebo od
25–29 July 2014
024 UK, female, 68 Death: type 2 respiratory
failure, COPD, multiple
sclerosis
Fatal 20 December 2014 200mg of
theophylline od
22 May–27 August
2014
034 UK, male, 74 Death: severe COPD Fatal 16 February 2015 200mg of
placebo od
16 June 2014–February
2015
035 UK, male, 46 Hyperventilation Recovered 11 November 2014 200mg of
placebo bd
10 September 2014–
ongoing at time of
event
044 UK, male, 73 Death: exacerbation of
COPD
Fatal 11 April 2015 200mg of
theophylline od
18 February–7 April
2015
046 UK, male, 90 Symptomatic pleural
effusions, hospital-
acquired pneumonia
Recovered with
sequelae
11 May 2015 200mg of
theophylline od
7 May 2014–18 May
2015
047 UK, male, 47 Shortness of breath;
most likely exacerbation
of COPD
Recovered 6 December 2015 200mg of
placebo bd
10 September 2014–
ongoing at time of
event
057 UK, female, 73 Death: end-stage COPD Fatal 15 June 2015 200mg of
placebo od
3–31 March 2015
058 UK, female, 74 Pleuritic chest pain Recovered 15 March 2015 200mg of
theophylline od
10 July–11 August 2014
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Case ID
Country, sex,
age (years) SAE Outcome Date of onset
Daily dose
route
formulation Dates of treatment Comments
061 UK, male, 72 Pleuritic chest pain Recovered 20 July 2015 200mg of
theophylline od
10 July 2015–ongoing
at time of event
067 UK, male, 62 Community-acquired
pneumonia, vomited,
aspirated and cardiac
arrest
Fatal 17 July 2015 200mg of
placebo od
18 September–October
2014 (18 doses in total)
069 UK, female, 67 Pleuritic chest pain Recovered 24 February 2015 200mg of
theophylline od
27 August–9 November
2014
083 UK, male, 71 Increased breathlessness Recovered 1 April 2015 200mg of
theophylline od
23 September 2014–
12 October 2015
088 UK, male, 79 Cor pulmonale
secondary to COPD
Fatal 4 October 2015 200mg of
placebo od
21 April–7 September
2015
089 UK, male, 83 Infective exacerbation of
COPD, pleural effusion
Unknown 11 July 2015 200mg of
theophylline od
18 August 2014–
27 May 2015
093 UK, male, 78 Shortness of breath Recovering 9 October 2015 200mg of
placebo od
1 December 2014–
ongoing at time of event
116 UK, female, 71 Pulmonary embolism Recovering 19 December 2015 200mg of
placebo od
7 August 2015–ongoing
at time of event
124 UK, male, 73 (1a) Acute kidney injury,
(1b) septicaemia, (1c)
lower respiratory tract
infection; (2) COPD,
atrial fibrillation,
acromegaly
Fatal 9 April 2015 200mg of
placebo od
1 May 2014–8 April
2015
Recorded as respiratory because the
prime driver was lower respiratory
tract infection and acute kidney injury,
with septicaemia a secondary driver
125 UK, male, 80 Pneumonia Fatal 31 December 2015 200mg of
placebo od
24 November–
30 December 2015
154 UK, female, 72 Pleuritic chest pain Recovered 12 January 2016 200mg of
theophylline od
14 November–
20 December 2015
155 UK, male, 55 Renal failure, secondary
to chest infection
Fatal 12 April 2016 200mg of
placebo bd
20 October 2015–April
2016
Recorded as respiratory because prime
driver was lower respiratory tract
infection, renal failure secondary
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TABLE 45 Events recorded as SAEsa (continued )
Case ID
Country, sex,
age (years) SAE Outcome Date of onset
Daily dose
route
formulation Dates of treatment Comments
165 UK, male, 71 Haemoptysis Recovered 11 May 2016 200mg of
placebo od
29 June 2015–ongoing
at time of event
166 UK, male, 76 Bronchiectasis Recovered 7 March 2016 200mg of
placebo od
10 December 2015–
ongoing at time of
event
170 UK, male, 72 Pneumothorax Recovered 1 May 2016 200mg of
placebo od
8 July 2015–ongoing at
time of event
175 UK, female, 64 Respiratory failure and
CO2 narcosis following
exacerbation of COPD
and chest infection
Recovering 12 May 2016 200mg of
theophylline od
14 March–12 May 2016
177 UK, female, 71 Pulmonary embolism Recovering 18 July 2016 200mg of
theophylline od
28 November 2015–
ongoing at time of
event
197 UK, male, 70 Pneumonia, pulmonary
embolism, cavitating
lesion on CT scan of chest
Recovered with
sequelea
22 August 2016 200mg of
placebo od
4 May–23 August 2016
208 UK, male, 63 Right pneumothorax Recovered 27 June 2014 200mg of
theophylline od
24 April–23 June 2014
209 UK, male, 63 Right pneumothorax Recovered 31 August 2014 200mg of
theophylline od
24 April–23 June 2014
212 UK, female, 64 Pleurisy or
musculoskeletal pain
Recovered 10 February 2016 200mg of
theophylline od
9 April 2015–ongoing at
time of event
226 UK, female, 59 Bronchiectasis Unknown 15 November 2016 200mg of
placebo od
1 June 2016–ongoing at
time of event
230 UK, female, 55 Hypoxia Recovering 28 November 2016 200mg of
placebo od
20 January 2016–
ongoing at time of
event
234 UK, male, 62 COPD Fatal Unknown 200mg of
theophylline od
19 January 2016–
ongoing at time of
event
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Case ID
Country, sex,
age (years) SAE Outcome Date of onset
Daily dose
route
formulation Dates of treatment Comments
248 UK, male, 79 Aspiration pneumonia Fatal 2 February 2017 200mg of
theophylline od
14 July 2016–31 January
2017
257 UK, male, 88 Chest infection Fatal 20 February 2017 200mg of
theophylline od
6 March 2016–
25 February 2017
264 UK, male, 68 l Bilateral
bronchopneumonia
l Pulmonary oedema
secondary to heart
failure and acute
kidney injury
l Progressive frontal
lobe dementia and
COPD
Fatal 22 November 2016 200mg of
placebo od
12 April–18 October
2016
266 UK, female, 71 Pleuritic chest pain Recovered 12 July 2015 200mg of
placebo od
15 September 2014–
2 February 2015
288 UK, female, 78 Death, pneumonia,
severe COPD, frailty
Fatal 9 December 2015 200mg of
theophylline od
20 April–17 November
2015
System Organ Class: gastrointestinal disorders
009 UK, male, 55 Adhesional bowel
obstruction
Recovered 11 September 2014 200mg of
theophylline od
24 May–1 September
2014
016 UK, male, 76 Blockage in oesophagus Recovered 1 November 2014 200mg of
theophylline od
2 October 2014–
ongoing at time of event
020 UK, male, 72 Inflammation of
oesophagus
Recovered 16 September 2014 200mg of
placebo od
8 July 2014–24 June
2015
030 UK, female, 82 Viral gastroenteritis Recovered 15 January 2015 200mg of
placebo od
1 April 2014–15 January
2015
037 UK, female, 43 Abdominal pain and liver
steatosis
Unknown 11 March 2015 200mg of
theophylline od
13 January 2015–
ongoing at time of event
038 UK, female, 79 Vomiting, fever, severe
abdominal pain
Recovering 21 March 2015 200mg of
placebo od
4 February–8 August
2015
continued
D
O
I:10.3310/hta23370
H
EA
LTH
TECH
N
O
LO
G
Y
A
SSESSM
EN
T
2019
VO
L.23
N
O
.37
©
Q
ueen
’s
Printer
and
C
ontroller
of
H
M
SO
2019.
This
w
ork
w
as
produced
by
D
evereux
et
al.
under
the
term
s
of
a
com
m
issioning
contract
issued
by
the
Secretary
of
State
for
H
ealth
and
SocialC
are.
This
issue
m
ay
be
freely
reproduced
for
the
purposes
of
private
research
and
study
and
extracts
(or
indeed,
the
fullreport)
m
ay
be
included
in
professional
journals
provided
that
suitable
acknow
ledgem
ent
is
m
ade
and
the
reproduction
is
not
associated
w
ith
any
form
of
advertising.
A
pplications
for
com
m
ercialreproduction
should
be
addressed
to:
N
IH
R
Journals
Library,
N
ationalInstitute
for
H
ealth
Research,
Evaluation,
Trials
and
Studies
C
oordinating
C
entre,
A
lpha
H
ouse,
U
niversity
of
Southam
pton
Science
Park,
Southam
pton
SO
16
7N
S,
U
K
.
137
TABLE 45 Events recorded as SAEsa (continued )
Case ID
Country, sex,
age (years) SAE Outcome Date of onset
Daily dose
route
formulation Dates of treatment Comments
048 UK, male, 78 Diverticulitis Recovered 8 September 2014 200mg of
placebo od
6 March–15 October
2014
049 UK, male, 78 Diverticulitis Recovered 8 December 2014 200mg of
placebo od
6 March–15 October
2014
051 UK, female, 72 Severe constipation Recovered 7 June 2015 200mg of
theophylline od
2–5 May 2014
054 UK, female, 54 Gastritis Recovered 25 April 2015 200mg of
theophylline od
9–11 December 2014
065 UK, female, 58 Diverticulitis Recovered 26 July 2015 200mg of
placebo od
3 July 2015–ongoing at
time of event
074 UK, male, 66 Appendicitis Recovered 28 August 2015 200mg of
theophylline od
29 July–27 August 2015
087 UK, male, 71 Laparoscopic
appendectomy
Recovered 9 November 2014 200mg of
theophylline od
5 September 2014–
ongoing at time of
event
090 UK, female, 82 Abdominal pain Recovered 5 October 2014 200mg of
theophylline od
14–17 May 2014
100 UK, female, 59 Strangulated small bowel
secondary to hernia
Recovered 1 November 2014 200mg of
placebo od
4 August–1 September
2014
101 UK, female, 60 Oesophagitis and
oesophageal stricture
Recovered 6 July 2015 200mg of
placebo od
4 August–1 September
2014
111 UK, male, 71 Haematemesis Recovered 22 November 2014 200mg of
placebo od
20 March 2014–
ongoing at time of
event
121 UK, male, 58 Perforated duodenal
ulcer
Recovered 25 September 2015 200mg of
theophylline od
3 February 2015–
15 January 2016
129 UK, male, 49 Laparotomy and
adhesiolysis following
severe abdominal pain
Recovering 15 February 2016 200mg of
theophylline bd
23 April 2015–ongoing
at time of event
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Case ID
Country, sex,
age (years) SAE Outcome Date of onset
Daily dose
route
formulation Dates of treatment Comments
136 UK, male, 70 Rectal bleed; possible
Infective/ischaemic colitis
Recovering 6 March 2016 200mg of
theophylline od
12 August–31
December 2015
150 UK, male, 71 Diverticular disease Recovered 6 April 2016 200mg of
theophylline od
22 March 2016–
ongoing at time of
event
158 UK, female, 72 Nausea and vomiting,
acute abdominal pain
Recovering 3 May 2016 200mg of
theophylline od
26 November 2015–
ongoing at time of
event
163 UK, male, 56 Anal abscess/fistula Not recovered 10 January 2016 200mg of
theophylline
twice daily
4 July 2015–ongoing at
time of event
171 UK, male, 71 Diverticulitis Unknown 27 June 2016 200mg of
theophylline od
21 March–29 June 2016
193 UK, male, 59 Bowel obstruction Recovered 5 August 2016 200mg of
theophylline od
29 July 2016–ongoing
at time of event
198 UK, female, 59 Gastroenteritis Recovered 1 May 2016 200mg of
theophylline od
21–29 March 2016
210 UK, female, 71 Acute pancreatitis Recovering 6 October 2016 200mg of
theophylline od
27 November 2015–
ongoing at time of
event
235 UK, male, 68 (COPD) and acute
upper gastrointestinal
haemorrhage due to
duodenal ulcer
Fatal Unknown 200mg of
theophylline bd
28 June–19 December
2016
Recorded as gastrointestinal because
exacerbation of COPD captured as
primary outcome
262 UK, male, 80 Constipation Recovered with
sequelae
5 March 2017 200mg of
placebo od
11 May 2016–ongoing
at time of event
275 UK, female, 88 Constipation Recovered 6 December 2016 200mg of
placebo od
1 June 2016–ongoing at
time of event
277 UK, male, 76 Constipation Recovered 28 December 2016 200mg of
theophylline od
3–22 June 2016
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TABLE 45 Events recorded as SAEsa (continued )
Case ID
Country, sex,
age (years) SAE Outcome Date of onset
Daily dose
route
formulation Dates of treatment Comments
279 UK, female, 73 Diverticulitis ‘flare-up’ Recovered 2 March 2017 200mg of
theophylline od
18 July–2 August 2016
287 UK, male, 77 Constipation Unknown 8 May 2017 200mg of
theophylline od
17 August–9 October
2016
System Organ Class: hepatobiliary disorders
008 UK, male, 66 Acute hepatitis Recovered 25 August 2014 200mg of
placebo bd
23–25 August 2014
130 UK, female, 67 Obstructive jaundiced
and evidence of
intraductal calculi
Recovered 11 January 2016 200mg of
placebo od
24 February
2015–ongoing at time
of event
138 UK, female, 68 Vomiting Recovered 22 November 2015 200mg of
theophylline od
20–11 March 2016
152 UK, female, 72 Cholangitis and
laparoscopic
cholecystectomy
Recovered 21 December 2015 200mg of
theophylline od
14 November–20
December 2015
236 UK, male, 76 Groin pain (possible
biliary sepsis)
Recovered 12 August 2016 200mg of
placebo od
7 June 2016–ongoing at
time of event
273 UK, male, 87 Gallstones Recovered with
sequelae
1 November 2016 200mg of
placebo od
24 August
2016–ongoing at time
of event
System Organ Class: skin and subcutaneous tissue disorders
135 UK, male, 80 Skin rash Recovered 29 December 2015 200mg of
theophylline od
3 February 2015–
14 February 2015
System Organ Class: musculoskeletal and connective tissue disorders
006 UK, male, 61 Suspected fractured ribs Recovering 31 May 2014 200mg of
placebo od
4 March–10 May 2014
084 UK, female, 55 Chest pain Recovered 3 July 2015 200mg of
placebo od
24 April 2015–ongoing
at time of event
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Case ID
Country, sex,
age (years) SAE Outcome Date of onset
Daily dose
route
formulation Dates of treatment Comments
092 UK, female, 58 Atypical chest pain Recovered 27 August 2015 200mg of
placebo od
11 May 2015–ongoing
at time of event
139 UK, female, 69 Chest tightness Recovered 11 January 2016 200mg of
theophylline od
23 September 2015–
ongoing at time of
event
144 UK, male, 82 Acute stiff neck Recovering 25 February 2016 200mg of
placebo bd
21 May 2015–
25 February 2016
145 UK, male, 82 GP referral owing to
swallowing problems
and neck pain ongoing
at time of event for 2 or
3 weeks
Recovered with
sequelae
21 March 2016 200mg of
placebo bd
21 May 2015–
25 February 2016
156 UK, female, 72 Left rib fracture
(osteoporotic, not
traumatic)
Recovering 25 April 2016 200mg of
placebo od
7 August 2015–ongoing
at time of event
159 UK, male, 71 Musculoskeletal chest
pain
Recovering 10 May 2016 200mg of
theophylline od
17 November 2015–
17 May 2016
161 UK, male, 56 Hyperaesthesia of insulin
injection site
Recovered 11 December 2015 200mg of
placebo od
25 June 2015–ongoing
at time of event
162 UK, male, 56 Right ankle pain possibly
due to cellulitis
Recovering 3 May 2016 200mg of
placebo od
25 June 2015–ongoing
at time of event
187 UK, male, 61 Musculoskeletal chest
pain
Recovered 3 May 2014 200mg of
theophylline od
24 April–23 June 2014
188 UK, male, 71 Chest pain Recovered 16 August 2016 200mg of
placebo od
17 November 2015–
ongoing at time of
event
199 UK, female, 59 Musculoskeletal pain Recovered 3 July 2016 200mg of
theophylline od
21–29 March 2016
211 UK, female, 76 Back pain following fall Recovered 14 May 2015 200mg of
placebo od
5–9 June 2014
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TABLE 45 Events recorded as SAEsa (continued )
Case ID
Country, sex,
age (years) SAE Outcome Date of onset
Daily dose
route
formulation Dates of treatment Comments
259 UK, female, 72 Primary diagnosis of gout
of her left big toe, with a
secondary diagnosis of
infection
Unknown 1 March 2017 200mg of
theophylline od
18 April 2016–ongoing
at time of event
261 UK, female, 76 Abdominal pain Recovered 1 February 2017 200mg of
placebo od
26 August
2016–ongoing at time
of event
Considered to be of musculoskeletal
origin
System Organ Class: renal and urinary disorders
076 UK, male, 60 Kidney stones Recovering 2 September 2015 200mg of
placebo od
6 January 2015–ongoing
at time of event
104 UK, male, 83 Urinary retention Recovering 18 November 2015 200mg of
placebo od
28 May 2015–ongoing
at time of event
106 UK, female, 82 Acute kidney injury Recovered 30 November 2015 200mg of
theophylline od
27 February
2015–ongoing at time
of event
157 UK, male, 63 Right renal colic Recovered 29 Feb 2016 200mg of
placebo bd
4 November 2015–
5 January 2016
200 UK, female, 59 UTI with stage 1 acute
kidney injury
Recovered 16 August 2016 200mg of
theophylline od
21–29 March 2016
207 UK, female, 75 Multiresistant Escherichia
coli UTI
Recovered 25 November 2014 200mg of
theophylline od
28 August–1 September
2014
229 UK, female, 73 Deranged renal function,
lower respiratory tract
infection
Recovered 20 November 2016 200mg of
theophylline od
11–20 April 2016
237 UK, male, 76 Haematuria Recovering 2 December 2016 200mg of
placebo od
7 June–12 August 2016
280 UK, male, 83 Shortness of breath due
to fluid overload,
secondary to renal
disease
Recovered 30 March 2016 200mg of
theophylline od
2 March–12 April 2016
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Case ID
Country, sex,
age (years) SAE Outcome Date of onset
Daily dose
route
formulation Dates of treatment Comments
283 UK, female, 78 Proximal ureteric stone
causing obstruction of
left kidney
Recovered 5 December 2016 200mg of
theophylline od
26 July 2016–ongoing
at time of event
System Organ Class: pregnancy, puerperium and perinatal conditions
None
System Organ Class: reproductive system and breast disorders
None
System Organ Class: congenital, familial and genetic disorders
None
System Organ Class: general disorders and administration site conditions
None
System Organ Class: investigations
113 UK, female, 55 Asymptomatic raised
calcium levels
Recovered 4 December 2015 200mg of
placebo od
23 June 2015–ongoing
at time of event
System Organ Class: injury, poisoning and procedural complications
005 UK, female, 68 Left tibial plateau
fracture
Recovering 1 July 2014 200mg of
theophylline od
8 May 2014–ongoing at
time of event
028 UK, female, 67 Fractured pubic ramus
and right acetabulum
Recovered 12 November 2014 200mg of
theophylline od
22 August–9 November
2014
041 UK, male, 55 Death: head injury Fatal 19 April 2015 200mg of
theophylline od
13 March–19 April 2015
075 UK, male, 90 Fall (mechanical) Recovered 12 March 2015 200mg of
placebo od
4 September 2014–
3 September 2015
091 UK, female, 58 Rectus sheath
haematoma
Recovered 23 September 2015 200mg of
placebo od
11 May 2015–ongoing
at time of event
Secondary to trauma
094 UK, male, 85 Fractured neck of femur Recovered 14 August 2015 200mg of
placebo od
23 March 2015–
ongoing at time of event
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TABLE 45 Events recorded as SAEsa (continued )
Case ID
Country, sex,
age (years) SAE Outcome Date of onset
Daily dose
route
formulation Dates of treatment Comments
095 UK, female, 82 Fracture left wrist Recovered 28 April 2015 200mg of
placebo od
30 October–5 November
2014
096 UK, female, 65 Fractured distal radius
and ulna
Recovered 4 September 2015 200mg of
placebo od
15 June 2015–ongoing
at time of event
108 UK, male, 49 Laceration to left hand Unknown 29 September 2015 200mg of
theophylline bd
23 April 2015–ongoing
at time of event
115 UK, female, 76 Fall Recovered 26 December 2015 200mg of
placebo od
12–31 December 2015
137 UK, male, 60 Lower back pain lasting
2 hours since fall on
floor during the night
Recovered 7 March 2016 200mg of
theophylline od
7 April 2015–ongoing at
time of event
153 UK, female, 72 Post-operative wound
infection
Recovered 9 January 2016 200mg of
theophylline od
13 November–
20 December 2015
169 UK, male, 80 Raised INR of 4.2 and HB
97; possibly due to GI
bleed
Recovering 1 July 2016 200mg of
theophylline od
21 October 2015–
ongoing at time of
event
Inappropriately high dose of warfarin
180 UK, male, 83 Head injury Recovered 6 July 2016 200mg of
placebo od
10 February 2016–
ongoing at time of
event
190 UK, male, 69 Fractured rib Not recovered 19 August 2016 200mg of
placebo od
21 March 2016–
ongoing at time of
event
204 UK, female, 81 Right distal fibula and
medial malleolus
Unknown 3 September 2016 200mg of
theophylline od
19 July–19 December
2016
206 UK, male, 74 Fell down stairs and
fractured clavicle and
shoulder, and broke ribs
Recovering 1 August 2016 200mg of
placebo od
24 August 2015–
11 February 2016
214 UK, male, 63 Fall Recovered 15 January 2015 200mg of
placebo od
4 March 2014–ongoing
at time of event
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Case ID
Country, sex,
age (years) SAE Outcome Date of onset
Daily dose
route
formulation Dates of treatment Comments
216 UK, male, 69 Persistent vomiting Recovered 17 January 2015 200mg of
theophylline od
7 July–24 November
2014
Thought to be related to chemotherapy
218 UK, male, 69 Confusion (steroid-
induced psychosis)
Recovered 4 April 2015 200mg of
theophylline od
7 July–24 November
2014
271 UK, female, 76 Closed fracture neck of
femur
Unknown 14 May 2017 200mg of
placebo od
27 May 2016–ongoing
at time of event
272 UK, male, 58 Fall-like syncopal attack Recovered 26 March 2015 200mg of
theophylline od
12 March–18 April 2015
274 UK, male, 84 Fall Fatal 14 October 2016 200mg of
placebo od
23 May–6 October 2016
278 UK, female, 61 Fractured neck of femur Recovered 8 May 2017 200mg of
placebo od
17 May 2016–ongoing
at time of event
System Organ Class: surgical and medical procedures
045 UK, male, 69 Optical urethrotomy Recovered 27 March 2015 200mg of
theophylline bd
30 July 2014 to 29 July
2015
System Organ Class: social circumstances
None
CT, computerised tomography; CVA, cerebrovascular accident; DVT, deep-vein thrombosis; HB, haemoglobin; ICA, internal carotid artery; ID, identification; INR, international normalised ratio;
M, metastasis; N, node; NSTEMI, non-ST elevation myocardial infarction; STEMI, ST elevation myocardial infarction; T, tumour; TIA, transient ischaemic attack; UTI, urinary tract infection.
a Seven other events were recorded by sites as SAEs. These are not reported in Table 43–45 (or in Table 17) for the following reasons: two were retracted because they were not
considered to be serious (IDs 167 and 191); one was retracted and resubmitted as a follow-up (ID 194); and four captured primary (COPD exacerbation) or secondary (pneumonia) outcome
data and are reported as such in Chapter 4 (IDs 142, 215, 227 and 232).
b Event not included in Table 17 as this person did not start the trial medication.
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